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Green Chemistry in the Design of Safer Anaerobic Adhesives 
By 
Adam Porter 
 
Abstract 
New cure accelerators for anaerobic adhesives have been designed to offer less 
harmful alternatives to current industry standard accelerators. Accelerators in current 
use are comprised of compounds such as acetylphenylhydrazine (APH), diethyl-p-
toluidine (DEpT), tetrahydroquinoline (THQ) and their derivatives, all of which can 
be classified as being acutely toxic or harmful to the user. Further to this, there is no 
consensus as to their mode of action within the curing of the adhesive and how they 
affect the radically initiated polymerisation mechanism.  
Safer alternative cure accelerators have been designed and added insight as to their 
mechanistic role gained through the conception, synthesis, and screening of 
“generations” of accelerators and structurally similar compounds for key properties 
such as anti-microbial toxicity, cytotoxicity, biodegradability, eco-toxicity, and cure 
activity. With the analysis of each generation, more information was gathered and 
the structure activity relationship for these properties further elucidated. This greatly 
aided the design of each succeeding generation of synthetic targets in order to 
maximise their accelerator activity whilst reducing their risk to the user and the 
environment. 
This approach not only yielded new ionic liquid based cure accelerators but also 
opened up new directions for their future development and design by identifying 
classes of compounds not previously used for this purpose. These saccharinate, 
acesulfamate, and phthalimate based compounds have been proven to possess 
activity equal to current industry benchmarks whilst being of low cytotoxicity and 
anti-microbial activity. Furthermore, these compounds offer significant room in their 
scope for derivitisation and development as custom designed cure catalysts.  
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Chapter 1: 
Introduction to 
Adhesives  
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1.1 A Brief History of Adhesion 
In its most fundamental sense, an adhesive is defined as any substance capable of 
holding materials together though surface attachment. 
The first examples of adhesion can be traced as far back as the late Palaeolithic era 
where hunter-gatherers fashioned axes by using bark-tar to bond stone to pieces of 
wood.
1
 Plant products such as these tars and tree resins were the basis for early 
bonding products with no evidence of the use of animal glues until c. 2000 B.C. 
which is also when we see the first recordings of the use of adhesives in literature. 
The Romans and Greeks further developed these glues using fish and other animal 
sources, as well as natural products such as egg whites, to form long lasting 
adhesives. It is also around this time that the use of cements and mortar became more 
common in addition to tar and beeswax as waterproofing agents and sealants.
2
  
The development of glues and adhesives surged from the late 17
th
 century through 
the industrial revolution forming the basis for the industry. This period saw the first 
commercial manufacturing facilities established as well as the first British and US 
patents for glue issued. Although these and many other developments greatly 
advanced the now established adhesive industry, they were all based on plant and 
animal sources. The first semi-synthetic polymer was created by Alexander Parkes
3
 
when he marketed a less nitrated form of nitrocellulose as “synthetic ivory” but not 
until the first fully synthetic commercial polymer was produced in the early 20
th
 
century did adhesives begin to develop into how we see them today. 
Bakelite was the trade name given to the phenol-formaldehyde based resin marketed 
by Leo Baekeland in 1907. Initially used as a mouldable plastic, it was first applied 
as an adhesive in 1912. Urea-formaldehyde resins soon followed along with other 
synthetic polymers, their production catalysed by World War II, and in these 
intervening years the vast majority of adhesive development has taken place despite 
the long and storied history.
3
 
To detail the discovery and development of each adhesive class and their importance 
would be beyond the scope of this study but a selected chronology of their discovery 
is shown in Table 1.1. 
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Table 1.1: Development of Selected Adhesives 
Year Adhesive 
1940 Polyurethane, Nitrile-phenolic, Acrylic 
1950 Epoxies, Cyanoacrylates, Anaerobics 
1960 Polyimide, Polybenzimidazole 
1970 Second-Generation Acrylics 
1980 Foamable Hot-Set Adhesives 
1990 Polyurethane Modified Epoxy, UV Curable 
2000 Water-Based Adhesives, Solvent-Free Adhesives 
 
It is clear from this illustration just how big of a leap adhesives have made in their 
development and technology over the past century. This development has been 
historically linked to the requirements of industries, such as aerospace, where it is of 
great benefit to replace mechanically fastened joints, as well as to the advances 
which have been made in organic and polymer chemistry.  
 
1.2 Anaerobic Adhesives 
This research project is specifically focused on anaerobic adhesives and, as the name 
suggests, these are adhesives which cure in the absence of air but remain liquid in its 
presence. They were developed by General Electric
4
 in the 1940‟s and consisted of a 
methacrylate monomer mixed with an organic peroxide at elevated temperature. 
Crucially, this mixture required pure oxygen to be continuously bubbled through to 
prevent polymerisation from taking place. This instability and the awkward handling 
conditions required ultimately led to GE discontinuing the product only for Loctite, 
now Henkel-Loctite, to acquire the license and develop a more stable product in the 
early 1950‟s.5 This mainly centred on developing packaging which allowed for air 
penetration and so removed the need for a constant flow to be artificially provided.  
Until their main patents on the technology began to expire in the 1970‟s, Loctite 
maintained firm control on the industry. Nowadays, many multi-national companies 
produce anaerobic adhesive products including Henkel-Loctite, Eastman, and 
Threebond amongst others.
6–8
 These adhesives are mainly utilised as threadlockers, 
4 
 
their role to keep components such as nuts and bolts from loosening with the 
vibration of machinery. For this use their penetrating ability allows them to be 
applied before or after assembly. Due to their curing mechanism, they are only suited 
to bonding close fitting materials but as they have been developed and their 
properties modified they have found further applications as “retainers” for 
cylindrical joints, and as sealants for a wide array of metal joints as well as 
gasketting. They are now applied across a broad range of industries from aeroplane 
assembly
9
 to dentistry
10,11
 with their properties and applications still being explored. 
The bond formed is resistant to a wide range of solvents including salt water as well 
as a broad temperature range from -54C to upwards of 232C.12 Curing can be 
accelerated by increasing the temperature but it is generally preferred to do so 
through the addition of catalytic compounds or surface pre-treatment of the substrate. 
Pre-treatment may involve the removal of the inactive metal-oxide layer by methods 
of abrasion or by applying a primer containing a reducing agent or initiating catalyst 
such as a copper salt. Anaerobic adhesives are applied across a wide range of 
materials however, for mechanistic reasons which will be explained in a later 
section, they are most commonly used to bond metals. The curing occurs through a 
redox initiated radical polymerisation where a hydroperoxide is used as the radical 
source through its degradation. The presence of metal ions greatly affects this cure 
rate but even so there is a broad range of activity depending on the metal in question 
with the adhesive being virtually inactive when used with materials such as glass or 
ceramics
13
 (Table 1.2). 
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Table 1.2: Material Activity of Anaerobic Adhesives
13
 
Very Active  Active Inactive Very Inactive 
Brass Aluminium Anodize 
aluminium 
Ceramics 
Copper Bronze Cadmium Composites 
Manganese Iron  Chrome finished Glass 
 Kovar Gold Plastics 
 Monel
®
 Inconel Paint-coated parts 
 Nickel Magnesium Rubber 
 Steel Plated parts  
  Galvanised steel  
  Stainless steel  
  Titanium  
  Zinc  
 
1.2.1 Formulation and Cure Accelerators 
A typical formulation of an anaerobic adhesive will contain monomer(s), a 
hydroperoxide, cure inducers/accelerators, along with stabilisers and performance 
modifiers (Table 1.3). 
Table 1.3: Typical Composition of an Anaerobic Adhesive 
Component Purpose Example 
Monomer Provides the adhesion  Polyethylene glycol 
dimethacrylate 
Cure Initiator Initiates the 
polymerisation 
Cumene hydroperoxide 
(CHP) 
Co-Initiator/Accelerator Takes part in 
polymerisation initiation 
Saccharin (benzoic 
sulfimide - BS) 
Cure Accelerator Reduces curing time Dimethyl-p-toluidine 
Radical Scavenger Stabilises the formulation Benzoquinone 
Performance Modifiers Tailor the properties of the 
adhesive 
Plasticizers, thickeners etc. 
6 
 
Multi-methacrylate functionalised monomers are commonly chosen for this class of 
adhesive as the carbon-carbon double bond provides a readily available site at which 
radical polymerisation can occur. The first monomers used were polyethylene glycol 
methacrylates of varying length
4
, and while they are still used widely in anaerobic 
products, they are now supplemented by other monomeric species in order to modify 
their bond properties and applications. Methacrylate derivatives used include 
hydroxyethyl-, lauryl-, isobornyl, and hydroxypropylmethacrylamide amongst many 
others as well acrylic acid derivatives used in the bonding of smoother surfaces.
14
 
Bisphenol A (Bis A) is the basis for many epoxy resins which are commonly 
thermally cured and these moieties are introduced in the form of compounds such as 
ethoxylated bis a dimethacrylate to impart greater thermal resistance on the adhesive 
bond
15. Diallyl bisphenol A‟s can be used to improve the shear strength16 of the bond 
while the strength and toughness can be altered through the introduction of urethane 
linkages
17
, most commonly by the reaction of toluene diisocyanate with 
hydroxyalkylmethacrylates (3) (Figure 1.1). 
 
 
 
Figure 1.1: Examples of Monomers used in Anaerobic Adhesives 
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Figure 1.2: Examples of Initiators used in Anaerobic Adhesives 
 
For any adhesion to occur, anaerobic adhesive formulations contain a hydroperoxide 
which, through its decomposition, acts as the source of the radical required in order 
for polymerisation initiation to take place. Many different hydroperoxides can be 
used for this purpose with the main requirements being that they are reasonably 
stable under aerobic conditions and that the activation energy for their 
decomposition can be achieved as part of a reduction process where a transition 
metal is oxidised. Cumene hydroperoxide (6) is commonly used example but many 
others have been utilised successfully such as t-butyl-, and tetramethylbutyl 
hydroperoxide (TMBH) (Figure 1.2). 
Although peroxides in general are inherently instable and will usually degrade to 
varying extents depending upon conditions, they must be stable enough to allow for 
application of the adhesive before curing begins and in the case of commercialised 
products – to allow for an acceptable shelf-life. A certain amount of radical 
decomposition will occur no matter what measures are taken but so long as this rate 
is not unmanageable, its effect can be mitigated by the process where molecular 
oxygen reacts to retard these radical reactions. In fact, this is the reason why this 
class of adhesive can be stored as a single mixture and still have a reasonable shelf 
life in that once they are packaged while in the presence of oxygen, and as long as 
this packaging allows for a certain level of air penetration, then these radicals will 
preferentially react with oxygen. For this purpose, low-density polyethylene 
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containers are used. The radicals then formed will not possess the activation energy 
necessary to initialise polymerisation, and in the case that they do, or if a radical 
does not react with a hydroperoxide radical then a certain amount of radical 
stabiliser/scavenger such as menadione (7) or napthoquinone (8) is included in the 
formulation to ensure the stability of the product.
18
 While these components are 
included, they are not in a large enough concentration to hamper the initiation phase 
of the polymerisation once the adhesive is applied to the substrate and oxygen 
removed. 
In order to mitigate the effect of any transition metal ion contamination, a small 
amount of EDTA (9) or other metal chelator is also included in the formulation to 
further stabilise and lengthen shelf-life.
19
 
 
 
 
Figure 1.3: Examples of Stabilisers/Inhibitors and Modifiers used in Anaerobic 
Adhesives 
 
Other components of the formulation may be present in small amounts to modify the 
cured or uncured properties of the adhesive. The viscosity and rheology of the 
adhesive may need to be altered in order to make the composition more fit for 
purpose. If the adhesive is intended as a threadlocker then it would be advantageous 
to have the viscosity lowered so as to allow for as much penetration of the threaded 
joint as possible, on the other hand if it is intended to be used for bonding smooth, 
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suspended parts then a high viscosity product would be desired so as to maximise 
contact. These properties can be designed for by the use of thickening agents such as 
polystyrene or thixotropic agents.
20
 Examples of methods used to alter the thermal 
resistance and strength of the adhesive bond are given above when discussing 
monomers. Maleimides (10) may further add to the thermal resistance
21
 while 
plasticisers such as polyester may be used to lower the bond strength and reduce the 
permanency of the adhesion.
22
 Calcium carbonate can be used as filler to add to the 
sealant effect of the product while dyes may be included so as to aid in identification 
and brand recognition.
23
 
The remaining significant components present in anaerobic adhesives are the co-
initiator/cure accelerators and it is these compounds which are the subject of this 
research project.  
Despite much attention, there is still no consensus as to the specific involvement 
these components play in the overall curing mechanism of the adhesive and how 
exactly they expedite the polymerisation process. 
The first generation of cure accelerators for commercial anaerobic adhesives relied 
on simple tertiary amines such as tributylamine to hasten the curing process.
24
 These 
were superseded by aromatic amines such as aniline and nowadays, accelerator 
compositions are typically comprised of a weak acid such as saccharin (BS) (13), 
accompanied by an aromatic amine e.g. diethyl-p-toluidine (DEpT) (11).
25,26
 Both of 
these compounds displayed cure accelerator activity on their own, but when used in 
tandem they proved to form an extremely effective curing composition. These 
compounds and their pairing represented a major step forward in the application of 
anaerobic adhesives as they greatly decreased the cure time required and by doing so 
broadened their range of applications. 
Along with anilines/toluidines, established cure accelerators to have been developed 
include many phenylhydrazines (16)
27
, tetrahydroquinolines (15)
28
, enamines
29
, and 
benzoxazines.
30
 These variations of aromatic amines have enjoyed varying degrees 
of success and hint at different possible modes of action but crucially none of the 
compounds thus far have been able to display the desired properties of a commercial 
anaerobic cure accelerator i.e. to possess excellent cure activity whilst posing no risk 
to the user or the environment. 
10 
 
 
Figure 1.4: Examples of Cure Initiators/Accelerators used in Anaerobic 
Adhesives 
 
Acetylphenylhydrazine (APH) (16) and DEpT/DMoT (11, 12) represent some of the 
most effective cure accelerators available in terms of cure time and strength. 
However, they are also proven to be acutely toxic towards human health
31,32
 and this 
places a restriction on not only the amounts which may be incorporated into 
formulations, but also the variety of applications for which the adhesive may then be 
used (Table 1.4).  
Any adhesive prepared with components such as these must be labelled accordingly 
to warn the end-user of the associated risk. For a commercial product, this 
automatically reduces the size of market to which the product may be sold as well as 
giving pause to the remaining target consumers. 
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Table 1.4: Acute Toxicity of Some Accelerator Compounds 
Compound LD50 
Dimethyl-p-toluidine Intraperitoneal – Mouse - 212 mg/kg32 
Dimethyl-o-toluidine Intraperitoneal – Mouse - 338 mg/kg33 
1-Acetyl-2-phenylhydrazine Oral – Mouse – 270 mg/kg31 
Indoline Intraperitoneal – Mouse - >238 mg/kg34 
 
For this reason there is substantial interest in the possibility of designing cure 
accelerators which would be non-toxic and completely “label free” while still 
possessing cure activity on par with the established compounds in use. This would 
result in a much safer product for the end user and, perhaps just as importantly, 
remove the restrictions on how much of these chemicals can be used as part of 
formulations in order to conform with industry guidelines & regulations, and 
therefore create a wider range of applications. 
 
1.3 The Curing Mechanism of Anaerobic Adhesives 
In order to be able to design new, safer cure accelerators, it would be of great benefit 
to establish their mechanism of action with respect to how they interact with and 
affect the overall curing process. This, however, is not straight forward with studies 
showing that depending on the accelerator used, and the substrate to which they are 
applied, varying possibilities and evidence as to the mechanism are apparent.  
Since anaerobic adhesives became commercially available in the 1950‟s, there has 
been much speculation as to the specific role each component plays in the curing 
mechanism observed and the resulting adhesion.  
Loctite maintained a firm hold on the industry until their main patents on the 
technology began to expire in the 1970‟s when this opened up a lot of anaerobic 
“knowledge” to the rest of the adhesives industry and allowed them to begin 
developing their own versions and products. Given how this technology was 
discovered and how it has evolved primarily within industry as opposed to academic 
research, the majority of published material in the area exists in the form of patent 
literature and a lot of the nuances and expertise, one can assume, has gone 
12 
 
unpublished in favour of the value placed on “in-house” knowledge by many major 
companies. As a result, the bulk of research into the understanding of this 
mechanism, and particularly the role of cure accelerators within it, did not take place 
until the 1990‟s but even then despite this increased attention, there is still no 
consensus as to the exact curing mechanism and how the polymerisation process can 
be modified and accelerated. 
In its most simplistic form, the adhesion process can be thought of to occur through a 
redox initiated radical polymerisation process. Since this process is an overall radical 
mechanism, the methacrylate C-C double bond provides the site at which this 
polymerisation occurs. 
In order for this to take place, the radical must first be generated in order to initialise 
polymerisation. The hydroperoxide present acts as the source of this initiator through 
its decomposition and one of the mechanisms by which this can occur is through a 
redox process whereby the transition metal, present on the substrate surface, acts as 
the reducing agent. 
                         
This radical is then able to react with the methacrylate carbon-carbon double bond of 
the monomer initialising polymerisation.  
As the name suggests, an absence of oxygen from the adhesion environment will 
promote curing. This is due to oxygen‟s ability to retard the process, either by 
reacting with the peroxide radical formed resulting in a radical unable to initialise 
polymerisation, or by oxidising the metal surface and preventing hydroperoxide 
decomposition. In saying this however, certain metals such as iron are still able to 
decompose hydroperoxides even when in an elevated oxidation state. 
                        
The radical formed in this case though is not as reactive as that of the radical formed 
from a metal in a lower oxidation state and is unable to reach the activation energy 
required to initiate polymerisation. Thus, despite the fact that various metals, of 
varying oxidation state, are able to decompose hydroperoxides, the lower the 
oxidation state of the metal substrate to be bonded, the more anaerobic adhesion will 
be promoted. 
13 
 
 
 
Scheme 1.1: Radical Initiated Polymerisation 
 
The methacrylate radical formed in the reaction between the peroxide radical and the 
methacrylate monomer is then free to react with other methacrylate functionalities 
and the reaction is thus propagated. The end result of this polymerisation is a strong 
adhesive bond which is resistant to both temperature change and solvent contact. 
 
As mentioned previously, anaerobic adhesives were first commercialised in the 
1950‟s and in these first products “simple” tertiary amines such as tributylamine 
were employed as cure accelerators. Without such compounds, and in the absence of 
any heat, these systems would have taken a prolonged time to cure and as a result 
would have been impractical in terms of commercial application. It was thought that 
these cure promoters were able to affect the cure time by forming a complex with the 
hydroperoxide which in turn made the oxygen-oxygen bond more susceptible to 
decomposition and radical formation, thus accelerating the initiation phase of 
polymerisation. However, as several studies have shown in the period since, there 
are many possibilities as to how these compounds are able to participate in the curing 
process. These studies have not resulted in a definitive consensus as to their exact 
mechanism of action but they have hinted at the possibility that they may take part in 
14 
 
different ways, with various accelerators emphasising some mechanisms more than 
others even though the net curing rate could end up the same. 
One of the issues with past studies into the source of accelerator activity or any 
attempt to elucidate their activity in a “QSAR-like” manner has been that the same 
few accelerator systems are analysed in a number of cases. This can be partly 
attributed to a lack of variation of the accelerators present in commercial products 
but when there is a situation such as this where there are several possibilities as to 
the mode of action, many of which could occur simultaneously only to differing 
extents, then there is a resulting bias inherently present in any conclusions reached 
i.e. the outcome will reflect the most favoured mode of action of that system and 
therefore no insight as to the possibilities and levels to which other modes of action 
affect the curing rate are gained. This is something which has been overlooked and 
by not giving enough attention to other accelerator systems, a “true” general mode of 
action for their activity cannot be described, only a likely mechanism of action for an 
individual system. 
The curing system which has been the focus of this attention is one mainly 
comprised of triethylene glycol dimethacrylate, cumene hydroperoxide (CHP), and a 
cure accelerator system comprising of either both dimethyl-p-toluidine & saccharin 
or acetylphenylhydrazine (APH) & saccharin (BS). Another important factor to take 
into account when critically analysing data reported is the choice of metal substrate. 
This will be explained in more detail later, but different adhesive formulations 
perform better depending on the choice of metal to be bonded illustrating that this 
factor too plays an important role in the curing process and the major mechanism 
through which polymerisation takes place i.e. a formulation which bonds copper 
very well may not do so with iron and vice versa. 
Y. Okamoto, in a two-part study of the curing mechanism of anaerobic adhesives, 
was one of the first to allude to the possibility that any cure acceleration could be as 
a result of a complex formed between saccharin and the amine present as opposed to 
either compound taking part in an unreacted state.
35,36
  Up to this point there was still 
much ambiguity as to the exact curing mechanism of anaerobic adhesives, and even 
more concerning the role of cure accelerators within it. Using methyl methacrylate 
(MMA) as the polymer, and CHP, BS, and DMpT as the curing system, temperature 
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and kinetic studies were carried out in order to elucidate the mechanism. With the 
rate of polymerisation increasing with temperature, and taking into account the 
apparent low activation energy also measured, the reaction was believed to occur 
through a redox radical polymerisation process as opposed to a thermally initiated 
one. The kinetic measurements carried out showed that the rate of reaction depended 
on close to equal concentrations of saccharin and DMpT and, quite surprisingly, 
occurred regardless of whether CHP was present or not. This indicated that the 
acceleration of the polymerisation reaction could be due to an interaction between 
saccharin and the amine. Okamoto proposed that this was through a charge transfer 
complex formed between BS and DMpT, the formation of which was believed to be 
illustrated by the deep purple colour formed upon addition of one to the other. 
 
 
Figure 1.5: Charge Transfer Complex between DMpT and Saccharin 
The formation of such a complex was supported by measurements carried out which 
showed that the curing time increased when electron donating groups were added to 
BS, or when the slightly electron donating effect of the methyl group on DMpT was 
removed by replacing DMpT with N,N-dimethylaniline, or when the cyclised 
derivatives tetrahydroquinoline (THQ) or indoline were used.  
The second part of this study by Okamoto was conducted using APH instead of 
DMpT as part of the curing system.
36
 However, this was conducted with one 
significant difference, because the induction period when using APH was perceived 
to be longer than when that of a curing system in which DMpT is used, a small 
amount of Cu
2+
 catalyst was also added. This alludes to an important factor which 
was mentioned earlier, and summarised in Table 1.2, in that depending on the metal 
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substrate, or in this case the metal ion present, certain curing systems will perform 
better than others and this can make studies markedly less comparable. 
Again, as with DMpT, the rate of polymerisation was faster as the temperature 
increased. The activation energy measured was lower than that of the system 
containing DMpT, however this can most likely be explained by the presence of the 
Cu
2+
 species. The reaction was found to occur regardless of BS concentration and 
this time was found to proceed faster with a molar ratio of 1 for APH-CHP 
concentration. It was postulated that the mechanism thus proceeds by APH acting as 
a reducing agent with respect to the metal substrate forming Cu
+
 which is then able 
to decompose the CHP (6) present to form a cumyloxy radical (17) which in turn 
initiates polymerisation (Scheme 1.2). The BS, in this system, was proposed to act as 
an acid catalyst protonating the CHP which would in turn lead to its decomposition 
into a cumyl cation and hydrogen peroxide which could act as another source of 
radical formation. 
 
 
Scheme 1.2: Reduction of Copper by APH and Decomposition of CHP 
 
The effect transition metals have on the curing activity of various anaerobic adhesive 
systems has been studied.
37–39
 Combined, these studies point to copper being the 
most active substrate followed by iron with metals such as zinc being completely 
inactive. Aluminium also possesses some activity but this is due to the small amount 
of copper commonly contained in aluminium alloys. 
The difference in activity that various transition metals display towards different 
adhesive systems could possibly mean that each promotes a different curing 
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mechanism and thus the substrate possibly may not act as a constant factor in their 
study of the curing mechanism, only another variable. 
Beaunez, Helary, and Sauvet published a two-part study where they investigated the 
effect of metal substrate on adhesive curing.
38,39
 The first study deals with copper 
curing systems where they use an initiator/accelerator system consisting of CHP, BS, 
DMpT, and crucially, copper saccharinate. In order to study the polymerisation 
reaction under representative practical adhesive conditions, a metal ion source was 
required, and, given the potential likelihood that metal salts of saccharin are formed 
under practical conditions, copper saccharinate was chosen. Using dilatometry, the 
kinetics of the reaction were studied with respect to each component and they 
concluded that an equilibrium of copper in its +1 and +2 oxidation states is reached 
in no small part due to CHP‟s ability to not only oxidise Cu+ to form reactive 
radicals but also reduce Cu
2+
 and thus keep regenerating the oxidising agent. In 
addition to this, they propose that the role of the amine accelerator is to complex 
metal ions and form a more reactive hydroperoxide decomposition reagent. 
The second part of this study was conducted in a similar manner but with the 
substitution of copper saccharinate for the iron salt. This study yielded several key 
differences in the curing process observed between the two substrates. CHP is able to 
reduce Cu
2+
 and therefore regenerate the Cu
+
 oxidising agent, this is not observed for 
Fe
3+
 but importantly DMpT is able to carry out this regeneration of iron in a lower 
ground state despite this not being observed for copper. 
George, Touyeras, Grohens, and Vebrel (1997) also carried out an investigation of 
the role of the metal substrate in the cure process.
37
 They arbitrarily chose a 
commercial adhesive which consisted of a saccharin-DMpT accelerating system and 
applied the formulation to steel, aluminium, and copper substrates to study their 
effect. Using infrared microscopy, in reflection mode, the adhesive was applied to 
the substrate surface and the change in intensity of the peaks relating to the C=C and 
C=O bond of the methacrylate monomer were used as a measure of the progression 
of the curing.  This resulted in a degree of curing which illustrated 
copper>steel>aluminium where copper was nearly 2.5 times more active than 
aluminium. This could potentially be as a result of copper being more susceptible to 
forming metal complexes with the saccharin and/or DMpT which are then able to 
decompose the hydroperoxide to form a radical species. 
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Raftery et al. used polarography in an attempt to study this change in oxidation state 
of iron and copper in the presence of the cure components.
40
 The accelerators APH, 
1-acetyl-2-phenyldiazene (APD), and THQ were each paired with BS or maleic acid, 
and CHP in order to study their individual effect on the redox state of the metal. The 
group was found that, in the presence of only the amine, there was little metal ion 
level detected. However, upon addition of either BS or maleic acid, the concentration 
of each metal in their various oxidation states increased greatly. This is thought to be 
as a result these compounds acting as an acidic species and liberating metal ions 
from the substrate surface. In the case of saccharin systems this resulted in more 
metal ions existing in their lower oxidation state than for the respective maleic acid 
based systems. Raftery and co-workers was proposed that this is due to maleic acid 
protonation of the amine hampering their ability to reduce the metal. Furthermore, it 
was observed that upon addition of CHP, the concentration of each metal in their 
reduced state decreased, highlighting their role in the oxidative decomposition of the 
hydroperoxide. 
Indeed a separate study conducted by the same research group highlighted the 
complexity of the factors affecting hydroperoxide decomposition as part of an 
anaerobic adhesive.
41
 Formulations containing various amine accelerators, BS or 
maleic acid, and one of several hydroperoxides were added to solutions of iron, 
copper, and cobalt salts of varying oxidation state. Generally, lower oxidation states 
of each metal decomposed the hydroperoxides to a greater extent while the higher 
oxidation states relied on the presence of the amine accelerators. Interestingly, in the 
case of metals in their lowest oxidation states, saccharin and maleic acted to inhibit 
the decomposition rate and promoted the rate in the case of higher ox. state metals. 
This could point to saccharin acting to alter the redox potential of the metals by 
forming a complex and not to protonate the hydroperoxide as proposed elsewhere. 
Another outcome of this study was the effect the acid-metal ratio had on the cure 
time. There is no real trend for this factor across the systems however and, 
practically speaking from an application standpoint, this will change with the area of 
metal being bonded and the type of species present. This has also been observed for 
other types of adhesives before.
42
 
Up to this point, we have only considered the effect of each component in isolation 
on the curing process and at most have considered possible ionic bonding 
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interactions and salt formation reactions between the components. However, it is 
possible that each of these formulation components may in fact react to form new 
compounds capable of altering the cure composition in their own right. 
Wellmann and Brockmann were the first to investigate the possibility of the 
formation of cure altering species in situ.
43
 They used a system consisting of DMpT, 
BS, and CHP and carried out reactions under both anaerobic and aerobic conditions 
to explore the possible products formed. Under anaerobic conditions, DMpT may be 
oxidised in the presence of CHP (6) to form the N-oxide (22) and cumene alcohol. 
However, this process is supressed under aerobic conditions i.e. adhesive storage 
conditions. Nevertheless, the possible reactions of this N-oxide with other species 
were considered leading to the isolation of aminal (23) as the product of the reaction 
with saccharin. Based on reactions of other metal salts with amine-N-oxides, a 
radical mechanism for its formation was proposed. However, because any radical 
formed is likely to react with the methacrylate present in an adhesive, this radical 
will be consumed before the N-oxide or aminal can be formed. A pathway for the 
aerobic formation of the N-oxide and aminal was thus formulated instead (Scheme 
1.3).  
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Scheme 1.3: Aerobic Formation of Aminal
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DMpT undergoes oxidation in the presence of air to form a radical cation (19), 
which can be isolated using TEMPO to prove formation.  This cation reacts with air 
to form the hydroperoxide (20) which reacts with another DMpT (18) molecule to 
form the alcohol (21) and N-oxide (22). The aminoalcohol finally reacts with 
saccharin to form aminal (23). 
Practically speaking, these species are only of interest if once formed they are able to 
affect the curing of the adhesive. The N-oxide was found to have no bearing on the 
cure time measured however aminal was found to greatly alter it. This was thought 
to be as a result of its ability to form metal complexes and also reduce copper ions. 
Other studies have further illustrated the positive effect aminal has on the cure time 
of copper based systems when added.
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Away from studying the cure mechanism itself, efforts in recent times have been 
made to create new compounds capable of speeding up the curing process. This has 
involved creating alternative amine cure accelerators, alternatives to saccharin and 
maleic acid, as well as attempts to form a single combined compound capable of 
carrying out the role of both. 
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Henkel have produced a series of accelerators based on the THQ and indoline 
scaffold which retain the cure activity of the parent molecule.
8
 Further to this they 
have designed and patented morpholine and benzoxazine based compounds capable 
of comparable activity to that of a 50:50 mixture of DEpT/DMoT.
29,30
 The set of 
derivatives prepared further displayed the electron environment of the aromatic ring 
as first shown by Okamoto
35
 in that when electron withdrawing groups were added, 
activity decreased, and likewise substitution with electron donating groups showed 
an increase in cure activity (Figure 1.6). 
 
  
 
 
Figure 1.6: Effect on Cure Activity of EWG and EDG 
 
In an effort to combine saccharin and the accelerator functionality into one molecule, 
acid functionalised derivatives of APH were synthesised.
45
 If the activity of 
saccharin is due to its acidic nature, then conceivably combining this property with 
an accelerator could form a compound capable to replacing both. With this in mind, 
Klemarczyk et al. reacted phenylhydrazine with cyclic anhydrides to create 
analogues of APH with acid functionality (Scheme 1.4).  
 
22 
 
 
Scheme 1.4: Reaction of Phenylhydrazine with Cyclic Anhydrides 
 
Other efforts have been made to find alternatives to saccharin while searching for 
new cure accelerators. Instead of concentrating on its acidity however, other 
compounds containing sulphonamide moieties were examined. These were based on 
various derivatives of p-toluenesulfonamide and were found to possess similar cure 
activity (Figure 1.7).
46
 
 
 
Figure 1.7: p-Toluenesulfonamide based Cure Accelerators 
 
From these studies and the species involved, there is potential for many possible cure 
accelerating mechanisms to take place. Considering the number of variables, it is 
difficult to determine which, if any, is the primary means of catalysis and perhaps it 
is in fact a result of a balance between several pathways occurring at once with 
certain systems displaying slight preferences for some over others. 
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1.4 The Necessity of Green Chemistry 
Traditionally, the means of reducing the risk or hazard posed by potentially 
dangerous substances was to reduce the level of exposure to the substance in 
question by making adjustments to the work environment such as handling, storage, 
and disposal. However, while such practices are not without merit they have no 
impact on the primary source of the exposure in the first place, the chemical. 
This is where green chemistry aims to make a difference by advocating the design of 
chemicals and synthetic pathways which minimise the use and formation of 
hazardous substances in the first place. Sheldon stated “Green chemistry efficiently 
utilises (preferable renewable) raw materials, eliminates waste and avoids the use of 
toxic and/hazardous reagents and solvents in the manufacture and application of 
chemical products.”47 Paul Anastas along with John Warner developed the twelve 
principles of green chemistry expressly outlining what should be considered when 
creating a new process or chemical and what issues should be addressed in order to 
make existing processes “greener”.48  
 
1. Prevention 
It is better to prevent waste than to treat or clean up waste after it has been 
created. 
2. Atom Economy 
Synthetic methods should be designed to maximize the incorporation of all 
materials used in the process into the final product. 
3. Less Hazardous Chemical Syntheses 
Wherever practicable, synthetic methods should be designed to use and 
generate substances that possess little or no toxicity to human health and the 
environment. 
4. Designing Safer Chemicals 
Chemical products should be designed to effect their desired function while 
minimizing their toxicity. 
5. Safer Solvents and Auxiliaries 
The use of auxiliary substances (e.g., solvents, separation agents, etc.) should 
be made unnecessary wherever possible and innocuous when used. 
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6. Design for Energy Efficiency 
Energy requirements of chemical processes should be recognized for their 
environmental and economic impacts and should be minimized. If possible, 
synthetic methods should be conducted at ambient temperature and pressure. 
7. Use of Renewable Feedstocks 
A raw material or feedstock should be renewable rather than depleting 
whenever technically and economically practicable. 
8. Reduce Derivatives 
Unnecessary derivatisation (use of blocking groups, protection/ deprotection, 
temporary modification of physical/chemical processes) should be minimized 
or avoided if possible, because such steps require additional reagents and can 
generate waste. 
9. Catalysis 
Catalytic reagents (as selective as possible) are superior to stoichiometric 
reagents. 
10. Design for Degradation 
Chemical products should be designed so that at the end of their function 
they break down into innocuous degradation products and do not persist in 
the environment. 
11. Real-time analysis for Pollution Prevention 
Analytical methodologies need to be further developed to allow for real-time, 
in-process monitoring and control prior to the formation of hazardous 
substances. 
12. Inherently Safer Chemistry for Accident Prevention 
Substances and the form of a substance used in a chemical process should be 
chosen to minimize the potential for chemical accidents, including releases, 
explosions, and fires. 
 
If we consider these as a general rule of thumb when designing new chemical 
products, and then combine them with the “twelve principles of green engineering”, 
also developed by Anastas with Julie Zimmerman
49
, which encourage the 
consideration of factors such as the production line and life-cycle of the product,   
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then the outcome is a product which poses as low a risk as possible to the user and 
the environment all the way through production, use, and disposal.  
There is an ever increasing need for new, safer cure accelerators for anaerobic 
adhesives. As we learn more about chemicals and their metabolism, hazard and risk 
labelling can change over time. When this happens, it alters the amounts and way in 
which they can be used and by continuing to include them in adhesive and sealant 
formulations, the labelling of the end product must also be changed to reflect their 
inclusion. This makes the product less attractive to the end user and the market to 
which is offered. Without coming up with safer alternatives, the only way to mitigate 
this effect is to alter the product formulation such that the harmful components only 
comprise such an amount which means their risks do not fully need to be disclosed 
on the product label. However, to do so and still retain the same performance 
requires redevelopment of the complete formulation, not to mention ignoring the 
problem at hand. 
 
Figure 1.8: Principles of Green Chemistry
48
 
 
If the new accelerators were to be designed using the principles of green chemistry 
as outlined above, then this would mean any such problems with hazard 
classification would inherently be accounted for and dealt with in the design stage as 
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the compound would have been created with the minimisation of its potential to pose 
risk in mind. 
Henkel are devoted to creating safer anaerobic adhesive products. In 2008 they 
carried out a consumer survey which revealed a demand for safer anaerobic 
products. As a result of this, in 2009 they launched the first two anaerobic adhesives 
to have a “white” MSDS sheet no containing any declarable CMR‟s or hazardous 
components, Loctite 2400 and Loctite 2700, and, in 2011 they launched a further 
three products with the same health and safety standards. These products have 
proved to be a success, largely without eating into the traditional market sales of 
anaerobic adhesives. While this represents a milestone in creating more innocuous 
anaerobic adhesives, work still needs to be done to replace harmful components and 
truly remove their risk. 
 
The aim of this research project is to not only design novel cure catalysts capable of 
replacing those established in the industry while considering these safety principles, 
but further to this, the environmental fate of the accelerators designed along with 
some of those which have already been established is to be evaluated through 
biodegradation and eco-toxicity screening. This represents the responsibility within 
green chemistry to ensure that an effort is made to make sure that any advances and 
breakthroughs made also encapsulate safety and environmental awareness as a 
design feature and do not treat it as a secondary concern to the primary challenge at 
hand. 
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Chapter 2: 
First Generation 
Cure Accelerators 
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2.1 Aim 
The overall aim of this research project was to design anaerobic adhesive cure 
accelerators which are not only of comparable cure activity to those established in 
industry, but which also do not have any of the associated safety risks for the user, 
and are readily biodegradable and environmentally friendly. 
In order to design these new, low toxicity cure accelerators however, the 
characteristics of these compounds which lead to their accelerator activity and those 
that lead to their toxicity first had to be identified. 
The approach taken to achieve this was to identify a primary set of compounds 
which were of varying accelerator activity, then establish their toxicity and 
biodegradation. This would be compiled from reported data in the literature and 
additional screening as part of this PhD project. Firstly, this would allow for 
benchmarks to be set in terms of the level of activity/toxicity of existing accelerators 
against which future compounds developed could be compared. Further to this, the 
evaluation of such compounds would also allow for conclusions to be drawn in terms 
of the structural characteristics which emphasise either toxicity or cure activity and 
therefore aid the design and development of new accelerators. 
Then by using these characteristics elucidated to develop new accelerators and 
evaluate their performance in the same areas, the more information about the 
structural-activity relationship of accelerator activity could be gathered and the 
design further refined. 
 
 
2.2 Criteria of First Generation Accelerators 
As explained above, with the first generation of anaerobic adhesive cure 
accelerators, the aim was to establish a primary set of correlation data against which 
future results could be contrasted and compared. Thus, this set of compounds was 
purposefully chosen to consist of those which were all of either – known toxicity, 
known accelerator activity, known biodegradation & eco-toxicity, or a mixture of 
these characteristics. This would, in theory, allow us to make estimations of the 
likely toxicity and/or activity of future compounds tested where one or both of these 
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properties was unknown and determine the positive/negative effects which the 
structural differences lead to. 
Also, by breaking down the overall design of new cure accelerators into these 
desired properties, a concise way of illustrating the properties of each compound 
evaluated and where they needed to be improved is provided. Namely these were: 
mammalian toxicity, anti-bacterial activity, anti-fungal activity, accelerator activity, 
formulation solubility, biodegradability, and aquatic toxicity. 
 
The structures of the compounds included in the first generation analysis are shown 
in Table 2.1 and in the subsequent sections their performance in the areas listed 
above is described. 
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Table 2.1: First Generation Accelerators 
Structures of First Generation Accelerators 
 
Diethyl-p-toluidine (11) 
 
Dimethyl-o-toluidine (12) 
 
Tetrahydroquinoline (15) 
 
Acetylphenylhydrazine 
(16) 
 
Dimethyl-p-toluidine (18) 
 
Julolidine (27) 
 
Benzoyl 
cyclohexylthiourea (28) 
 
N-Butyl THQ (29) 
 
Benzoylisothiocyanate 
(30) 
 
Indoline (31) 
 
Indazolinone (32) 
 
Benzoylurea (33) 
 
Dimethyl-m-toluidine (34)  
THQ “Diol” (35) 
 
Indoline “Diol” (36) 
 
Indole (37) 
 
Benzo[c]cinnoline (38) 
 
Isatin (39) 
 
Phthalazone (40) 
 
Phthalazine (41) 
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2.3 Anti-Microbial Results & Discussion 
In order to assess the toxicity of accelerator compounds, it would be of a great 
benefit if the need for screening methods such as mammalian testing could be 
modelled for by creating a correlation between their mammalian toxicity and a more 
accessible method of screening. 
With this in mind, anti-microbial screening was chosen whereby it was proposed that 
by screening accelerator compounds of known mammalian toxicity against several 
bacterial and fungal strains, and then comparing these two sets of values, a 
correlation could be drawn between the two properties. This would serve to create a 
much more cost-effective, quicker method of evaluating the likely mammalian 
toxicity of any accelerator candidates during the design stage. Ultimately, where lead 
compounds are then established and possess the other desired properties of an 
accelerator, further toxicity screening can be carried out to further determine their 
toxicity and risk profile. 
Anti-microbial screening was carried out at Charles University, Prague by Dr.Marcel 
Spulak as per Section 7.3 and 7.4. The anti-bacterial and anti-fungal activity of the 
first generation accelerator compounds is tabulated and discussed below. 
 
2.3.1 Anti-Bacterial Test Results 
Each compound (11-12, 15-16, 18, 27-34) was tested against eight different strains 
of bacteria listed below and where the minimum inhibitory concentration (MIC) 
value for each strain is reported as >2000 µM, no activity was observed within the 
limits of the test. For all compounds where activity was observed, the MIC is 
highlighted in bold font. 
In the case of compounds 14-20, the maximum concentration tested was 1000 µM 
due to limited solubility in the media used for screening. 
The full name of each strain is also provided after the results (Table 2.5). 
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Table 2.2: Anti-Bacterial Screening of Compounds 11-12, 15-16, 18, 27-28 
Bacterial 
Strain 
Time 
(h) 
Bacterial Response – MIC IC95 (µM) 
11 12 15 16 
(APH) 
18 27 28 
SA 24 >2000 >2000 >2000 >2000 >2000 500 >2000 
48 >2000 >2000 >2000 >2000 >2000 500 >2000 
MRSA 24 >2000 >2000 >2000 >2000 >2000 1000 >2000 
48 >2000 >2000 >2000 1000 >2000 1000 >2000 
SE 24 >2000 >2000 >2000 1000 >2000 1000 >2000 
48 >2000 >2000 >2000 1000 >2000 1000 >2000 
EF 24 >2000 >2000 >2000 1000 >2000 >2000 >2000 
48 >2000 >2000 >2000 >2000 >2000 >2000 >2000 
EC 24 >2000 >2000 >2000 >2000 >2000 >2000 >2000 
48 >2000 >2000 >2000 >2000 >2000 >2000 >2000 
KP 24 >2000 >2000 >2000 >2000 >2000 >2000 >2000 
48 >2000 >2000 >2000 >2000 >2000 >2000 >2000 
KP-E 24 >2000 >2000 >2000 >2000 >2000 >2000 >2000 
48 >2000 >2000 >2000 >2000 >2000 >2000 >2000 
PA 24 >2000 >2000 >2000 >2000 >2000 >2000 >2000 
48 >2000 >2000 >2000 >2000 >2000 >2000 >2000 
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Table 2.3: Anti-Bacterial Screening of Compounds 29-34  
Bacterial Strain Time (h) Bacterial Response – MIC IC95 (µM) 
29 30 31 32 33 34 
SA 24 >2000 250 >2000 >2000 >2000 >2000 
48 >2000 250 >2000 >2000 >2000 >2000 
MRSA 24 >2000 250 >2000 >2000 >2000 >2000 
48 >2000 250 >2000 >2000 >2000 >2000 
SE 24 >2000 250 >2000 >2000 >2000 >2000 
48 >2000 1000 >2000 >2000 >2000 >2000 
EF 24 >2000 250 >2000 >2000 >2000 >2000 
48 >2000 1000 >2000 >2000 >2000 >2000 
EC 24 >2000 >2000 >2000 >2000 >2000 >2000 
48 >2000 >2000 >2000 >2000 >2000 >2000 
KP 24 >2000 >2000 >2000 >2000 >2000 >2000 
48 >2000 >2000 >2000 >2000 >2000 >2000 
KP-E 24 >2000 >2000 >2000 >2000 >2000 >2000 
48 >2000 >2000 >2000 >2000 >2000 >2000 
PA 24 >2000 >2000 >2000 >2000 >2000 >2000 
48 >2000 >2000 >2000 >2000 >2000 >2000 
 
 
 
 
 
 
 
 
 
 
 
37 
 
Table 2.4: Anti-Bacterial Screening of Compounds 35-41 
Bacterial 
Strain 
Time 
(h) 
Compound – MIC IC95 (µM) 
35 36 37 38 39 40 41 
SA 24 >1000 >1000 >1000 1000 >1000 >1000 >1000 
48 >1000 >1000 >1000 1000 >1000 >1000 >1000 
MRSA 24 >1000 >1000 >1000 1000 >1000 >1000 >1000 
48 >1000 >1000 >1000 1000 >1000 >1000 >1000 
SE 24 >1000 >1000 >1000 250 1000 >1000 >1000 
48 >1000 >1000 >1000 250 1000 >1000 >1000 
EF 24 >1000 >1000 >1000 1000 1000 >1000 >1000 
48 >1000 >1000 >1000 1000 >1000 >1000 >1000 
EC 24 >1000 >1000 >1000 1000 >1000 >1000 >1000 
48 >1000 >1000 >1000 1000 >1000 >1000 >1000 
KP 24 >1000 >1000 >1000 >1000 >1000 >1000 >1000 
48 >1000 >1000 >1000 >1000 >1000 >1000 >1000 
KP-E 24 >1000 >1000 >1000 >1000 >1000 >1000 >1000 
48 >1000 >1000 >1000 >1000 >1000 >1000 >1000 
PA 24 >1000 >1000 >1000 >1000 >1000 >1000 >1000 
48 >1000 >1000 >1000 >1000 >1000 >1000 >1000 
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Table 2.5: Abbreviations of Each Bacterial Strain 
Bacteria Code Full Name Strain Gram 
Positive/Negative 
SA Staphylococcus 
aureus 
ATCC 6538 Gram + 
MRSA Staphylococcus 
aureus (Methicillin 
Resistant) 
HK5996/08 Gram + 
SE Staphylococcus 
epidermidis 
HK6966/08 Gram + 
EF Enterococcus sp. HK14365/08 Gram + 
EC Escherichia coli ATCC 8739 Gram - 
KP Klebsiella 
Pnuemoniae 
HK11750/08 Gram -  
KP-E Klebsiella 
Pnuemoniae (ESBL 
Positive) 
HK14368/08 Gram - 
PA Pseudomonas 
Aeruginosa 
ATCC 9027 Gram - 
 
 
 
2.3.2 Anti-Fungal Test Results 
Each compound was tested against twelve different strains of fungi listed below and 
where the minimum inhibitory concentration (MIC) value for each strain is reported 
as >2000 µM, no activity was observed within the limits of the test. For all 
compounds where activity was observed, the MIC is highlighted in bold font. 
In the case of compounds 14-20, the maximum concentration tested was 1000 µM. 
The abbreviation and information of each strain is detailed in Table 2.9.  
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Table 2.6: Anti-Fungal Screening of Compounds 11-12, 15-16, 18, 27-28 
Fungal 
Strain 
Time 
(h) 
Fungal Response – MIC IC80/IC50
a
 (µM) 
11 12 15 16 
(APH) 
18 27 28 
CA1 24 >2000 >2000 >2000 31.25 >2000 1000 1000 
48 >2000 >2000 >2000 125 >2000 1000 2000 
CA2 24 >2000 >2000 >2000 7.81 >2000 1000 2000 
48 >2000 >2000 >2000 31.25 >2000 1000 >2000 
CP 24 >2000 >2000 >2000 15.62 >2000 1000 >2000 
48 >2000 >2000 >2000 125 >2000 1000 >2000 
CK1 24 >2000 >2000 >2000 3.9 >2000 2000 >2000 
48 >2000 >2000 >2000 7.81 >2000 2000 >2000 
CK2 24 >2000 >2000 >2000 3.9 >2000 1000 >2000 
48 >2000 >2000 >2000 7.81 >2000 1000 >2000 
CT 24 >2000 >2000 >2000 125 >2000 2000 >2000 
48 >2000 >2000 >2000 250 >2000 2000 >2000 
CG 24 >2000 >2000 >2000 125 >2000 2000 >2000 
48 >2000 >2000 >2000 1000 >2000 2000 >2000 
CL 24 >2000 >2000 >2000 15.62 >2000 2000 >2000 
48 >2000 >2000 >2000 62.5 >2000 2000 >2000 
TA 24 >2000 >2000 >2000 >2000 >2000 2000 125 
48 >2000 >2000 >2000 >2000 >2000 >2000 250 
AF 24 >2000 >2000 >2000 >2000 >2000 1000 >2000 
48 >2000 >2000 >2000 >2000 >2000 >2000 >2000 
AC 24 >2000 >2000 >2000 250 >2000 1000 65.5 
48 >2000 >2000 >2000 >2000 >2000 >2000 125 
TM 24 >2000 >2000 >2000 3.9 >2000 250 31.25 
48 >2000 >2000 >2000 3.9 >2000 500 31.25 
a
IC50 values were assessed for AF, AC, and TM. For all other fungi strains IC80 
values were obtained 
 
40 
 
Table 2.7: Anti-Fungal Screening of Compounds 29-34 
Fungal Strain Time (h) Fungal Response – MIC IC80/IC50
a
 (µM) 
29 30 31 32 33 34 
CA1 24 >2000 250 >2000 >2000 >2000 >2000 
48 >2000 500 >2000 >2000 >2000 >2000 
CA2 24 >2000 2000 >2000 >2000 >2000 >2000 
48 >2000 >2000 >2000 >2000 >2000 >2000 
CP 24 >2000 250 >2000 >2000 >2000 >2000 
48 >2000 250 >2000 >2000 >2000 >2000 
CK1 24 >2000 1000 >2000 >2000 >2000 >2000 
48 >2000 2000 >2000 >2000 >2000 >2000 
CK2 24 >2000 >2000 >2000 >2000 >2000 >2000 
48 >2000 >2000 >2000 >2000 >2000 >2000 
CT 24 >2000 >2000 >2000 >2000 >2000 >2000 
48 >2000 >2000 >2000 >2000 >2000 >2000 
CG 24 >2000 >2000 >2000 >2000 >2000 >2000 
48 >2000 >2000 >2000 >2000 >2000 >2000 
CL 24 >2000 125 >2000 >2000 >2000 >2000 
48 >2000 250 >2000 >2000 >2000 >2000 
TA 24 >2000 >2000 >2000 >2000 >2000 >2000 
48 >2000 >2000 >2000 >2000 >2000 >2000 
AF 24 >2000 >2000 >2000 >2000 >2000 >2000 
48 >2000 >2000 >2000 >2000 >2000 >2000 
AC 24 >2000 >2000 >2000 >2000 >2000 >2000 
48 >2000 >2000 >2000 >2000 >2000 >2000 
TM 24 >2000 125 >2000 1000 250 125 
48 >2000 250 >2000 1000 250 250 
a
IC50 values were assessed for AF, AC, and TM. For all other fungi strains IC80 
values were obtained 
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Table 2.8: Anti-Fungal Screening of Compounds 35-41 
Fungal 
Strain 
Time 
(h) 
Fungal Response – MIC IC80/IC50
a
 (µM) 
35 36 37 38 39 40 41 
CA1 24 >1000 >1000 >1000 500 >1000 >1000 >1000 
48 >1000 >1000 >1000 1000 >1000 >1000 >1000 
CA2 24 >1000 >1000 >1000 500 >1000 >1000 >1000 
48 >1000 >1000 >1000 500 >1000 >1000 >1000 
CP 24 >1000 >1000 >1000 1000 >1000 >1000 >1000 
48 >1000 >1000 >1000 1000 >1000 >1000 >1000 
CK1 24 >1000 >1000 >1000 500 >1000 >1000 >1000 
48 >1000 >1000 >1000 500 >1000 >1000 >1000 
CK2 24 >1000 >1000 >1000 500 >1000 >1000 >1000 
48 >1000 >1000 >1000 500 >1000 >1000 >1000 
CT 24 >1000 >1000 >1000 1000 >1000 >1000 >1000 
48 >1000 >1000 >1000 1000 >1000 >1000 >1000 
CG 24 >1000 >1000 >1000 250 >1000 >1000 >1000 
48 >1000 >1000 >1000 500 >1000 >1000 >1000 
CL 24 >1000 >1000 >1000 500 >1000 >1000 >1000 
48 >1000 >1000 >1000 500 >1000 >1000 >1000 
TA 24 >1000 >1000 >1000 1000 >1000 >1000 >1000 
48 >1000 >1000 >1000 1000 >1000 >1000 >1000 
AF 24 >1000 >1000 >1000 1000 >1000 >1000 >1000 
48 >1000 >1000 >1000 1000 >1000 >1000 >1000 
AC 24 >1000 >1000 >1000 500 >1000 >1000 >1000 
48 >1000 >1000 >1000 500 >1000 >1000 >1000 
TM 24 >1000 >1000 >1000 250 >1000 >1000 >1000 
48 >1000 >1000 >1000 250 >1000 >1000 >1000 
a
IC50 values were assessed for AF, AC, and TM. For all other fungi strains IC80 
values were obtained 
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Table 2.9: Fungal Strain Abbreviations 
Fungal Code Full Name Strain Fungi Type 
CA1 Candida albicans ATCC 44859 Can be grown as 
either yeast or 
filamentous(ATCC) 
CA2 Candida albicans ATCC 90028 Can be grown as 
either yeast or 
filamentous(ATCC) 
CP Candida 
parapsilosis 
ATCC 22019 Yeast (ATCC) 
CK1 Candida krusei ATCC 6258 Yeast 
CK2 Candida krusei E28 Yeast 
CT Candida tropicalis 156 Yeast 
CG Candida glabrata 20/I Yeast 
CL Candida lusitaniae 2446/I Yeast 
TA Trichosporon asahii 1188 Yeast 
AF Aspergillus 
fumigatus 
231 Filamentous 
AC Absidia 
corymbifera 
272 Filamentous 
TM Trichophyton 
mentagrophytes 
445 Filamentous 
 
 
Using this first set of anti-microbial data, a complete correlation between anti-
microbial activity and mammalian toxicity was difficult to establish. This is due to 
an inconsistency between which compounds the screening is identifying as active 
towards microorganisms and which compounds we already know to be toxic towards 
mammals. As can be seen, many of the compounds appear to be inactive towards all 
bacterial and fungal strains. Nevertheless, there are still several important outcomes 
illustrated by this study. 
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Acetylphenylhydrazine (APH) (16) showed a high level of toxicity towards ten of 
the twelve fungal strains tested and moderate toxicity towards several of the strains 
of bacteria. This result is an example of the premise which it was hoped the study as 
a whole would clearly demonstrate i.e. APH is already known from other sources to 
be acutely toxic towards mammals, and the anti-microbial data obtained, particularly 
the anti-fungal data, is in agreement with this. Thus, this displays how anti-microbial 
testing could be used as an indicator of the toxicity of accelerator compounds 
towards mammals. 
The relationship between anti-fungal activity and mammalian toxicity does not come 
as a surprise given the cellular structure similarity of mammals and fungi. Both are 
eukaryotic and share similarities in how they synthesis proteins, replicate DNA, and 
the sterol make-up of their cell membranes. Thus, if the compound tested interferes 
with processes such as these in the fungal strains, they may also behave similarly 
towards mammalian cells. 
However, other results obtained contradicted this theory. Three of the four toluidine 
based accelerators tested (11, 12, 18) showed no toxicity towards any of the bacterial 
or fungal strains tested with the fourth (34 – Dimethyl-m-toluidine) exhibiting 
toxicity to only some of the strains of fungi. It would be expected that, given what is 
already known about the toxicity of these compounds and toluidines generally, that 
all four of these accelerators would exhibit higher toxicity. 
For the most part, the compounds tested showed little or no toxicity towards any of 
the selected microbial strains. Benzocinnoline (38) displayed activity towards all of 
the fungal strains and many of the bacterial strains tested against and of the others 
that did, julolidine (27) and benzoyl isothiocyanate (30) exhibited moderate levels of 
toxicity towards a portion of both the bacterial and fungal strains with benzoyl 
cyclohexylthiourea (28) showing toxicity towards some of the fungal strains only.  
With regards to the significance of the anti-fungal data, one should note that the 
strain, TM (Trichophyton mentagrophytes), is particularly sensitive and so any of the 
compounds which appear as toxic towards only this strain of fungi may actually not 
be particularly active. Furthermore, any which do not show any toxicity towards this 
strain could be tentatively thought of as being quite inactive. The sensitivity of the 
TM strain also allows us to construct a loose trend for increasing toxicity. For 
instance, the compounds which do not show any activity towards TM are of lower 
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toxicity than those which show only activity towards the strain, followed finally by 
compounds which possess toxicity towards TM as well as other strains: 
11-12, 15, 18, 29, 31 < 32-34 < 16, 27-28 
Looking purely at this set of toxicological data, bicyclic compounds such as those 
based on tetrahydroquinoline (THQ) and indoline scaffolds appear to be least active 
and would show the most promise as a direction of development. This is in 
agreement with how anaerobic accelerators have been developed over the years in 
that despite now knowing that THQ and its analogues are harmful, they were seen as 
safer alternatives to the continued use of toluidines and APH.  
When considering this study as a whole, even though APH was shown to be the most 
active of all the compounds tested and therefore in agreement with the original 
theory, a concrete trend between anti-fungal activity and mammalian toxicity cannot 
be constructed, at least until further testing is carried out and a larger dataset 
compiled. 
 
2.4 Biodegradation & Eco-Toxicity Study 
Fifteen of the first generation accelerator compounds were submitted for 
biodegradation and eco-toxicity evaluation at IQAC, Barcelona by Dr Teresa Garcia. 
Their biodegradation was evaluated using the CO2 headspace test (OECD Test No. 
310) under which conditions each compound must degrade by 60% over 28 days in 
order to be considered readily biodegradable (Section 7.1).  
The aquatic toxicity of the compounds was evaluated using both microtox as well as 
against daphnia magna (Section 7.2).  
 
2.4.1 Aquatic Toxicity 
Each of the fifteen compounds were submitted for both Microtox and Daphnia 
magna aquatic toxicity evaluation and the results are tabulated below.  
Under OECD standards, of the fifteen compounds analysed using Daphnia Magna, 
seven were classified as „acute toxicity II‟ (Toxic to aquatic life) and seven as „acute 
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toxic III‟ (harmful to aquatic life) with the EC50 of the remaining sample 
(Benzoylurea - 33) unable to be determined due to its low solubility.  
Comparing the compounds within the group, certain derivitisations have shown to 
have no effect whereas others have been shown to have quite a positive impact on 
the toxicity observed. Concerning the THQ‟s tested, julolidine (27) and n-Butyl 
THQ (29) show little deviation from the parent molecule THQ (15) whereas when 
the THQ “diol” derivative (35) is tested we see a sizeable decrease in the toxicity 
observed. The positive effect of this derivitisation is further illustrated by the same 
conversion being applied to indoline (31) whose toxicity has also been favourably 
altered (36). This is an example of the low logPo/w “rule” for designing less aquatic 
toxic compounds. This “rule” states that the more water soluble a chemical is, the 
less bioavailable and by extension less toxic it is to aquatic life as the chemical must 
have high enough lipid solubility to cross the cell membrane. In this case the 
addition of the diol functionality makes both compounds more water soluble and 
therefore less harmful than their similar analogues. A similar trend involving the ΔE 
(HOMO-LUMO) of compounds exists whereby the higher this value is, the less 
likely it is to be toxic towards aquatic life. 
Unfortunately experimentally determined LogPo/w values could not be found for the 
majority of the compounds and so a broader analysis of the aquatic toxicity of these 
compounds and their water solubility was not able to be made. We can nevertheless 
make estimations when designing derivatives as to whether they are likely to be 
more or less water soluble and thus design for more benign compounds. 
Concerning the Microtox results, they largely did not deviate from the same trends 
seen in the Daphnia magna assay apart from the value determined for 
acetylphenylhydrazine. The daphnia magna test generated an EC50 value of 12 mg/L 
whereas the Microtox test returned an EC50 of 104 mg/L. While these tests are not 
directly comparable and the difference likely due to the greater sensitivity of the 
molecule to one than the other, this is not uncommon as of the many eco-toxicity 
assays which exist, no one is able to evaluate every class of chemical compound 
correctly and so rather the information gained from each such be pooled in order to 
gain a larger perspective on the toxicity of a compound. 
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Table 2.10: Microtox Evaluation of Compounds 11-12, 15-16, 18, 27-36 
Compound MICROTOX 
(30 min) 
EC50 concentration 
range 
(mg/L) 
EC50 
mg/L 
IC95% 
Diethyl-p-toluidine (11) 
5.8 4.3-7.7 1 to 10 
Dimethyl-p-toluidine (18) 
4.5 2.6-8.1 
Tetrahydroquinoline (15) 
7.3 6.7-7.9 
Julolidine (27) 
5.4 3.2-9.2 
Benzoyl cyclohexylthiourea 
(28) 
1.7 1.3-2.1 
n-Butyl THQ (29) 
6.7 3.8-12 
Dimethyl-o-toluidine (12) 
2.3 2.0-2.6 
Benzoyl isothiocyanate (30) 
3.0 1.9-4.9 
Indoline (31) 
24 22-27 10 to 100 
Dimethyl-m-toluidine (34) 19 16-24 
Indoline Diol (36) 69 43-110 
THQ Diol (35) 23 16-34 
Indazolinone (32) >100 - >100 
Benzoylurea (33) >100 - 
APH (16) 104 84-129 
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Table 2.11: Daphnia Magna Screening of Compounds 11-12, 15-16, 18, 27-36 
Compound Daphnia magna 
(48 h) 
EC50 concentration 
range (mg/L) 
Hazard 
Classes 
(OECD, 2001) 
EC50 
mg/L 
IC95% 
Diethyl-p-toluidine 
(11) 
5.6 4.9-6.5 
1 to 10 
Acute toxicity 
II 
(toxic to 
aquatic life) 
THQ (15) 1.8 1.4-2.3 
Julolidine (27) 
1.6 
0.07-
6.2 
Benzoyl 
cyclohexylthiourea 
(28) 
1.1 
0.97-
1.2 
n-Butyl THQ (29) 
1.0 
0.81-
1.2 
Benzoyl 
isothiocyanate (30) 
5.9 5.1-7.9 
Indoline (31) 2.9 1.5-5.1 
Dimethyl-p-toluidine 
(18) 
13 9.8-21 
10 to 100 
 
Acute toxicity 
III 
(harmful to 
aquatic life) 
- 
Dimethyl-m-toluidine 
(34) 
50 43-67 
Indazolinone (32) 13 12-13 
Dimethyl-o-toluidine 
(12) 
29 24-39 
APH (16) 12 7.9-16 
Indoline Diol (36) 31 26-40 
THQ Diol (35) 27 26-40 
Benzoylurea (33) >50 - - - 
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2.4.2 Biodegradation Results 
Of the fifteen compounds tested (11-12, 15-16, 18, 27-36), benzoyl isothiocyanate 
(30), benzoylurea (33), and APH (16) reached the 60% pass threshold of the CO2 
headspace test and could be classified as readily biodegradable. Due to the 
experimental procedure, the set of fifteen compounds was split into two batches for 
analysis with two separate controls run. For this reason the results are split into two 
separate tables when reported.  
 
 
 
Figure 2.1: Readily Biodegradable First Generation Accelerators 
 
Of the remaining twelve compounds, Benzoyl cyclohexylthiourea (28) and 
Indazolinone (32) showed significant biodegradation over the 28 day period (33-
41%) but not enough to pass the CO2 headspace test with compounds 35 and 36 
showing little biodegradation and the remaining compounds showing no 
biodegradation. 
 
 
Figure 2.2: First Generation Accelerators which Displayed Some 
Biodegradation 
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When comparing the readily biodegradable compounds (16, 30, and 33) it can be 
seen that sites which are susceptible to enzymatic hydrolysis as well as the 
enzymatic insertion of oxygen into the molecule are key when it comes to the design 
of a less persistent organic compound. This is the main biodegradability feature of 
the three compounds shown in Figure 2.1 and forms the main basis for their high 
activity along with the remaining phenyl ring fragments, particularly where an 
aniline-like group is a conceivable metabolite, still offering quite a straightforward 
site for the oxygen inserting oxygenase enzymes.
1
 
These features can be better highlighted when 16, 30, and 33 are compared to those 
in Figure 2.2 which displayed some level of biodegradation and then to those which 
showed little to none. The majority of these contain bicyclic heterocycle fragments 
which structurally on their own are quite resistant to biodegradation as can be seen 
from the results of tetrahydroquinoline (15), 1%, and indoline (31), 1%. This is most 
likely due to the lack of positions across which cleavage or oxygen insertion can 
occur along with the electronegativity of the nitrogen making oxygen insertion of the 
aromatic ring less likely due to the electrophilic nature of this process. 
Therefore if derivatives of these structures were to at some point arrive at this base 
fragment or another similarly persistent fragment in their biodegradation pathways 
then the process would slow down dramatically. This can perhaps be seen when the 
results of the indoline diol compound (36) are compared to that of indoline. We can 
see that after 28 days 12% of the compound had biodegraded compared to 1% of 
indoline. The difference in activity is possibly due to the diol substitution at the 
nitrogen position offering a good site for metabolism to begin. However, the still 
relatively low level of biodegradation of the indoline diol could be due to the 
pathway reaching an indoline-like structure and so slowing dramatically as we can 
see in the final seven day period the total biodegradation only increases by 1%. The 
same point can be illustrated by the comparison of THQ (15) and 
tetrahydroquinoline diol (35) which biodegraded by 1% and 8% respectively over 
the 28 days.  
Further comparisons of THQ and similar structures illustrate some negative and 
ineffective ways of altering the biodegradability of a molecule. In the case of 
julolidine (27), where a third ring fused to both existing rings is added, and N-butyl 
THQ (29), where a butyl chain is added, the total biodegradation has decreased to 
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less than 1% in both cases. A general “rule of thumb” in the design of biodegradable 
molecules is that the more rings that are added to a molecule the more persistent the 
compound becomes and this indeed holds true. However, these same “rules” also 
show that adding unsubstituted alkyl chains should decrease a molecule‟s persistence 
which has not been evident in this study although this factor is only thought to have 
an impact if the chain length is at least  ≥4 carbons. 
The toluidine compounds selected for testing also demonstrated poor 
biodegradability. This is most likely due to the disubstitution of the aromatic ring 
and the presence of the nitrogen atom which makes the oxygen insertion of the 
aromatic ring less likely as the oxygenase enzymes utilise an electrophilic form of 
oxygen in order to achieve this. 
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Table 2.12: Biodegradation (First Batch) 
Compound Biodegradation (%) Inhibition 
(%) 6 
Days 
13 
Days 
21 
Days 
28 
Days 
SDS 78 85 93 93±0.7 
Diethyl-p-toluidine (11) 0 0 0 1±0.7 0 
Dimethyl-p-toluidine (18) 0 0 0 0±0.5 0 
Tetrahydroquinoline (15) 0 0 0 1±0.7 0 
Julolidine (27) 0 0 0 0±0.8 11 
Benzoyl cyclohexylthiourea 
(28) 
3 1 35 33±1.3 0 
n-Butyl THQ (29) 0 0 0 0±1 15 
Dimethyl-o-toluidine (12) 1 0 0 1±0.9 0 
Benzoyl isothiocyanate (30) 74 88 87 85±1.7 0 
Indoline (31) 0 4 0 1±0.9 0 
Indazolinone (32) 32 41 48 41±2.3 0 
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Table 2.13: Biodegradation (Second Batch) 
Compound Biodegradation (%) Inhibition 
(%) 6 
Days 
13 
Days 
21 
Days 
28 
Days 
SDS 78 87 95 91±0.6 
Benzoylurea (33) 58 89 77 91±7.1 0 
Dimethyl-m-toluidine (34) 0 0 0 0±0.5 0 
Acetylphenylhydrazine 
(16) 
22 39 70 74±4.5 0 
Indoline Diol (36) 0 1 11 12±5.5 0 
THQ Diol (35) 1 0 3 8±3.1 0 
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2.5 Prediction of Biodegradability of Cure Accelerators & –like 
Compounds 
Given the considerable amount of time and cost required to carry out biodegradation 
screening, it would be extremely advantageous if existing predictive models could be 
successfully used for the prediction of the biodegradation of accelerator compounds. 
Likewise, in order to better aid the design of non-persistent accelerators, a survey of 
existing experimental biodegradation data on accelerator-like compounds was 
conducted. This was done with the aim of providing a base set of physical data with 
which to direct the initial design process as, due to the length of time required, the 
experimental testing of only accelerator molecules to construct this data set would 
take a prohibitive amount of time. 
A number of prediction models exist which have been developed based on various 
approaches. Group contribution models have been designed from the approach that 
the overall biodegradation of a compound is determined by the contribution of its 
different chemical fragments and the frequency at which they occur. These 
fragments are defined on the basis of existing biodegradation evidence and are used 
with a training set of compounds to develop and tune the model. 
„Chemometric‟ and artificial intelligence models on the other hand have been 
developed with various statistical models at their core of determining molecular 
descriptors of importance. This can result in the descriptors having no bearing on 
observed biodegradation processes but these models can be combined with sets of 
transformation rules in order to predict not just the extent of biodegradability but 
also the pathway through which degradation occurs. 
 
2.5.1 Software Information 
The chosen model for this study was the group contribution model BIOWIN. 
BIOWIN is a set of predictive models for the biodegradation of chemicals which 
forms part of the Estimation Programs Interface (EPI) Suite developed by the United 
States Environmental Protection Agency‟s office of Pollution Prevention & Toxics 
and the Syracuse Research Corporation. The software consists of seven models 
which have been developed using different means and with different chemical 
classes and tests in mind. 
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 BIOWIN Models 1 & 22,3 are linear and non-linear regression models 
respectively which were developed using weight of evidence evaluations of 
295 compounds resulting in the determination of 36 biodegradability relevant 
chemical fragments. These 36 fragments along with the frequency at which 
they occur are combined with a chemical‟s molecular weight to determine 
how quickly a compound biodegrades. For the training set of compounds 
(295 – of which 186 degrade fast and 109 degrade slowly), both models were 
able to predict their biodegradability with >90% accuracy. 
 BIOWIN Models 3 & 44 are ultimate and primary biodegradation models 
respectively which were developed using the same 36 fragments determined 
by the same 295 compound training set for models 1 & 2. In order to semi-
quantitatively predict the time for biodegradation, a panel of 17 experts were 
surveyed by the EPA to predict the length of time, hours->months, it would 
take a series of 200 compounds to degrade in a typical aquatic environment. 
The predictions were averaged to gain a single number which was combined 
with the 36 fragments and molecular weight parameters to form the models 
which both predict the fate of the 200 compound training set with >80% 
accuracy. 
 BIOWIN Models 5 & 65 are also linear and non-linear regression models 
respectively which were developed for predicting the performance of 
chemicals in the Ministry of International Trade and Industry (MITI)-1 test. 
This is a test which is carried out under Japan‟s chemical substance control 
law and is one of the six “Organization for Economic Co-operation and 
Development” (OECD) approved tests for ready biodegradability. The 
dataset of 884 compounds was split into a 589 compound training set and a 
295 compound validation set. The relevant chemical fragments were 
determined in much the same manner as for models 1 & 2 with 42 being 
determined and this combined with a chemical‟s molecular weight is used to 
predict the ready biodegradability with both models able to predict the 
outcome of the validation set with >80% accuracy. 
 BioWin Model 76 is an anaerobic model which predicts the degradation of a 
compound under the „‟serum bottle‟‟ test conditions. 169 compounds were 
used in its development with all incorporated into both training and 
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validation stages. A total of 37 fragments were identified and molecular 
weight is not included as a parameter in its calculation. The model correctly 
predicted 90% of the compounds with Musson et al.
7
 carrying out further 
independent evaluation.  
 
 
2.5.2 Testing 
In order to carry out this study, compounds of interest were chosen from each of the 
tetrahydroquinoline, indoline, benzoxazine, and toluidine classes of accelerator. 
Beginning with the base accelerator structures for each class, changes were made 
which could be perceived to either enhance or diminish their persistence. In order to 
assess what changes the software recognised to be positive or negative, each of these 
structures were input into the BIOWIN prediction program and their performance in 
each of the seven models recorded. For BIOWIN models 1-2 & 5-7, this 
performance is either positive or negative result but for models 3 and 4 a timeline for 
the likely degradation is output. 
These results were then compiled and trends constructed in order to determine which 
structural changes were likely to increase or decrease the likelihood of a compound 
to be predicted as readily biodegradable. One could then potentially use these trends 
to aid the design of less persistent accelerators. 
In order to determine the accuracy of predictions for anaerobic accelerators, the 
software was also used to predict the fate of the fifteen “first generation” accelerators 
tested experimentally. 
A list of all structures evaluated and their results can be found in Appendix A. 
 
2.5.3 Results 
The results, with respect to what changes the models consider to strengthen/weaken 
a compound‟s biodegradability, were largely expected given what we know about 
the principles of biodegradation. 
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 The introduction of oxygen atoms, whether in the form of carbonyl, 
carboxyl, ether functionalities etc. greatly improve the biodegradation due to 
the increased propensity for hydrolysis to occur. 
 Likewise, the reduction in bioavailability caused by the addition of groups 
such as sulfonated moieties is recognised. The addition of amine and nitro 
groups also has a negative impact upon biodegradation.  
 The less aromatic or aliphatic rings in a structure, the better the 
performance, and in the case of THQ/Indoline derivatives, substitution of 
the aromatic ring improves the biodegradation greater than substitution of 
the aliphatic heterocycle.    
These points are illustrated below in the results of the best performing compounds 
from each class. 
 
Tetrahydroquinolines 
 
Figure 2.3: Best Performing THQ Based Compounds 
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Indolines 
 
Figure 2.4: Best Performing Indoline Compounds 
 
Benzoxazines 
 
Figure 2.5: Best Performing Benzoxazines 
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The tetrahydroquinolines best illustrate the points made above where the addition of 
oxygen atoms along with the substitution of the aromatic ring system results in 
greatly reduced environmental persistence. As expected given their similarity, the 
derivitisations made to the indoline compounds followed much the same trend as 
those for the THQ‟s. Strictly speaking benzoxazines BNZ12 and BNZ14 do not 
belong to the class but as changes were made to the base structure in order to study 
the effects on biodegradation, they became less similar. 
Unfortunately whilst these examples represent the best performing compounds from 
a biodegradation standpoint, this does not necessarily mean they will also possess 
anaerobic accelerator activity. Not every derivitisation made to the base structures 
could be considered positive in terms of retaining accelerator activity and so it was 
expected that some would not be useful as accelerators. Examples of such changes 
are the removal of the aromaticity of a compound such as THQ and Indoline 17, the 
movement of the nitrogen atom too far from the aromatic centre of the compound 
such as in BNZ12. Thus, if we also take the likelihood of accelerator activity into 
account, then the best lead compounds to rise from this short study would be THQ 
15 and benzoxazine 16 as they best retain the structural characteristics of an 
accelerator whilst still yielding promising predicted biodegradation results. 
It should also be pointed out that the design trends predicted to enhance 
biodegradability come as no surprise. These are largely the same “rules of thumb” 
which would already be incorporated into the design and evaluation of possible 
biodegradable compounds and so there is little necessity for prediction software to 
aid in their identification. Ultimately the applicability of the predictions made will be 
determined by the comparison with the physical data already generated. 
 
2.5.4 Comparison of CO2 Headspace Results with BIOWIN Predictions 
Using the BioWin program included in the EPI software suite, the biodegradation of 
the same fifteen compounds discussed in Section 1.3 was predicted. In order to 
evaluate the accuracy of the prediction software for structures of these types the 
results are compared below. 
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Table 2.14: Comparison of Predicted and Experimental Biodegradation Results 
Compound BIOWIN Prediction Models CO2 Headspace 
Test Result (%) 1 2 3 4 5 6 7 RB 
Prediction 
11 BF DNBF W-
M 
D-
W 
NRD NRD DNBF No 1±0.7 
18 BF DNBF W-
M 
D-
W 
NRD NRD DNBF No 0±0.5 
15 BF DNBF W-
M 
D-
W 
NRD NRD DNBF No 1±0.7 
27 BF DNBF W-
M 
W NRD NRD DNBF No 0±0.8 
28 BF BF W-
M 
D-
W 
NRD NRD DNBF No 33±1.3 
29 BF BF W-
M 
D-
W 
NRD NRD DNBF No 0±1 
12 BF DNBF W-
M 
D-
W 
NRD NRD DNBF No 1±0.9 
30 BF BF W D-
W 
NRD NRD BF No 85±1.7 
31 BF DNBF W-
M 
D-
W 
NRD NRD DNBF No 1±0.9 
32 BF BF W D-
W 
NRD NRD DNBF No 41±2.3 
33 BF BF W D-
W 
NRD NRD BF No 91±0.7.1 
34 BF DNBF W-
M 
D-
W 
NRD NRD DNBF No 0±0.5 
16 BF BF W D-
W 
NRD NRD DNBF No 74±4.5 
36 BF BF W D-
W 
NRD NRD DNBF No 12±5.5 
35 BF BF W-
M 
D-
W 
NRD NRD DNBF No 8±3.1 
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Table 2.15: Abbreviations of BIOWIN Prediction Output Results 
Abbreviation Explanation Abbreviation Explanation 
BF Biodegrades fast DNBF Does not biodegrade 
fast 
NRD Not readily 
degradable 
D Days 
W Weeks M Months 
 
Although none of the compounds (16, 30, 33) which passed the CO2 headspace test 
(Tables 2.12 and 2.13) and can be considered readily biodegradable, were predicted 
as degradable by all of the BioWin model tests,, certain loose trends can still be seen. 
The two compounds (30, 33) which showed the highest levels of biodegradation in 
the CO2 headspace test were the only two compounds to pass the BioWin model 7 
prediction, although this is an anaerobic model, BioWin may still suggest that if a 
compound is likely to be readily biodegradable it will be predicted so by this model. 
Also any compound (16, 28-30, 32-33, 35-36) which showed a biodegradation level 
of greater than 1% was predicted to biodegrade fast by BioWin model 2 which 
suggests that any compound which passes this test will degrade to some extent but is 
not guaranteed to degrade to a level where it can be considered to be readily 
biodegradable. Likewise this group of compounds is the most likely to have their 
ultimate degradation predicted to be weeks by BioWin model 3.  
It should also be pointed out where the only the disagreement between the predicted 
and the actual results was in failures of BioWin models 5 & 6 (as is the case with the 
readily biodegradable compounds 16, 30, 33) and that this is not entirely unexpected 
as the MITI-1 test is often regarded as one of the hardest tests to gain a pass result in 
and so its prediction models are equally tough to pass given they were constructed 
using physical MITI-1 test results. 
It is important to note that these correlations are loose at best and, from this set of 
data points concrete trends between the BioWin prediction software and the CO2 
headspace test cannot be constructed. It is evidence to suggest that the BioWin set of 
predictive models is not accurate enough to predict the fate of anaerobic cure 
accelerators and like compounds.  
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The main limiting factor of a group prediction model such as BioWin is the training 
set of compounds used to develop it. If there are not enough compounds of sufficient 
similarity to the compounds which the model is being used to predict, then one 
possibility is that the “rules” the model uses simply do not transfer completely from 
one class to the other and so the result may not be 100% accurate. Each model‟s 
level of accuracy is also affected by the number of positive and negative “real” 
results within the training set. If there is a large favouring of one over the other then 
the predictions which the model makes will reflect this, i.e. when a compound is 
input that the model does not completely recognise or is uncertain of then it will 
wrongly make a positive or negative prediction by default. 
 
2.5.5 Existing Data 
Whilst carrying out this predictive study, an analysis of existing biodegradation 
databases was carried out to assess the level of existing biodegradation data relating 
to accelerator and accelerator-like compounds.  
This was carried out by surveying the Syracuse Research Corporation‟s 
environmental fate database, BIODEG.
8
 This is a database of experimental 
biodegradation data in which the fate of each compound is recorded in terms of 
likely time to degrade as well as an attached confidence factor of that result which is 
based on the number of tests carried out, availability of concurring data from other 
sources, and the source itself. 
This database was examined for not only existing anaerobic accelerators but also 
molecules of similar structure whose environmental fate could aid the design of 
biodegradable cure accelerators. The results are tabulated in Appendix B and results 
are highlighted where there is a high confidence in the degradative process 
proceeding either fast or slow, as well as the results of any current accelerators. 
The data largely agrees with the trends displayed by the biodegradation study of the 
first generation accelerators in Section 1.3. For example it further illustrates the slow 
degradation of aniline/toluidine compounds where there is substitution at the 
nitrogen position. When this substitution is removed the degradation process speeds 
up, but unfortunately this substitution is also crucial in terms of maximising cure 
activity for these compounds. 
62 
 
2.6 First Generation Analysis Outcomes 
Although the evaluation of this first set of accelerators has not entirely been 
successful in building the correlations which were hoped, there are still a lot of 
encouraging outcomes. The anti-microbial tests did not match up completely with 
the known mammalian toxicity data, however, the anti-fungal data did show possible 
signs that incorporation into the estimation of mammalian toxicity is possible. This 
can be built upon with the screening of further sets of compounds but it appears that 
at least anti-fungal data may be used as a primary method of eliminating lead 
compounds and then with the addition of cytotoxicity or other toxicological 
evaluation methods, the viability of the remaining compounds could be assessed. By 
building up a broader set of screening data using non-mammalian assays, a 
correlation between mammalian and non-mammalian toxicity may then be able to be 
constructed. This approach could then also lead to more concrete assertions as to the 
source of toxicity of accelerator structures and how best to alleviate this whilst 
retaining cure activity.  
The biodegradation screening carried out determined that three of the fifteen 
compounds (16, 30, 33) passed the 60% threshold for readily biodegradability. This 
illustrated the “rules” of designing less persistent chemicals in effect which is an 
important factor that should not be overlooked as it reinforces the logic behind the 
premise on which this study hopes to design safer anaerobic accelerators. The 
biodegradation data readily displayed the positive effect of introducing structural 
components which are susceptible to hydrolysis and oxygen insertion while 
illustrating the drawbacks of modifications such as short chain alkyl substitution. 
This can also be observed in the eco-toxicity study carried out where the respective 
guidelines for the design of chemicals which are non-toxic to aquatic organisms can 
be seen quite clearly. 
Where the predicted biodegradation results did not agree in most cases with the 
actual results obtained, this is potentially due to a lack of a training set of data large 
enough for accelerator compounds to create an accurate software prediction. This 
opens up the possibility that biodegradation results obtained during this project may 
ultimately be submitted for the further development of predictive models. 
The results obtained across these initial studies and the key outcomes can be used to 
determine possible candidates for the next generation of accelerator compounds to be 
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tested. For instance, the structural subunits of APH lend it to being aquatically non-
hazardous as well as biodegradable and so alternative cure accelerators should retain 
this property for favourable comparison. However, since we already know of the 
mammalian toxicity of APH
9
, and the subsequent classification as “acutely toxic 
(category 3)” under GHS criteria,  APH is not a viable, safe accelerator. Likewise we 
can see with the THQ and indoline derivatives how the changes made to the base 
molecule have improved their biodegradability and eco-toxicity and can therefore be 
used in the selection of more environmentally friendly accelerator compounds. 
Whilst structural changes such as these may appear insignificant, in the overall 
design of a novel safer cure accelerator, the establishment of primary parameters to 
aid the incorporation of biodegradability and reduce eco-toxicity are crucial, 
particularly at an early phase such as this. 
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Chapter 3: 
Second Generation 
Cure Accelerators 
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3.1 Screening & Evaluation of Second Generation Accelerators 
Based on the screening results of the first generation accelerators examined in 
Chapter 2, fused bicyclic ring structures clearly pose a problem in terms of their 
persistence in the environment. Despite their favourable cure activity, compounds 
such as THQ and indoline are not considered environmentally friendly due to their 
classification as “toxic to aquatic life” and their poor biodegradability. They do 
however represent progress in terms of having replaced APH and DEpT amongst 
others in certain adhesives to create safer products for the user.  
They still possess some safety drawbacks, but if a group of analogous derivatives 
were to be synthesised whereby the environmental issues were addressed whilst 
retaining the cure activity, then this would result in an accelerator which is a step 
closer to be being inherently safer and environmentally benign. 
To identify molecules which could potentially address these issues, a survey of 
naturally occurring nitrogen heterocycles was carried out. If a naturally produced 
group of compounds were to be identified as cure accelerators, then they could 
possibly be intrinsically of no threat to the environment. 
 
3.2 Natural Sources of Accelerator-like Compounds 
Were a naturally occurring compound to be identified as an active accelerator, this 
could prove to be extremely advantageous. Given that this project is being carried 
out with “green” chemistry ethics in mind, identifying natural sources of accelerators 
or the building blocks required to synthesise them would fulfil a number of the 
“twelve principles of green chemistry”1. Any suitable natural product identified 
could represent a renewable feed stock which is possibly of low toxicity, both 
mammalian and to the wider environment, as well as being inherently degradable.  
To this end, naturally occurring nitrogen heterocycles were explored with a shortlist 
drawn up of any which displayed reasonable structural resemblance to existing 
anaerobic adhesive accelerators and were therefore likely to possess activity.‟ 
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3.2.1 Tryptophan 
Of the 21 common eukaryotic amino acids, there is one, tryptophan, which bears a 
striking resemblance to the structure of some known anaerobic accelerators. When 
the structure of tryptophan is examined, it can be seen quite clearly that it is very 
similar to the indoline accelerators (31, 36) which were tested as part of the first 
generation accelerator study discussed in chapter two.  
 
 
Figure 3.1: Comparison of Indoline and Tryptophan Structures 
 
Judging the molecule based on the same criteria as introduced in chapter two: anti-
microbial toxicity, eco-toxicity, and biodegradability, tryptophan compares quite 
well to some of the established accelerators. 
In terms of mammalian toxicity L-tryptophan has an oral LD50 of 16000 mg/kg (rat - 
oral)
2
 which, while not being directly comparable, is considerably less harmful in the 
context of other commonly used accelerators, acetylphenylhydrazine (LD50 oral – 
mouse – 270 mg/kg)3, and its parent molecule indole (LD50 Oral – rat 1000 mg/kg).
4
 
This results in L-tryptophan being available “label-free” as per GHS chemical hazard 
identification and would represent a significant improvement in the risk associated 
with handling anaerobic adhesive. 
Tryptophan as a molecule does not persist in the environment due to it being 
susceptible to photolysis by sunlight.
5,6
 These favourable properties coupled with the 
fact that there are established methods of its production on an industrial scale
7
 and 
readily available feed stocks make it an attractive lead target. 
Be that as it may, when evaluating the potential for accelerator activity in the 
molecule there is one significant drawback to the application of tryptophan. 
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Indoline is a compound which has already been proven to be active as an 
accelerator,
8
 but its parent molecule, indole, has very little activity even though the 
two compounds only differ by the presence of an unsaturated carbon-carbon bond. If 
we compare tryptophan to indole we can see that it can be thought of as a substituted 
indole where this bond is present and so to truly evaluate possible activity, this bond 
should be reduced. Doing so results in the compound 2,3-dihydrotryptophan which, 
in theory allows for maximised accelerator activity whilst potentially retaining the 
benefits of using an amino acid based source. From a green chemistry perspective, 
this transformation is satisfactory given that 100% atom economy is attained and the 
reactions is carried out under mild, aqueous conditions using a reusable catalyst.  
 
3.2.1.1 Dihydrotryptophan 
The preparation of dihydrotryptophan (42)  was achieved through the hydrogenation 
of L-tryptophan as outlined by Daly et al.
9
 Under the reaction conditions outlined in 
scheme 1 below, a yield of 55% was achieved.  
 
 
Scheme 3.1: Synthesis of Dihydrotryptophan 
 
The reason for this lower than expected yield is thought to be a degradation of the 
product or starting material in the reaction solvent, 1 M hydrochloric acid, as upon 
analysis of the aggregate it does not appear to be solely unreacted starting material, 
but a decomposition product. In fact, the photo-oxidation of tryptophan in solution 
has been shown to occur under room conditions
5
 as well as at low pH.
6
  
Unfortunately, the reaction must be carried out under these acidic conditions in order 
to completely dissolve the tryptophan starting material due to its low solubility in the 
reaction solvent. The reaction then must also be allowed to progress for this length of 
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time in order to ensure the optimum reaction of the starting material and balance 
between product formation and decomposition with the monitoring of the reaction by 
methods such as TLC difficult due to the marginal polarity difference between the 
starting material and product. 
Once enough material was successfully synthesised, anaerobic cure accelerator 
testing was carried out. This involved the incorporation of dihydrotryptophan into a 
test formulation of an anaerobic adhesive as outlined below in Table 3.1. 
 
Table 3.1: Test Formulation of an Anaerobic Adhesive 
Component % Weight 
Polyethylene glycol dimethacrylate 95.5 
Saccharin 0.5 
TMBH 2 
Premix 16 0.5 
Premix 17 0.5 
Dihydrotryptophan  1 
 
In order to do so the monomer and both premixes 16 & 17 are mixed for 10 minutes 
before the dihydrotryptophan (42) accelerator is added. This solution was allowed 
stir at room temperature for two hours, however, after doing so no dissolution of the 
accelerator had occurred. The mixture was therefore heated to 45C whilst stirring 
for 45 minutes after which the dihydrotryptophan appeared to have gone into 
solution. The saccharin was then added before subsequently adding the TMBH  
hydroperoxide after cooling to room temperature. 
A fixture time test was set up to evaluate the shear strength by affixing two pieces of 
grit-blasted mild steel together using the adhesive formulation such that they 
overlapped. In addition to this, black oxide nuts and bolts were thread-locked and 
sealed with the mixture in order to test the torque strength of the bond after 24 hours. 
A stability test was also carried out by leaving a sample of the formulation at 82
o
C in 
an oil bath overnight.  
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The strength of the lap shear specimens were tested by attaching a 3 kg weight to one 
of the steel pieces and measuring the time taken for the bond to fail. The joint failed 
almost immediately illustrating that no curing of the adhesive and bond formation 
had taken place. When the stability test solution was analysed after being left 
overnight, the accelerator had precipitated out of solution. This failure of the 
formulation stability rendered both the fixture time and torque strength tests null and 
void and so they were not completed. The absence of any observed curing was most 
likely due to the precipitation of the dihydrotryptophan upon cooling of the 
formulation after bond preparation. 
In an effort to study the solubility properties of dihydrotryptophan and its feasibility 
as a cure accelerator, it‟s solubility in several other monomers was examined. These 
were lauryl methacrylate, isobornyl methacrylate (IBOMA), and hydroxypropyl 
methacrylate (HPMA). 
 
 
Figure 3.2: Structures of Selected Monomers 
 
Unfortunately, dihydrotryptophan did not dissolve in any of these monomers but it 
was noted that when the pH was lowered, dissolution occurred. For this purpose 
acrylic acid was used given its use within certain adhesive formulations. It was 
attempted to prepare another test formulation using PEGMA as the monomer, 
however for every 1 g of PEGMA used, 1 mL of acrylic acid was required to 
dissolve the 1% w/w of dihydrotryptophan present. This would not accurately 
represent any anaerobic adhesive formulation and thus it was recommended that no 
testing be carried out using this mixture as the results gathered would not offer any 
comparability to other anaerobic systems. 
This occurrence represents a simple yet challenging aspect of this research project. A 
novel cure accelerator can be designed to be both of low toxicity and 
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environmentally friendly, and the time spent in order to synthesise and purify the 
compound efficiently. However, unless the molecule proves to be soluble in a 
desired monomer and anaerobic adhesive formulation, the work will ultimately 
prove fruitless as its curing activity cannot be evaluated. 
It was proposed that the preparation of a more lipophilic derivative of 
dihydrotryptophan may solve this solubility issue, for example at either nitrogen 
position. This however would require protection group chemistry in order to ensure 
that substitution only took place at the intended position and not at both nitrogen 
positions. 
In order to try and circumvent this multi-step synthesis and keep in line with the 
green chemistry approach of this project, a more straight forward solution was 
sought. The most facile way of making more lipophilic dihydrotryptophan analogues 
would be to synthesise ester derivatives. Their solubility in the PEGMA monomer 
could then be determined. This offered two synthetic routes: to reduce the tryptophan 
double bond and then carry out esterification directly on dihydrotryptophan, or to 
synthesise the tryptophan ester before reduction of the unsaturated bond.  
To determine which order of synthesis is the most efficient, the synthesis of 
dihydrotryptophan ethyl ester was attempted. Both methods were evaluated and it 
was determined that the most efficient way to synthesise dihydrotryptophan esters 
was to synthesise the corresponding tryptophan first followed by hydrogenation to 
reduce the double bond. 
 
 
Scheme 3.2: Esterification of L-Tryptophan 
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Using a modified procedure of that outlined by Kir‟yanova et al10, the methyl (43), 
ethyl (44), butyl (45), and octyl ester (46) hydrochloride salts of L-tryptophan were 
synthesised. This offered a range of lipophilic compounds with which to assess the 
solubility of dihydrotryptophan. The reduction of the double bond between positions 
two and three was then attempted as before under slightly modified conditions. 
Under these conditions the methyl (47) and butyl (48) derivatives of 
dihydrotryptophan were synthesised successfully, however the octyl ester showed no 
evidence of even partial reduction. The difference in activity displayed by the long 
chain derivative was thought to possibly be as result of the long alkyl chain 
restricting interaction between the C-C double bond and the catalyst surface.  
The methyl and butyl esters were tested for their solubility at 1% w/w in the 
PEGMA monomer to determine whether to prepare a full adhesive formulation to 
carry out accelerator evaluation or not. They too were also found to be insoluble both 
at room temperature and when heated to 50

C. Dihydrotryptophan and its methyl and 
butyl esters were also tested for their solubility in hydroxyethyl methacrylate 
(HEMA) in addition to HPMA as before but with the same outcome. 
With these results in hand, and knowing that the design “rules-of-thumb” for anti-
microbial toxicity state that the effects worsen as unsubstituted carbon chains grow 
beyond four carbon atoms in length
11
, the decision was made to move on to the next 
set of dihydrotryptophan targets. 
Derivitisation at either nitrogen position represented the next most facile position at 
which to attempt to modify the physical properties of dihydrotryptophan analogues. 
The chosen targets were N
α
-alkyl- as well as 1-alkyl tryptophan derivatives. As is 
illustrated by Scheme 3.3, their synthesis also involves the preparation of several 
intermediates which could also prove to be of interest in terms of studying their 
solubility effects and potentially consolidate the synthesis of several targets. As 
before, it was decided to first synthesise the corresponding tryptophan derivative 
before attempting reduction of the double bond to yield the dihydrotryptophan. 
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Scheme 3.3: Synthesis of 1-Butyl Tryptophan 
The preparation of 1-butyl tryptophan (52) was achieved through the boc-protection 
of L-tryptophan followed by bromo-alkylation after which the ester and boc-
protecting groups were cleaved. 
However, as was the case with Tryptophan octyl ester, no reduction of the double 
bond was observed under the same reaction conditions. Again, this could possibly be 
due to steric hindrance around the C-C double bond preventing interaction between 
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52 and the catalyst surface. Although dealing with a shorter carbon chain in this 
instance, substitution at either nitrogen position means that the effect of any 
shielding towards the unsaturated bond could be amplified.  
Many reaction conditions were tested in an attempt to establish a method of reducing 
tryptophan derivatives to their corresponding dihydrotryptophan. This included the 
variation of the reaction solvent, temperature, catalyst, time, and pH. As well as 
these direct catalysed hydrogenations, several other reductive methods were carried 
out in an attempt to achieve tryptophan reduction (Table 3.2).  
 
Table 3.2: Hydrogenation Conditions  
Entry Catalyst Catalyst 
Loading 
pH Temperature 
(
o
C) 
Solvent H Source 
1 10% Pd/C 20% w/w 2 RT THF H2 
2 10% Pd/C 10% w/w 2 RT THF H2 
3 10% Pd/C 20% w/w 7 RT THF H2 
4 10% Pd/C 20% w/w 11 RT THF H2 
5 10% Pd/C 20% w/w 2 50 THF H2 
6 10% Pd/C 20% w/w 2 RT MeOH H2 
7 10% Pd/C 20% w/w 2 RT EtOAc H2 
8 10% Pd/C 20% w/w 2 RT EtOH H2 
9 20% Pd/C 20% w/w 2 RT THF H2 
10 Pt/C 10% w/w 2 RT THF H2 
11 PtO2 2% w/w 2 RT THF H2 
12 PtO2 5% w/w 2 RT THF H2 
13 PtO2 10% w/w 2 RT THF H2 
14 Wilkinson‟s 
Cat. 
10%w/w 2 RT THF H2 
15  Rh(nbd)2BF4 
- Taniaphos 
5% w/w 7 RT THF H2 
Transfer Hydrogenation  
16 - - - 50 TFA Triethylsilane 
17 10% Pd/C 20% w/w - 50 TFA Triethylsilane 
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These included transfer hydrogenation with triethylsilane-trifluoroacetic acid as 
carried out by Lanzilotti et al using substituted indoles (Table 3.2 - Entry 16)
12
 as 
well as a modified method which incorporated 10% Pd/C as a catalyst for the 
reaction (Table 3.2 - Entry 17). 
Reductive alkylation of the indole nitrogen using sodium borohydride combined 
with the desired carboxylic acid has been proven to simultaneously reduce the indole 
bond whilst also alkylating the nitrogen
13,14
 and thus was attempted but to no avail. 
Apart from using palladium and platinum based catalysts, others based on rhodium 
were used such as Wilkinson‟s catalyst as well as a bis(norbornadiene)rhodium 
tetrafluoroborate-Taniaphos ligand system which had previously been demonstrated 
within the research group to be capable of reducing the benzene ring and double 
bond of methyl α-acetamido cinnamate under room conditions.15  
Unfortunately these alternative methods of double bond reductions did not prove to 
be successful in the case of tryptophan derivatives. Other more aggressive methods 
of double bond reduction such as using hydrazine as a source of diazene were 
considered however they bring with them considerable risk and, ultimately it was 
decided to cease development of dihydrotryptophan as a cure accelerator. 
Considerable time and resources had already been devoted in an attempt to get to a 
stage where dihydrotryptophan could be primarily evaluated for any accelerator 
activity, and so without the guarantee of it actually being cure active, the expenditure 
of further resources would have been implausible. 
The single reaction parameter that was not explored, but which may have been likely 
to have a significant effect on bond reduction was the pressure at which the process 
was carried out. By increasing the pressure under which the hydrogen gas and the 
respective tryptophan derivatives were placed, it may have been possible to convert 
them to their corresponding dihydrotryptophan. However, the capability to do so 
does not currently exist within the research centre and thus was not pursued for the 
reasons outlined above. 
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3.2.2 Purine Bases 
Another series of naturally occurring compounds which were considered when 
identifying possible natural sources as candidates for anaerobic adhesive accelerators 
were the purine bases. Along with its derivatives, purine is the most widely 
occurring nitrogen heterocycle in nature, and, coupled with the pyrimidines which 
would also be of interest, they make up the two groups of nucleotide bases forming 
DNA and RNA. 
 
 
Figure 3.3: Structures of Purine and Pyrimidine 
 
As can be seen in Figure 3.3, the structure of purine is not that dissimilar to the 
indoline and THQ classes of accelerators which have been discussed previously. 
What separates it, and makes it such an interesting target however, is the presence of 
multiple nitrogen centres. This could mean there is a reasonable possibility that 
purine and its derivatives may indeed possess accelerator activity. Furthermore, there 
is the added possibility that the extra centres could lead to increased activity, 
particularly when compared in equal mole quantities to established accelerators. If 
indeed several of the nitrogen centres were to be active in the cure acceleration 
process, then conceivably a lower amount of material could be capable of the same 
activity as some established compounds making for a more efficient formulation.  
From an environmental stand point, several purine derivatives have also been shown 
to be non-persistent in the environment. Caffeine, theophylline, and theobromine  are 
all readily biodegradable.
16
 
It must be noted that depending on the particular compound chosen, purines can be 
expensive but if they indeed were proven to possess multi active cure accelerator 
sites then the amount required for formulation could be minimal compared to the 
amount currently used for existing accelerators. 
76 
 
3.2.2.1 The Development of Purines as Possible Cure Accelerators 
Of purine and its derivatives, caffeine was chosen for preliminary solubility testing 
to determine the viability of any possible application as anaerobic adhesive cure 
accelerators. Under room conditions caffeine was not soluble in PEGMA at 1% w/w 
but with sonication at 40
o
C, dissolution in the monomer occurred and when left at 
RT for several days no precipitation from solution evident. Although not completely 
unsuitable, this meant more suitable compounds with which to evaluate the activity 
of the purine class were considered and a shortlist of those likely to exhibit a variety 
of activity was drawn up. 
 
 
Figure 3.4: Structures of Selected Purines 
  
Adenine, Guanine, and Xanthine were chosen for further investigation of purines as 
accelerators but unfortunately they too proved to be insoluble in PEGMA at 1% 
w/w. 
Thus, as with tryptophan, methods of derivitisation so as to increase their solubility 
were examined. Beginning with adenine, alkylation of the nitrogen position was 
identified as the most straight forward method of creating analogues of the structure. 
9-Butyl-Adenine (54)  was synthesised as per the method described by Lambertucci 
et al
17
 in 83% yield (Scheme 3.4). 
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Scheme 3.4: Synthesis of 9-Butyl Adenine 
 
9-Butyl-Adenine (54) proved to be soluble in PEGMA when tested and thus an 
adhesive formulation was prepared using 54 as the cure accelerator. During this 
process saccharin is added after the cure accelerator has been dissolved fully and, 
curiously, when done so, caused precipitation of a white solid which despite stirring 
would not re-dissolve. When isolated, this solid was identified as 9-butyl-adenine by 
NMR spectroscopy and indicated that a form of competing solubility in PEGMA 
may be occurring between 54 and saccharin. This was investigated further by 
attempting preparation of another adhesive formulation but this time reversing the 
order in which the two components were added. After saccharin was dissolved fully, 
9-butyl adenine was added but no dissolution occurred. It was postulated that this 
problem may be due to a charge complex formation or hydrogen bond interactions 
between the two molecules. 
 
Figure 3.5: Possible H-Bonding Interactions between Saccharin and 9-Butyl 
Adenine 
In order to try and prevent interactions such as these, the synthesis of adenine 
derivatives whereby bulky groups would serve to block possible H-bonding sites as 
well as hinder any form of charge transfer between the aromatic rings of saccharin 
and adenine was performed. These derivatives were chosen to be based on the use of 
amine protecting groups due to their inherent purpose as methods of dissuading 
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interaction as well as their necessity in the synthesis of further more complex 
derivatives should they be required. 
Using benzyl chloroformate, N
6
-cbz-adenine (55) was prepared in 41% yield
18
 and 
the tris-boc (56) protected analogue was prepared as per Dey & Garner.
19
 
 
 
Figure 3.6: Structures of Tris-Boc Adenine and N
6
-Cbz Adenine 
 
Cbz protected adenine proved insoluble in the monomer and so could not be tested to 
evaluate its cure activity but the boc protected derivative did prove to be so and an 
adhesive formulation was prepared for testing which will be discussed in Section 
3.7. 
Regarding xanthine and guanine, the preparation of their derivatives was not pursued 
due to the prohibitive amount of synthetic steps and protecting group chemistry 
required. Further to this, with the outcome of the tryptophan investigation in mind, 
the amount of time devoted to developing compounds for primary evaluation had to 
be considered. 
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3.3 Benzomorpholine 
Benzomorpholine and analagous compounds have already been illustrated to be of 
interest when developing anaerobic cure accelerators.
8,20
 At the beginning of the 
project they were outlined as possible compounds of interest in terms of exploring 
the potential of their activity. Following the results of the screening of the “first 
generation” accelerators in chapter two, the interest in exploring their activity and 
properties became of more significance. 
Specifically, this was in relation to the performance of THQ (15), indoline (31), and 
their derivatives (29, 35-36), particularly in the biodegradation evaluation as well as 
the eco-toxicity screening. All compounds were found to be persistent and the 
derivatives where there was substitution present at the N position (35, 36) were 
found to degrade slightly more than their parent compound. This suggests that this 
lack of degradation may be due to the persistence of the bicyclic ring structure. Thus, 
it was postulated that by introducing another heteroatom, such as oxygen, into the 
heterocyclic ring another “handle” for the biodegradation of the compound by 
microorganisms could be created whilst also retaining the cure activity. Morpholine 
has been shown to be readily biodegradable
21
 and so by introducing this fragment 
into the accelerator structure, degradation may possibly be directed through this, 
possibly to an aniline-like molecule which we also know to be inherently degradable.  
Likewise in terms of the toxicity displayed in the microtox and daphnia magna 
screenings, it was proposed that by introducing an oxygen atom the lipophilicity of 
the compounds would be reduced. This would reduce their ability to cross the 
membrane of any organisms and reduce their overall harm to any water borne 
entities. 
Two main routes to its synthesis were identified, the simultaneous alkylation and 
ring formation using 2-aminophenol combined with a dihaloethane
22
 or reduction of 
the corresponding benzoxazinone
23
 to form benzomorpholine (Scheme 3.5). 
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Scheme 3.5: Possible Synthetic Routes to Benzomorpholine 
 
The alkylation method was evaluated first due to the ready availability of the 
required materials. Despite successful product formation, due to the lengthy time 
required to isolate and purify the benzomorpholine, the reduction and removal of the 
carbonyl group path was evaluated. 
Despite the structural similarity, the benzoxazinone above is not a target cure 
accelerator due to the position of the carbon oxygen double bond next to the nitrogen 
centre of the molecule. It is believed that the presence of the carbonyl group alpha to 
the nitrogen affects the distribution of the electron density, specifically the lone pair 
on the nitrogen, and weakens any activity which would otherwise be present 
(Personal Communication, Henkel).  
When evaluating potential benzomorpholine derivatives for preparation, several 
factors were evaluated. Firstly the nitrogen centre stood out as both the most facile 
position at which to derivatise, but also potentially where the largest effects on 
accelerator activity could be displayed. When determining the derivatives 
themselves, none were chosen which would potentially break the “rules” of 
designing green chemicals such as adding long alkyl chains, but also given the 
structural similarities to benzomorpholine, the decision was made to include 
derivatives which were analogous to those synthesised for THQ and indoline as this 
would allow us to compare and contrast the classes of molecules more directly.  
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Figure 3.7: Benzomorpholine Target Derivatives 
 
Short chain alkyl chain derivatives were thus chosen and, depending on their 
performance in the various screenings, a larger set of targets could be drawn up. The 
N-methoxyethyl- derivative (60) was chosen due to the possibility that the ether 
group may enhance any positive effects in the environmental fate and toxicity studies 
whilst also having analogous activity to the butyl derivative in an isostere-like 
manner. 
Firstly, benzomorpholine (57) was isolated in 94% yield by reduction through 
stirring benzoxazine-3-one with 2.5 equivalents of LiAlH4 in THF at reflux.  Myrboh 
& Mizar prepared N-substituted benzomorpholines through reductive alkylation 
using sodium borohydride and the respective acid.
22
 
 
 
Scheme 3.6: Synthesis of N-Substituted Benzomorpholines 
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To a flask containing both benzomorpholine and the acid, ten equivalents of NaBH4 
were added whilst cooling before being allowed to warm to room temperature and 
stirred for three to four hours. N-ethyl- (58), N-butyl- (59), and N-methoxyethyl (60) 
benzomorpholine were synthesised by this method in 47%, 61%, and 65% yields 
respectively.  
In terms of accelerator evaluation, each of the derivatives prepared proved soluble in 
PEGMA at the required 1% w/w level for formulation. Thus, these compounds were 
tested in order to evaluate their cure activity, anti-microbial toxicity, 
biodegradability, and eco-toxicity.  
 
3.4 Anti-Microbial Evaluation of Compounds Prepared 
All of the dihydrotryptophan and benzomorpholine derivatives synthesised in the 
previous sections were submitted for screening of their anti-bacterial and anti-fungal 
activity.  It was decided not to submit any of the purines for this testing due to the 
inability to fully evaluate them as possible cure accelerators coupled with the amount 
of information which is already known about their toxicity and effects. 
Anti-microbial screening was carried out at Charles University, Prague by Dr.Marcel 
Spulak and the anti-bacterial and anti-fungal activity of the first generation 
accelerator compounds is tabulated and discussed below. 
 
3.4.1 Anti-Bacterial Test Results 
As in Chapter 2, for each of the eight strains tested against, where the MIC recorded 
is >2000 µM no activity was observed within the parameters of the test. 
Note: Due to dissolution problems in the media, dihydrotryptophan could only be 
tested to a max concentration of 500 µM. 
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Table 3.3: Anti-bacterial Activity of Second Generation Compounds 
Bacterial 
Strain 
Time 
(h) 
Compound - MIC/IC95 (µM) 
42 47 48 57 58 59 60 61 
SA 24 500 >2000 1000 2000 >2000 >2000 >2000 >2000 
48 500 >2000 1000 2000 >2000 >2000 >2000 >2000 
MRSA 24 >500 >2000 2000 >2000 >2000 >2000 >2000 >2000 
48 >500 >2000 2000 >2000 >2000 >2000 >2000 >2000 
SE 24 250 >2000 1000 2000 2000 >2000 >2000 >2000 
48 250 >2000 1000 2000 2000 >2000 >2000 >2000 
EF 24 >500 >2000 >2000 >2000 >2000 >2000 >2000 >2000 
48 >500 >2000 >2000 >2000 >2000 >2000 >2000 >2000 
EC 24 >500 >2000 >2000 >2000 >2000 >2000 >2000 >2000 
48 >500 >2000 >2000 >2000 >2000 >2000 >2000 >2000 
KP 24 >500 >2000 >2000 >2000 >2000 >2000 >2000 >2000 
48 >500 >2000 >2000 >2000 >2000 >2000 >2000 >2000 
KP-E 24 >500 >2000 >2000 >2000 >2000 >2000 >2000 >2000 
48 >500 >2000 >2000 >2000 >2000 >2000 >2000 >2000 
PA 24 >500 >2000 >2000 >2000 >2000 >2000 >2000 >2000 
48 >500 >2000 >2000 >2000 >2000 >2000 >2000 >2000 
 
 
3.4.2 Anti-Fungal Test Results 
As in Chapter 2, for each of the twelve strains tested against, where the MIC 
recorded is >2000 µM no activity was observed within the parameters of the test. 
Note: Due to dissolution problems in the media, dihydrotryptophan could only be 
tested to a max concentration of 500 µM. Thus unless otherwise stated, results for 
each strain were >500 µM. 
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Table 3.4: Anti-Fungal Activity of Second Generation Compounds 
Fungal 
Strain 
Time 
(h) 
Fungal Response – MIC IC80/IC50
a
 (µM) 
42 47 48 57 58 59 60 61 
CA1 24 >500 >2000 >2000 >2000 >2000 >2000 >2000 >2000 
48 >500 >2000 >2000 >2000 >2000 >2000 >2000 >2000 
CA2 24 >500 >2000 2000 >2000 >2000 >2000 >2000 >2000 
48 >500 >2000 2000 >2000 >2000 >2000 >2000 >2000 
CP 24 500 >2000 2000 >2000 >2000 >2000 >2000 >2000 
48 500 >2000 2000 >2000 >2000 >2000 >2000 >2000 
CK1 24 >500 >2000 >2000 >2000 >2000 >2000 >2000 >2000 
48 >500 >2000 >2000 >2000 >2000 >2000 >2000 >2000 
CK2 24 >500 >2000 >2000 >2000 2000 1000 2000 >2000 
48 >500 >2000 >2000 >2000 2000 >2000 >2000 >2000 
CT 24 >500 >2000 >2000 >2000 >2000 >2000 >2000 >2000 
48 >500 >2000 >2000 >2000 >2000 >2000 >2000 >2000 
CG 24 >500 >2000 2000 >2000 >2000 >2000 >2000 >2000 
48 >500 >2000 2000 >2000 >2000 >2000 >2000 >2000 
CL 24 >500 >2000 >2000 >2000 >2000 >2000 >2000 >2000 
48 >500 >2000 >2000 >2000 >2000 >2000 >2000 >2000 
TA 24 >500 >2000 >2000 >2000 >2000 >2000 2000 >2000 
48 >500 >2000 >2000 >2000 >2000 >2000 >2000 >2000 
AF 24 >500 >2000 >2000 >2000 >2000 >2000 >2000 >2000 
48 >500 >2000 >2000 >2000 >2000 >2000 >2000 >2000 
AC 24 >500 >2000 >2000 >2000 >2000 >2000 >2000 >2000 
48 >500 >2000 >2000 >2000 >2000 >2000 >2000 >2000 
TM 24 >500 >2000 >2000 >2000 >2000 1000 2000 >2000 
48 >500 >2000 >2000 >2000 >2000 1000 2000 >2000 
a
IC50 values were assessed for AF, AC, and TM. For all other fungi strains IC80 
values were obtained 
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Unlike the results generated for the first generation accelerators discussed in chapter 
two, there is very little existing anti-microbial or mammalian toxicological 
information for this set of compounds to compare and contrast with. What is known 
is discussed below and we can draw comparisons within the two sets of data, 
particularly where there is structural similarity of the compounds. 
Beginning with the dihydrotryptophans tested (42, 47, 48), we can see that the three 
molecules display different inhibition activity of some of the gram positive strains. 
Dihydrotryptophan (42) appears to be the most active of the group, especially when 
we compare the structure to the methyl ester (47) which displays no activity. It is 
reasonable to suggest that this inhibition may be due to the ionisation of the acid 
group. This could potentially facilitate uptake of the molecule and increase 
interaction with the cell membrane disrupting cell activity. Likewise, if we compare 
the methyl ester to the inhibition activity of the butyl ester (48), we can see that this 
trend is reversed. There is some inhibition at 2000 µM to three of the gram positive 
strains screened against and this is a representation of a general “rule of thumb” 
when designing low toxicity compounds alluded to earlier; unsubstituted alkyl 
chains will increase anti-microbial inhibition when ≥4 carbons in length. This can be 
explained somewhat by the associated increase in lipophilicity of such derivitisations 
making it more facile for the compound to cross the organism membrane. 
This same trend of dihydrotryptophan < -methyl ester > -butyl ester also exists when 
we look at the anti-fungal data and is possibly as a result of similar processes 
occurring. Whilst none of these compounds could be evaluated in terms of their cure 
accelerator activity, they still illustrated important design trends for inactive anti-
microbial compounds. 
Of the benzomorpholines examined (57-60), we can see that both the parent 
molecule (57) and the ethyl derivative (58) display activity towards two and one of 
the bacterial strains respectively with neither the butyl (59) nor the methoxyethyl 
(60) derivatives showing any selectivity. This activity however is at the limit of 
detection of the screening and so no real conclusions can be taken from this 
difference other than perhaps the possibility that it is due to molecule size or 
conformation affecting any cellular interaction. 
On the other hand, the anti-fungal data displays the opposite trend. As the chain 
length increases, so does the selectivity of inhibition towards certain fungal strains. 
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The same caution should be noted as was with the bacterial results in that the active 
concentration is at the upper limit of detection for the screening and as a result, no 
major definitive conclusion as to how to direct the design of other accelerator 
compounds should be based on these points alone. 
It was hoped that the benzomorpholines synthesised would exhibit the same 
inactivity displayed by THQ (15) and indoline (31) towards microbial organisms 
whilst performing better in other areas. However, in comparison to THQ and 
indoline, they display an increase in activity in so far as the inhibition at high 
concentrations of certain bacterial and fungal strains. Whilst not ideal, this activity is 
only observed at higher concentrations and so does not definitively prohibit the 
development of benzomorpholines should they display positive results in the other 
areas screened. 
 
In the case of 61, structurally it can be thought of as a cyclised version of APH (16) 
which was screened as part of the “first generation accelerators”.  APH was 
determined to possess activity to several of the bacterial and particularly fungal 
strains screened against.  This toxicity towards fungi was somewhat expected given 
its mammalian toxicity but with this cyclised derivative this activity has been 
removed. This may represent the formation of a safer molecule which does not 
present the same level of risk associated with APH and displays the potential for 
removal of anti-microbial activity through incorporation of chain-like substitution as 
a closed ring instead.  
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3.5 Environmental Toxicity of Compounds Prepared 
 
Table 3.5: Microtox Results of Second Generation Compounds 
Compound Microtox 
(30 min) 
EC50 concentration 
range 
(mg/L) 
EC50 
mg/L 
IC95% 
Dihydrotryptophan (42) 
28 14-55 10 to 100 
Dihydrotryptophan 
Methyl Ester (47) 
43 22-83 
Dihydrotryptophan 
Butyl Ester (48) 
49 41-58 
Benzomorpholine (57) 
49 38-62 
N-Ethyl Benzomorpholine (58) 
11 8.8-14 
N-Butyl Benzomorpholine (59) 
12 8.6-16 
N-Methoxyethyl 
Benzomorpholine (60) 
20 14-29 
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Table 3.6: Daphnia Magna Screening Results of Second Generation 
Compounds 
Compound Daphnia magna 
(48 h) 
EC50 
concentration 
range (mg/L) 
Hazard 
Classes 
(OECD, 
2001) 
EC50 
mg/L 
IC95% 
Benzomorpholine (57) 
8.9 5.7-11 1 to 10 Acute toxicity 
II 
(toxic to 
aquatic life) 
N-Ethyl 
Benzomorpholine (58) 
7.7 4.7-9.9 
N-Butyl 
Benzomorpholine (59) 
4.9 4.5-5.5 
N-Methoxyethyl 
Benzomorpholine (60) 
13 8.3-15 10 to 100 Acute toxicity 
III 
(harmful to 
aquatic life) 
Dihydrotryptophan 
(42) 
>100 - >100 - 
Dihydrotryptophan 
Methyl Ester (47) 
>100 - 
Dihydrotryptophan 
Butyl Ester (48) 
>100 - 
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The eco-toxicity of the set of compounds was evaluated using the microtox assay as 
well as against daphnia magna. Classification by OECD standards results in 
labelling benzomorpholine (57) along with its ethyl (58) and butyl (59) derivative as 
“acute toxicity II – toxic to aquatic life” with the methoxyethyl (60) analogue classed 
as harmful. The trend within these four compounds confirms that the replacement of 
the butyl substitution with the methoxyethyl derivative does indeed result in a 
decrease in the aquatic toxicity due to the increase in water solubility. The 
hypothesis was that changes such as these, as well as the introduction of an oxygen 
atom into the structure, would result in a decrease in the toxicity compared with 
THQ (15) and indoline (31) based compounds. Whilst there was a marginal change, 
this was not significant enough to change the toxicity classification. In fact, the 
overall toxicity of indoline and THQ was altered most positively by way of the 
“diol” derivatives (35, 36) synthesised. This suggests that, in terms of reducing 
aquatic toxicity, introduction of groups to increase the water solubility in more 
“free” positions as opposed to having them “locked” within a cyclic structure is 
favoured. 
There was a larger degree of contradiction between the results of the microtox and 
daphnia magna screenings concerning this set of compounds. This can be illustrated 
with the dihydrotryptophans (42, 47, 48) tested; in the latter test their EC50 was 
deemed to be >100 mg/L and so requires no toxicity classification, however the 
microtox assay places them within the 10-100 mg/L range. While this is a significant 
difference, one should highlight that no single eco-toxicity assay is accurate for 
every class of chemical compound.  
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3.6 Biodegradability of the Compounds Prepared 
 
Table 3.7: Biodegradation of Second Generation Compounds 
Compound Biodegradation (%) Inhibition 
(%) 6 
Days 
13 
Days 
21 
Days 
28 
Days 
SDS 80 93 95 97±3.6 
Dihydrotryptophan (42) 1 2 3 5±0.3 0 
Dihydrotryptophan 
Methyl Ester (47) 
0 0 0 0±0.5 0 
Dihydrotryptophan 
Butyl Ester (48) 
0 0 0 0±1.9 0 
Benzomorpholine (57) 0 0 1 0±1.2 11 
N-Ethyl Benzomorpholine 
(58) 
0 0 0 0±2.4 0 
N-Butyl Benzomorpholine 
(59) 
0 0 2 0±1.4 15 
N-Methoxyethyl 
Benzomorpholine 
(60)  
1 1 3 1±2.3 0 
 
 
The results of the biodegradation screening did not show any of the 
dihydrotryptophan (42, 47, 48) or benzomorpholine (57-60) compounds to be readily 
biodegradable. 
The dihydrotryptophans proved to be quite persistent with the methyl (47) or butyl 
ester (48) derivatives showing little to no impact on improving this level. However, 
as was discussed in section 3.2.1, tryptophan itself readily undergoes photo-
oxidation and so does not persist in the environment. Thus, it is possible that if a 
similar evaluation were to be carried out using dihydrotryptophan, this compound 
may also readily degrade abiotically when irradiated with sunlight and would not 
pose as a pollution risk. 
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It had been postulated that the introduction of the oxygen atom into the heterocyclic 
ring as in benzomorpholine would result in a THQ/indoline-like compound which 
has a much more positive environmental fate. Unfortunately this has not proven to be 
the case with no discernable level of degradation occurring for any of the derivatives. 
This set of results along with those relevant from Chapter two serve to illustrate that 
fused bicyclic ring structures are persistent by nature and if readily biodegradable 
analogues are to be found, significant alteration to the structure will have to be 
carried out. This represents a significant challenge when we take into account the 
fact that any derivitisation that does take place will in turn affect the cure activity 
and toxicity of the compound. Therefore there is a careful balance to be struck 
between the desired properties as if we design a compound solely to fulfil the 
requirements of one, then it is at the risk of comprising the performance in other 
areas.  
 
3.7 Cure Accelerator Evaluation of Compounds Prepared 
As described in section 3.2.1, the primary means of evaluating any cure accelerator 
was to perform a fixture time test. This involved the preparation of an adhesive 
formulation as per Table 3.9. 
 
Table 3.8: Formulation Parameters of Anaerobic Adhesives Prepared 
Component % Weight 
Polyethylene glycol dimethacrylate 95.5 
Saccharin 0.5 
Trigonox TMBH-L 2 
Premix 16 0.5 
Premix 17 0.5 
Accelerator 1 
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As was noted earlier, none of the dihydrotryptophans prepared were soluble in 
PEGMA at 1% w/w and so were not tested, as was also the case with all of the 
purines except for tris-boc adenine (56). The only complete class which could be 
evaluated was benzomorpholine (57) and the three derivatives prepared (58-60). 
The fixture time test involves the application of the adhesive on two pieces of grit-
blasted mild steel such that they are bonded across a half-inch overlap. The substrate 
is grit-blasted prior to testing in order to remove any oxidized metal layer present 
which would otherwise inhibit the redox curing mechanism. 
A series of these bonds are prepared and allowed to cure. At 30 minute intervals, the 
strength of a bond is tested by attaching a 3 kg weight to one of the steel pieces and 
measuring the length of time for the bond to fail. If no failure occurs after five 
minutes the bond is deemed to have set and reached the test strength specification. 
Once a 30 minute window cure time has been established, e.g. a bond failed after 30 
minutes for a particular formulation but passed after 60 minutes, then further bonds 
are prepared until this window is narrowed until the cure time is known within 5-10 
minutes, i.e. after further tests the bond was found to cure between 40-45 minutes. 
However, if the cure time was found to be too long such that the test compound was 
not of interest as a cure accelerator, no further consolidation of the cure time was 
carried out. As a reference and a control, a formulation using APH (16) as an 
accelerator was also tested. 
 
The results of the benzomorpholines and tris-boc adenine were as follows: 
Table 3.9:Fixture Times of Formulations Tested 
 Accelerator Cure Time (Minutes) 
Benzomorpholine (57) 35-40 
N-Ethyl Benzomorpholine (58) 40-45 
N-Butyl Benzomorpholine (59) 40-45 
N-Methoxyethyl Benzomorpholine (60) 40-45 
Tris-boc Adenine (56) 120-150 
APH (16) 0-5 
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For an accelerator to be considered of interest a cure time of <30 minutes is required, 
and to be of pertinent developmental interest the cure time should be approaching 
that of APH. 
As can be seen, the adenine derivative (56) is of poor cure acceleration activity. This 
however may not be exactly due to adenine or the purine class as a whole inherently 
being of poor activity but possibly due to the boc substitution present. In Chapter 1, 
possible curing mechanisms and interactions of the accelerator component were 
described and some of these such as the formation of a charge-transfer complex 
could be influenced by the accelerator molecule size and shape. If bulky groups were 
to be present as part of an accelerator, such as the three boc groups in this example, 
then they may hinder the formation of any possible charge transfer complex and 
therefore inhibit any accelerator activity which would otherwise have been present. 
Unfortunately, as previously discussed other less bulky purines synthesised (54-55) 
could not be evaluated due to their solubility properties. 
The benzomorpholines tested did possess interesting activity. One can see that the 
cure process time has been shortened significantly compared to tris-boc adenine, but 
it still is not of the level of activity exhibited by APH.  One can also see that activity 
has decreased with the substitution of the nitrogen position. This derivitisation 
affects several of the properties of the benzomorpholine molecule which may in turn 
affect the cure activity. Firstly the overall shape and size of the molecule is altered 
and for reasons which were alluded to when discussing the activity of the adenine 
molecule, this could be of significant consequence. The position of the nitrogen lone 
pair of electrons is also altered; they may possibly be of importance to activity and 
whether they interact with the aromatic ring or not, the ability to do so would be 
affected by any substitution. Accelerators can be thought of as weak bases, and their 
interaction or ability to form salt complexes with the weak acid saccharin is of 
interest in terms of a possible curing mechanism. The protonation of the nitrogen 
position would be affected by any substitution and therefore may inhibit activity.  
The decrease in activity with substitution may also be due to drop in the mole 
amount of accelerator added. Formulations are prepared based on their gram amount 
of accelerator. This does not take into account the difference in molecular mass of 
accelerators and so an accelerator with a large molecular mass will result in a lower 
concentration of accelerator molecules present compared to one of a lower molecular 
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mass. This could have a significant effect if we are to think of cure accelerators as 
playing a catalyst-like role in the process and therefore any change in mole amount 
will alter the loading and any potential impact.  
 
3.8 Second Generation Analysis Outcomes 
From the compounds screened and the attempts made to synthesise new targets, 
several key outcomes in how to design new accelerators have been determined. 
From a structure property standpoint, through the synthesis of benzomorpholine and 
its derivatives (57-60), efforts were made to enhance the biodegradability and 
decrease the environmental toxicity or fused bicyclic nitrogen heterocycles. It had 
been postulated that the introduction of an oxygen atom into the saturated ring would 
aid the improvement of both of these properties. However, from the biodegradation 
and eco-toxicity screening carried out it is clear that this has little impact on the 
persistence and potential harm of these compounds. Therefore, if possible, the 
further addition of saturated rings to any aromatic target molecule should be avoided. 
However, the cyclisation of APH (61) was observed to result in more favourable 
anti-microbial results. APH we know to be acutely toxic to mammalian life and this 
was exhibited in its anti-fungal activity discussed in Chapter 2; 61 resulted in an 
elimination of this activity towards micro-organisms and illustrated the potential 
advantages which can be gained through cyclisation.  
From the exploration of tryptophan and the purines as possible natural sources of 
accelerators, the solubility of certain classes of nitrogen heterocycles in PEGMA 
monomer is an issue. As a result of this, the solubility of classes of compounds 
should be treated as a key property used when evaluating their possible applicability 
as candidates for catalyst development. Otherwise, a significant amount of time and 
resources may be expended in an effort to simply make derivatives which are soluble 
enough just to preliminarily assess their activity. Ideally, these same resources and 
time could be better spent furthering the actual curing activity of other compounds 
and develop their properties. 
Apart from extending the time required to fundamentally assess the viability of 
compounds, this also serves to add a sometimes lengthy pathway to the synthesis of 
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the target molecule, before any steps (if needed) are even added to enhance its cure, 
toxicity, or environmental properties. 
In order to avoid these issues, the solubility of any class of compounds should be 
evaluated in detail prior to any study taking place. Doing so will allow for a more 
comprehensive structure-activity study of the molecules and how to alter their 
framework to better their cure performance, toxicity profile, and environmental fate. 
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Chapter 4: 
Imidazolium Cure 
Accelerators  
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4.1 Imidazoles – Cure Accelerator Structure-Activity Study 
In the previous studies carried out there had been an emphasis on designing and 
developing nitrogen heterocycle based cure accelerators with a view to moving to 
more natural and sustainable sources whilst enhancing their biodegradability and 
lowering their toxicity profile. However, due to the increased attention to these 
characteristics, and due to the solubility issues encountered whilst attempting to 
improve them, not as much information was elucidated about the cure accelerator 
structure-property relationship. 
In an effort to learn more about the possible source of the catalytic activity, the focus 
was switched to be able to more efficiently gain an insight into the factors which 
affect it. In order to achieve this, it would be preferential to study a class of 
compounds which were already likely to possess activity so that, as was the case in 
previous studies, significant time would not be spent developing the physical 
properties required to be able to evaluate the level activity present, much less 
improve upon it. In addition, it would be preferable to study a class of compound 
which also offers a broad scope for derivitisation so that a wider understanding of 
substituent effects could be realised. 
Imidazoles are one such class of heterocycle which fulfil these prerequisite 
conditions. They have already been utilised as cure catalysts in other types of 
adhesive systems such as epoxy resins
1,2
 and have been included in anaerobic 
systems to modify the properties of the overall bond.
3
 It would therefore not be 
unreasonable to expect that they would also be capable of modifying the cure time 
for anaerobics given their functional group and structural similarity to established 
accelerators. Moreover, the two nitrogen centres offer a facile handle with which to 
create derivatives and examine the effect on cure time. 
4.2  Determining Suitability as a Test Case 
The suitability of imidazoles for investigation was assessed through first establishing 
a set of derivatives which displayed a satisfactory variation in structure and then 
determining their solubility in PEGMA at formulation level, 1% w/w. This would 
allow for the preparation of test adhesive formulations for cure analysis and, as can 
be seen in Table 4.1, the range of imidazoles selected all displayed solubility in the 
monomer. Next, three compounds were selected from the list and evaluated to 
determine whether or not imidazoles would possess cure activity, particularly that of 
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a level which would indicate if they would be a viable test case for a structure-
activity investigation. If the activity present proved to be too low and completely 
incomparable to existing catalysts capable of practical application, then the class 
would be deemed unsuitable for investigation. 
 
Table 4.1: Solubility of Imidazole Compounds in PEGMA 
Compound Structure Soluble 
Imidazole (62) 
 
 
1-Methylimidazole (63) 
 
 
2-Methylimidazole (64) 
 
 
4-Methylimidazole (65) 
 
 
1-Methyl-2-imidazolecarboxaldehyde (66) 
 
 
1-Butylimidazole (67) 
 
 
1-Benzylimidazole (68) 
 
 
1-(3-Aminopropyl)-imidazole (69) 
 
 
N-Butyl-1H-benzimidazole (70) 
 
 
1,1-Carbonyldiimidazole (71) 
 
 
(2S,5S)-(-)-2-tert-Butyl-3-methyl-5-benzyl-4-
imidazolidinone (72) 
 
 
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Using a formulation prepared to the specification outlined in Table 4.2, the 
compounds were evaluated using a fixture time test. This was carried out through 
bonding two pieces of grit-blasted mild steel across a half inch overlap. The time 
taken for this bond to reach a cure strength capable of supporting a 3 kg weight for 
five minutes was then recorded and used as an indication of the catalyst 
performance. To do so, a series of bonds were initially prepared in tandem and were 
tested at 30 minute intervals. Once a preliminary 30 minute cure window had been 
established, further series‟ of bonds were then prepared and tested until a five minute 
cure time window was achieved. To be considered of possible practical interest, an 
accelerator should lead to a cure time in this evaluation test of <30 minutes and for 
comparative purposes, as well as to act as a control, the cure time of 
acetylphenylhydrazine was also measured. If the initial 30 minute window 
established was deemed to be too long, then no further refinement of the cure time as 
carried out. 
 
Table 4.2: Test Formulation Parameters 
Component % Weight 
Polyethylene glycol dimethacrylate 95.5 
Saccharin 0.5 
Trigonox TMBH-L 2 
PM 16 0.5 
PM 17 0.5 
Accelerator 1 
 
Table 4.3: Fixture Time Results of Selected Imidazoles  
Compound Cure Time (minutes) 
Imidazole 10-15 
1-Methylimidazole 15-20 
2-Methylimidazole 15-20 
APH 0-5 
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4.3 Selecting Compounds for Investigation 
In both preliminary evaluation screenings the imidazoles examined indicated that the 
class of compound would be suitable as a test case for a structure-activity 
investigation into anaerobic cure accelerator activity. Not only do they possess 
adequate activity comparable to catalysts capable of commercial application, but 
they also may be derivitised without the loss of monomer solubility. This allows for 
the examination of the effects of various structural changes on activity without 
investing significant time in the design and synthesis of compounds which ultimately 
may not be evaluated as in previous studies. 
Thus, in addition to the compounds examined as part of the preliminary study in 
Table 4.1, a set of imidazole compounds of possible significance with regards 
accelerator structure-activity were drawn up. This was done so based on their readily 
availability as well as structural variety.  
In Chapter 1, possible curing mechanisms as well as possible active cure accelerator 
compounds and their role were described. One such possibility was the formation of 
salts within the product formulation which then proceed to act as the active 
accelerator molecule as opposed to any of the respective neutral formulation 
components.
4
 These salts are formed as a result of interactions occurring between 
acidic species, such as saccharin, and alkaline species, such as the amine cure 
accelerators present. The very fact that the catalytic compounds currently used are all 
largely alkaline in nature gives encouragement to the possibility that the accelerating 
component could indeed be a salt. Scheme 4.1 shows the salt formed between 
dimethyl-p-toluidine and saccharin for example. 
 
 
Scheme 4.1: Formation of DMpT-Saccharin Salt 
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By examining the imidazole family, this represents an excellent opportunity to study 
the activity of salt compounds as cure accelerators. Imidazolium salts can be 
synthesised by protonation or quarternarisation of the N-3 position and have been 
applied across a range of areas, particularly as ionic liquids.
5
 They may also be used 
as a source of carbenes
6
 which could potentially play a unique role in the mechanism 
of the radical polymerisation process. One of their applications has been use as 
catalysts for a host of reaction types, importantly including polymerisation reactions. 
One of the expertise of the research group is the design and synthesis of novel green 
nitrogen heterocycle based ionic liquids. This provides access to a vast amount of 
knowledge regarding the alteration of charged heterocycle structures to improve their 
toxicity and biodegradability as well as to the methodology required to make and 
library of novel compounds.  
Although the emphasis of this study was to be centred on the cure properties of 
accelerators, consideration was still given to the potential toxicity and environmental 
impact of imidazole based compounds. Histidine may be considered a substituted 
imidazole and as an amino acid offers a sustainable, potentially safer alternative. For 
these reasons it would extremely favourable if this amino acid were to possess 
accelerator activity comparable to that of the unsubstituted parent compound. To this 
end a selection of histidine based compounds as well as imidazolium ionic liquids 
were preliminarily assessed as before by evaluating their solubility in PEGMA at 1% 
w/w (Table 4.4). 
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Table 4.4: Solubility of Histidine and Ionic Liquid Compounds in PEGMA at 1% w/w 
Compound Structure Soluble 
DL-Histidine (73) 
 
 
D-Histidine 
monohydrochloride 
(74)  
 
L-Histidine methyl 
ester dihydrochloride 
(75) 
 
 
N,N-Dimethylhistidine 
hydrochloride hydrate 
(76) 
 
 
L-2-Thiohistidine (77) 
 
 
2,4,5-
Triphenylimidazole 
(78) 
 
 
1-Butyl-3-
methylimidazolium 
chloride (79) 
 
 
1-Butyl-3-
methylimidazolium 
octyl sulfate (80) 
 
 
1-Butyl-3-
methylimidazolium 
tetrafluoroborate (81) 
 
 
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1-Butyl-3-
methylimidazolium 
hexafluorophosphate 
(82)  
 
1-Butyl-3-
methylimidazolium 
Acetate (83) 
 
 
2-Amino imidazole 
sulfate (84) 
 
 
AJ169 (85) 
 
 
AJ189 (86) 
 
 
MG135 (87) 
 
 
MG168 (88) 
 
 
MG168 NTf2 (89) 
 
 
HP58 (90) 
 
 
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Unfortunately, as with the tryptophan amino acid compounds examined previously, 
all histidine derivatives proved to be insoluble and so were not tested further. This 
was the case for both the free base analogues as well as the hydrochloride/hydrate 
salts and the decision was made not to pursue any derivitisation to increase their 
formulation solubility until more was known about the potential application of 
imidazoles as accelerators. The ionic liquids showed much more promise on the 
other hand. The examples tested were all largely soluble meaning that the presence 
of any cure activity could be evaluated. Be this as it may, if we are to take a closer 
look at the solubility, derivatives with a halide counter ion are generally insoluble. 
The effect of larger anions such as bistriflimide should therefore not be ignored as 
they appear to be more adept at solvating the molecule in the monomer. This can be 
seen directly in a comparison of compounds 88 and 89 where the bromide derivative 
is insoluble yet the bistriflimide soluble, and likewise with the BMIM compounds 
evaluated. This is an example of how ionic liquids offer an extra dimension when 
altering the properties of a molecule - the solubility of the compound is increased 
through replacing the counter-ion whilst not drastically changing the heterocycle 
scaffold allowing for its cure activity to be evaluated. With neutral compounds it 
would have been required to directly alter the heterocycle structure to confer 
solubility and thus the possibility that in the process end up with an unrealistic 
accelerator molecule.  
As well as evaluating some more common place imidazolium ionic liquids such as 
the 1-butyl-3-methylimidazolium derivatives, several novel compounds were 
included. Within the research group exists a large library of ionic liquid compounds 
synthesised as part of other research projects. The availability of these compounds 
allowed for the ready investigation of the effect of different functionalisations on 
solubility and then potentially their impact on cure activity (85-90). Compounds 85 
and 86 can be thought of as phenylalanine ester functionalised imidazoliums and it 
was postulated that the introduction of further nitrogen heterocycle fragments may 
have a positive effect on cure activity whilst also being a sustainable means of 
derivitisation. Compounds 87-89 on the other hand contain ethylene glycol 
substitution and were included in the evaluation study in order to assess their impact 
on solubility. If the presence of ethylene glycol chains could be shown to have an 
enhancing effect on the level of solubility in PEGMA, this could then be used as a 
method of solubilising and “delivering” heterocyclic fragments designed for 
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maximum catalytic ability. As a short chain ester, compound 90 acted as a 
comparison to the BMIM compounds evaluated as well as to 87-89. Unfortunately, 
the ethylene glycol functionalization did not turn out to possess any discernable 
effect on solubility in PEGMA at 1% w/w with the solubility of 87 and 89 attributed 
to the bistriflimide counterion. Figure 4.1 contains further structural analogues of the 
soluble compounds 86 and 87. After they had proven to be soluble the decision was 
made to evaluate whether similar compounds comprising of a different heterocycle 
head group or amino acid ester could be evaluated. This included the addition of 
pyridinium, morpholinium, dimethylaminopyridinium, and cholinium head groups 
combined with phenylalanine and tyrosine esters of varying chain length. If soluble, 
this would have allowed for the evaluation and comparison of a wide range of ionic 
liquids and the determination of effects of factors such as varying nitrogen 
environment or alkyl chain length/lipophilicity. Given that these compounds have 
been developed as part of other research projects with similar toxicity and 
biodegradation goals in mind, the presence of any cure accelerator activity would 
open up a wide range of anti-microbial and biodegradation data for the development 
of anaerobic polymerisation accelerators. Unfortunately all compounds proved 
insoluble at 1% w/w and so could not be included for catalytic activity estimation. 
This could possibly again be due to the halide counterion but was still somewhat 
unexpected, particularly in the case of 96 which only differs from 86 by the 
extension of the ester chain by two carbons. 
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Figure 4.1: Selected Ionic Liquids from Other Projects which were Insoluble in 
PEGMA 
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4.4 Cure Activity Evaluation of Soluble Compounds 
The catalytic activity of the imidazoles in Table 4.1 was evaluated along with some 
of the ionic liquid compounds identified which proved to be soluble in PEGMA. 
This was carried out using the fixture time test as described in Section 4.1.  
The fixture time test offers a good method of evaluating the level of cure activity any 
catalyst may have and identifying potential lead compounds. If this initial test then 
results in a compound of interest, i.e. of comparable activity to a commercial cure 
accelerator such as APH, the molecule may be marked for further development 
and/or evaluated in a complete series of cure time/strength tests. For the purposes of 
this screening, the accelerators were added at a level of 1% w/w when preparing the 
adhesive formulations. This is representative of current anaerobic adhesive products 
and the amount of accelerator contained within. 
 
Table 4.5: Fixture Time Results of Compounds Analysed 
Compound Cure Time Molecular Weight (g/mol) 
62 10-15 68.08 
63 15-20 82.11 
64 15-20 82.11 
65 15-20 82.11 
67 30-40 124.19 
68 80-90 158.20 
72 60-120 246.35 
80 0-5 348.50 
86 60-70 480.45 
87 80-90 493.39 
89 130-140 565.50 
1-Acetyl-2-phenylhydrazine 0-5 150.18 
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As can been from the results in Table 4.5, unsubstituted imidazole (62) as well as its 
methyl derivatives (63-65) all performed well in the screening, displaying activity 
similar to that of APH. This in itself was not hugely surprising given that they have 
been used as cure catalysts for other adhesive systems to good effect. The 
performance of 1-butyl-3-methylimidazolium octyl sulfate (80) however was a 
stand-out result performing to the same level as APH which has been used in many 
commercial adhesive products. Ionic liquids have not been explored in depth as cure 
catalysts previously but this result represents the possibility that they may be applied 
as such and opens up a new avenue for the design of cure accelerators. As noted 
earlier, their nature as being essentially two separate components attracted only by 
charge offers more freedom to develop and tweak their properties by altering the 
structural make-up of either the cation or anion to enhance performance in one area 
while retaining the performance in another by leaving the other untouched. This 
extra dimension for development possibly makes the charge of combining high cure 
activity, low toxicity, and biodegradability more achievable given the wide scope of 
charged compounds which may be combined. Their unique physical properties also 
represent different possibilities as to how cure accelerators affect the overall radical 
polymerisation mechanism. For example, ionic liquids have been applied as solvents 
in many other areas and their activity in this case could be due to enhanced solvation 
of the transition metal ions at the surface interface making them more accessible to 
the redox process. Likewise the same effect could be achieved if the transition metal 
ions were to exchange with the cation of the ionic liquid to form a new complex. 
In terms of the effect of further derivitisation on the cure performance, it appears that 
as the molecule size gets bigger, the more the cure rate slows. However, one cannot 
definitively say based on these results that the size or conformation of the catalyst 
directly impacts the curing mechanism. Instead, this serves to magnify an issue 
which is brought about by the subtle differences between commercial product 
development and chemical research into novel substances. 
The specification of products for purposes of formulation and production are 
measured in gram amounts in order to be as streamlined and user friendly as 
possible, particularly in any environment where the person(s) involved may not have 
a chemistry background. On the other hand, when working with chemicals, and 
especially where two or more compounds need to be directly compared, the logical 
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approach is usually to use mole units of material. This was not as pertinent an issue 
where small molecules were being compared by activity per gram amount used as 
they were of comparable molecular weight, for example diethyl-p-toluidine (163.26 
g/mol) and APH (150.18 g/mol), and thus of comparable mole amount. Add to this 
the fact that as established accelerators, the rest of the product formulation 
components and the amounts used have been carefully optimised to achieve the most 
efficient cure performance from them. In the case of this study however, a 
representative formulation comparable to that of a commercial adhesive was used 
and each compound of interest was simply “swapped” using the same gram amount 
across the series without any further optimisation and without any previous 
knowledge of how that compound may interact with a polymerisation reaction. In 
order to be able to draw conclusions from a SAR study such as this, there is an 
inherent need to be able to directly compare different chemical compounds 
regardless of mass or conformation. This is something which becomes quite difficult 
where we have molecules which differ greatly in terms of their molecular mass, for 
example 100 mg of 1 = 1.6 mmol whereas the same amount of 25 = 0.17 mmol. In 
this example there is a difference of almost one order of magnitude between the two 
accelerators and, without knowing whether or not the accelerator amount affects the 
cure rate observed, we cannot compare with any degree of confidence the two results 
achieved. To this end, a study on the relationship between accelerator amount and 
activity was carried out. 
 
4.5 The Effect of Accelerator Amount on Cure Activity 
In order to examine the effect of catalyst amount on cure activity, several adhesive 
formulations were prepared as per Table 4.2 differing only in the amount of 
accelerator added. For this study APH was chosen as the accelerator of interest due 
to its establishment in the role. To carry out the fixture time evaluations described, 
10 g formulations were prepared of which the accelerator comprised 1% w/w or 100 
mg. This is equivalent to 0.7 mmol of APH and thus in addition to this amount, 
samples were prepared using 0.1-0.5 mmol as well as 1.5 mmol of APH. The method 
used to evaluate the samples was the fixture time test as before with the results 
presented in Table 4.6. 
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Table 4.6: Cure Activity of APH at Varying Concentrations 
Amount 
(grams)  
Amount 
(mmol) 
Accelerator % w/w of 
Overall Formulation 
Cure Time Range 
(minutes) 
0.015 0.1 0.15 15-25 
0.030 0.2 0.30 5-10 
0.045 0.3 0.45 5-10 
0.060 0.4 0.60 5-10 
0.075 0.5 0.75 0-5 
0.100 0.7 1 0-5 
0.23 1.5 2 0-5 
 
From this data generated one can see that the amount of accelerator added does 
indeed have an effect on the time required for curing to occur. As the amount of 
accelerator is increased, the more quickly polymerisation occurs. Although this 
factor may be reasonably self-evident, it is important to note that no study on the 
effect of cure accelerator concentration on cure speed for anaerobic adhesives had 
been published previously. Catalyst loading is no doubt an important reaction 
condition in any catalytically altered process but the extent to which it interacts 
varies for each unique catalyst and application. In the case of using APH as the 
catalyst, this appears to have a low impact but nonetheless indicates that for true 
comparisons to be drawn between any novel cure accelerators evaluated, the mole 
amount used must be consistent so as to avoid any erroneous conclusions. It should 
also be noted that the effect of accelerator loading on cure time was carried out using 
the fixture time test and not another means of observing the polymerisation time as 
the shortest cure time may not always result in a strong adhesive bond, and for the 
purposes of this investigation, bond formation of adequate strength is just as 
important as the cure time. 
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4.6 Re-Testing - Concentration Studies 
The compounds examined in Section 4.3 were retested at three concentrations, 0.2, 
0.7, and 1.5 mmol, using the fixture time test as before.  By doing so this allows for 
the direct comparison of the cure speeds measured and conclusions based on the 
structural properties of each compound to be drawn. 
Table 4.7: Cure Activity of Compounds Analysed at Multiple Concentrations 
Compound Accelerator Amount – Cure Time (minutes) 
0.2 mmol 0.7 mmol 1.5 mmol 
62 120-240 10-15 10-15 
63 120-180 20-30 10-20 
64 120-180 20-30 0-5 
65 120-180 5-10 0-5 
67 60-120 30-40 15-20 
68 80-90 80-90 10-20 
72 - 100-180 60-70 
80 0-5 0-5 0-5 
83 40-45 0-5 15-20 
86 60-70 20-25 15-20 
87 80-90 30-35 40-50 
89 130-140 20-30 >150 
1-Acetyl-2-phenylhydrazine 5-10 0-5 0-5 
 
Analysing each potential cure accelerator at different concentrations yielded several 
key outcomes. The results suggest that there is indeed a relationship between 
accelerator size/conformation and activity. A general trend can be constructed from 
the data whereby as the molecular mass of the catalyst increases, the activity 
decreases. Depending on how the accelerator affects the curing mechanism this may 
mean that bulky molecules are not able to fit or interact at the active site. This may 
be with the metal substrate surface or one of the other components present in the 
formulation. 
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The screening also highlighted another issue when evaluating novel cure catalysts. 
The activity increased with accelerator concentration in almost all of the cases 
analysed. In the case of compounds 87 and 89 however, we see the shortest cure time 
is between 0.2-1.5 mmol as at the 1.5 mmol point the cure time increases from that 
measured using 0.7 mmol, The presence of too many accelerator molecules actually 
begins to inhibit cure speed and this  yields the complication that if there may be a 
“bell-shaped” relationship for every compound where without analysing activity at 
many more catalyst loadings there is no way of knowing where along the curve the 
data points are. For example, the optimum activity concentration of compound 2 may 
in fact be between 0.7-1.5 mmol despite the fact that the cure speed appears to have 
increased by raising the concentration. Increasing the catalyst amount can also in 
some cases lead to solubility issues and therefore may mean some cannot be 
evaluated at higher concentrations; this solvation issue may somehow be responsible 
for the “bell-shaped” curves of compounds 87 and 89 observed given that they are 
two of the larger compounds analysed.  
As noted in the analysis at 1% w/w loading, the performance of BMIM octyl sulfate 
(80) is at a level whereby it may be considered a lead compound and of great 
interest. In order to learn more about this result and the possible source of activity, 
another BMIM derivative was included for analysis in this screening. BMIM acetate 
(83) was obtained through the anion metathesis of BMIM chloride with silver acetate 
and differs only in the counterion present but having the added advantage of being 
considered hazard free. At 0.7 mmol 83 displayed the same activity as the octyl 
sulfate analogue (80) and APH indicating that the BMIM scaffold is capable of 
significantly altering the cure time. Despite this however, the performance at 0.2 and 
1.5 mmol of 83 is lower than APH and 80. Nonetheless, on a broader scope it is 
further evidence to support the exploration of ionic liquids as catalysts for redox 
radical polymerisations. 
The level of deviation of activity whilst varying concentration may offer an 
indication of how reliable or robust an accelerator is. Although there is a change in 
cure speed, APH largely retains its performance across the concentrations analysed 
and 80 does not vary at all, whilst we see in other cases that where they perform very 
well at one concentration, they vary massively when this is altered. This displays that 
some of the compounds are very sensitive to concentration change and is another 
way in which the potential of any novel accelerator can be evaluated. Given that 
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BMIM octyl sulfate (83) does not vary at all across the concentration levels tested at, 
then this is only further evidence to strengthen its viability as a lead compound. 
 
4.7 Conclusions 
In the studies described in the previous chapters more priority had been paid to the 
development of anaerobic accelerators with respect to improving their toxicity and 
environmental persistence. Not as much information about the source of their 
catalytic activity had been elucidated as a result but this was partially due to the 
compounds synthesised not possessing the required physical properties, i.e. 
solubility in the formulation monomer, and not neglect of the importance of this 
aspect of the research. This created a necessity for a concerted effort to be made to 
study a class of compounds which could provide an insight into the cure 
accelerator‟s role in the polymerisation mechanism. Suitable test candidates were 
therefore required to be able to undergo wide structure derivitisation without the loss 
of solubility in PEGMA so that the effect of structural changes on activity could be 
investigated. These prerequisites resulted in the selection of imidazoles for 
investigation as preliminary tests showed widespread solubility of imidazole based 
compounds in the monomer at 1% w/w as well as promising cure activity. Not only 
were they suitable, they also offered the opportunity to study other aspects of the 
cure mechanism through synthesis of charged imidazolium compounds. 
The evaluation of this range of imidazoles resulted in several key outcomes. The 
preparation of the adhesive formulations first had to be altered in order to account for 
and create comparability between all compounds analysed. It was found that the 
catalyst loading in the formulation can have a large impact on the rate of curing 
observed. Generally speaking activity increased with the addition of more catalyst 
however several results pointed to the possibility that this relationship between 
activity and concentration may deteriorate at higher catalyst concentrations where 
the accelerator will eventually begin to inhibit the curing process.  
Most importantly, the testing of these compounds resulted in the identification of 
lead cure accelerator compounds. In the fixture time test, BMIM acetate (83) and 
BMIM octyl sulfate (80) yielded the same performance as the commercial 
accelerator, APH. BMIM octyl sulfate resulted in faster cure times at lower 
concentration than APH and this extent of activity in the two molecules is thought to 
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be as a result of the imidazolium cation. The difference in performance between the 
two compounds suggests that the anion does play a role however, and as pointed out 
earlier, variation of the counterion present could assist in enhancing the safety and 
environmental aspects of the compound while the cation retains the accelerator 
activity. For example, in this scenario BMIM octyl sulfate (80) is considered an 
irritant whereas BMIM acetate (83) is label-free. 
For these reasons they are deserving of further analysis as cure accelerators and 
imidazolium salts as well as ionic liquids as a whole should be explored as sources 
of new anaerobic cure accelerators. Their potential for structural variation allows for 
a wide range of possibilities with which to optimise their cure activity and explore 
the mode of action.  
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5.1 Identifying Lead Cure Accelerators 
In the previous chapter the discovery of the use of 1-butyl-3-methylimidazolium  
(BMIM) based ionic liquids as anaerobic cure accelerators was detailed. Through use 
of the fixture time test to analyse various imidazoles and imidazolium salts, two 
compounds which performed at and above the level of the commercially used cure 
catalyst, APH, were identified. These were the octyl sulfate (80) and acetate (83) 
salts of butyl-3-methylimidazolium which displayed optimum performance when -
incorporated at a level of 0.7 mmol as part of a 10 g formulation. Given the catalytic 
efficiency displayed by the molecules, the decision was made to fully evaluate them 
as potential anaerobic adhesive cure accelerators by carrying out complete lead 
adhesive formulation testing. 
Further to this, the results of the two compounds, (80) and (83), along with the 
potential shown by the other ionic liquids analysed, meant that the alkyl 
imidazoliums as well as nitrogen heterocycle based ionic liquids as a whole merited 
further development and investigation. Given that anaerobic cure accelerators are all 
nitrogen containing compounds, the better of which are in addition usually aromatic, 
the source of the activity displayed was thought to be due to the cation portion of the 
ionic compound. There is little evidence to support the use of non-nitrogen based 
compounds as cure accelerators and so, despite the octyl sulfate and acetate 
analogues possessing differing performance the initial understanding was that the 
anion would not be cure active. This difference could instead be explained by the 
octyl sulfate and acetate anions leading to differing physical properties such as 
solvation. This in turn would affect how each molecule may interact with the other 
formulation components as well as the overall polymerisation mechanism resulting 
in contrasting results. 
By altering the structure of the imidazolium cation, and by varying the anions used, 
it was postulated that more could be learned about the structural characteristics 
behind the cure activity and how the level of performance can be controlled and 
modified. Alteration of the chemical structure also offered an opportunity to examine 
the effect on cytotoxicity and anti-microbial toxicity. 
 
118 
 
5.2 Full Performance Testing of Lead Compounds 
In the evaluation tests, BMIM octyl sulfate (80) and BMIM acetate (83) both 
performed to a level of cure accelerators already used commercially. In order to 
examine the extent of this activity and indeed their applicability as possible 
commercial cure catalysts, a full anaerobic adhesive evaluation was carried out 
where they were incorporated into the formulation. 
These methods involve preparing a formulation using the cure accelerator of interest 
and then applying it in tests more representative of practical applications to generate 
an indication of its performance capabilities. Namely, these are tests using nuts and 
bolts (ISO 10964) which give an indication of their ability to act as thread lockers or 
sealants, and pins and collars (ISO 10123) where the shear strength of the adhesive is 
determined. 
 
                      
Figure 5.1: Pin and Collar Shear Strength Test Setup 
 
The pin and collar test is comprised of a cylindrical pin and a collar which fits 
around it but which leaves a small gap between the two surfaces. Both specimens are 
prepared by going through a degreasing process to remove any residues which may 
interfere with the adhesive curing and are made of mild steel with a smooth surface. 
Adhesive is applied to both substrate surfaces such that the gap between the two is 
bonded and the specimen supported for the duration of the cure. The shear strength 
of the adhesive bond formed is then measured by placing the test specimen on a 
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stage where a load is applied to the pin and the force and pressure required to move 
the pin through the collar measured (Figure 5.1). 
The nuts and bolts evaluation is carried out by applying adhesive to the bolt and 
assembling the nut and bolt joint. After the specified cure time, the test specimen is 
placed in a torque analyser and the torque required to break the bond formed is 
measured. The initial break torque is measured along with the prevail torque (180

) 
and the maximum torque reached. The break torque is the force required to initially 
break the bond and move the nut, the prevail torque is the force required to achieve 
continuous movement of the nut with the maximum torque being the maximum 
resistance reached when rotating the nut. The significance of prevail torque as 
compared to break torque is that the break torque is the force required to cause an 
initial break in the adhesive seal or “lock” formed, whereas the prevail torque is the 
force required to actually move the nut along the threads or, in practical terms, 
loosen and remove the nut from the bolt. This would be significant in an 
environment where the bond has to withstand prolonged levels of vibrations which 
otherwise would cause the nut to move. 
As another measure of the formulations activity, the nuts and bolts test is carried out 
using test specimens made from more than one grade of metal. The strength of the 
adhesive is measured using black oxide bolts coupled with mild steel nuts as well as 
stainless steel nuts and bolts. With stainless steel, the steel has been protected by 
adding a certain amount of chromium to the alloy. This chromium protects the steel 
by oxidising to form chromium oxide which forms an inactive layer preventing 
further oxidation of the either the chromium or iron present. In doing so, this restricts 
any redox interaction of the metal ion species with the adhesive and so the reaction 
cannot be initiated and thus no bonding occurs.  
The surface of black oxide nuts is much more active in comparison, here the iron has 
been reacted to form an iron oxide where there are both Fe
2+
 and Fe
3+
 species 
present, Fe3O4 ((Fe
2+
(Fe
3+
)2O4) – Magnetite), and as such interacts with and initiates 
the polymerisation and bond formation much more efficiently.  
The pins and collars used for evaluation are made from mild steel. This is an alloy of 
steel where there is no significant content of chromium or any other element which 
could lead to surface inactivation and as such the iron molecules present are free to 
take part in the redox initiation of the radical mechanism. 
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Given that the anaerobic cure mechanism relies on the activity of the metal surface, a 
strong bond is much harder to generate with metals which have been treated or 
protected and so if when analysing such substrates significant bond strengths are 
achieved, this can be taken as an indication of a very active cure catalyst.  
For each test, the formulations were evaluated after one hour and 24 hour cure times 
with APH used to prepare a formulation to act as a control. Each measurement was 
carried out in quintuplicate with the average result reported. 
 
In addition to BMIM octyl sulfate (80) and BMIM acetate (83), BMIM saccharinate
1
 
(100) was prepared for analysis. This compound was prepared
1
 through anion 
metathesis of BMIM chloride (79) with sodium saccharinate.H2O (101) and 
combines the active cation with an anion which is the charged analogue of a 
compound already widely used in anaerobic adhesives to alter cure time, saccharin. 
Since saccharin is already known to be cure active as an initiator/accelerator and is 
commonly included in many adhesive formulations,
2,3
 incorporating it into the 
accelerator component of the formulation creates the possibility of not only 
improving upon the good activity displayed by BMIM based compounds, but also 
combining two formulation components and negating the need for saccharin and the 
accelerator to be added separately. Having a compound which is able to fulfil more 
than one function of the adhesion mechanism and reduce the number of formulation 
constituents would make the process more efficient and possibly more cost effective. 
Due to these reasons BMIM saccharinate (100) did not undergo preliminary 
screening using the fixture time test and instead was incorporated into the lead 
accelerator evaluation along with BMIM octyl sulfate (80) and BMIM acetate (83). 
 
 
Scheme 5.1: Formation of BMIM Saccharinate (100) 
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For the purposes of this evaluation, each accelerator was tested as part of two 
separate types of formulation (Tables 5.1 & 5.2). The first formulation is the same as 
that which was prepared when carrying out the fixture time tests described in the 
previous chapter while the second introduces an additional monomer and replaces 
some of the stabilisers and hydroperoxide. This second formulation is more akin to a 
commercial anaerobic adhesive product and as such gives a more accurate indication 
of the practical application of any novel accelerator evaluated as well as further 
comparability with the performance of existing commercial products.
 
 
Table 5.1: PEGMA Formulation 
Component % Weight 
Polyethylene glycol dimethacrylate 95.5 
Saccharin 0.5 
Trigonox TMBH-L 2 
PM 16 0.5 
PM 17 0.5 
Accelerator 1 
 
 
Table 5.2: Model Product Formulation 
Component % Weight 
Polyethylene glycol dimethacrylate 50 
Rigid Resin Oil Cutting Monomer 45.05 
PM17 2 
Saccharin 1 
Paramenthane Hydroperoxide 1 
PM40 0.4 
Accelerator 0.95 
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Since the BMIM octyl sulfate (80) and BMIM acetate (83) both displayed optimum 
performance at a level of 0.7 mmol per 10 g in the fixture time test (Table 4.7), the 
decision was made to prepare the PEGMA only formulations using this 
concentration of accelerator.  
 
No previous analysis had been carried out using the model product formulation 
(Table 5.2) before and so in order to establish the optimum accelerator concentration 
required, only one of the accelerators was tested as part of this mixture. BMIM 
saccharinate was chosen and tested at both the 0.7 mmol per 10 g level as well as the 
formulation specification 0.95% w/w level with APH used as the control once more.   
 
 
5.2.1 Results of PEGMA Formulations: 
 
Each compound (80, 83, 100) as part of the PEGMA only formulation (Table 5.1) 
was tested as a cure accelerator using the nuts & bolts and pins & collar tests as 
described at the beginning of Section 5.2. After both 1 hour and 24 hour cure times 
the force required to cause bond failure was measured and this was used an 
indication of the level of polymerisation which had occurred. 
 
The break torque strength for each compound in both of the nuts and bolts tests is 
presented below. The complete set of results including the prevail torque (Graph 
5.1(b) and 5.2(b)) and maximum torque measurements (Graph 5.1(c) and 5.2(c)) can 
be found in Appendix C. 
Likewise the compressive strength (Graph 5.3(a)) for each compound tested as part 
of the pins and collars evaluation is presented below with their maximum load 
(Graph 5.3(b)) found in Appendix C. 
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Graph 5.1(a): Black Oxide Bolts with Mild Steel Nuts - Break Torque 
 
 
 
 
Graph 5.2(a): Stainless Steel Nuts and Bolts - Break Torque 
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Graph 5.3(a): Mild Steel Pins and Collars - Compressive Srength 
 
 
 
When analysing the outcomes of the nuts and bolts tests (Graphs 5.1(a, b, c) and 
5.2(a, b, c), the results are separated into three measurements; the break torque 
(Graph 5.1(a)) which indicates the initial force required to cause a break in the 
adhesive bond, the prevail torque (Appendix C - Graph 5.1(b)) which is the force 
required to turn the nut 180, and the maximum torque reached (Appendix C - Graph 
5.1(c)). 
Where the break torque provides us with the force required to cause the primary 
failure of the adhesive bond, the prevail torque indicates the ability of the bond to 
resist movement. This is particularly important where the adhesive is applied as a 
threadlocker as it will illustrate how much force (due to mechanical vibrations for 
example) can be resisted before beginning to loosen. For adhesives to be fit for 
applications such as this it is preferable for this value to be as large as possible and 
for the cure strength to be achieved in as short a time as possible, i.e. the polymer is 
able to cure quickly but yet still reach an operational strength. In other types of 
adhesives factors such as how brittle the bond formed is have to be accounted for as 
well as the overall strength but in anaerobic adhesives where the bond gap is usually 
quite small, this is not as large an issue. If we compare the 24 hour break torque of 
the formulation which contained no accelerator to the others (Graph 5.1(a)), we can 
see that it actually resulted in the strongest bond. By introducing catalysts in an 
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attempt to speed up the polymerisation reaction, weakness is inherently introduced 
into the bonds formed, whereas if the reaction is allowed to proceed at its “natural” 
rate then it will result in optimum polymerisation and bond strength. Thus, whilst the 
objective is to accelerate the polymerisation rate, attention must also be paid to how 
far the strength of the end bond is compromised as compared to the maximum 
strength achievable. 
One of the reasons APH is so widely used as a cure accelerator can be seen from the 
break torque measured along with its performance in the other tests (Graphs 5.1-3). 
Whilst APH does not possess the best 24 hour cure time strengths of all the 
accelerators tested, 11.5 Nm, this strength is very similar to that observed after one 
hour cure time, 11.3 Nm (Graph 5.1(a)). This is an illustration of the efficiency of 
the catalyst showing that APH is able to reach its final bond strength in a short 
period of time and that a prolonged cure time is not required for the adhesive to set. 
The one hour break strengths of two of the three BMIM accelerators (80, 100) 
compare very favourably to APH with 6.3 and 8.3 Nm respectively. Whilst APH 
performs better, the difference is not hugely significant in the case of BMIM 
saccharinate and shows that it too is an efficient cure catalyst. The acetate (83) 
derivative on the other hand performed extremely poorly, 1.0 Nm, even worse than 
the formulation which contained no accelerator at all in fact. Clearly, there is a very 
different interaction with the formulation occurring compared to the other BMIM 
based compounds and does not allow for polymerisation to occur. One should note 
that upon addition of the BMIM acetate to the formulation a colour change was 
observed which may indicate a possible reaction with the formulation component(s) 
as no other accelerator displayed this stark colour change. If so, this could prevent 
the polymerisation mechanism from proceeding as intended. 
If we consider the PEGMA formulation results as a whole (Appendix C - Graphs 
5.1-3), one can see that BMIM octyl sulfate (80) showed very promising cure 
activity and a distinct ability to affect the polymerisation reaction. However, the 
most significant result of the series was that of BMIM saccharinate (100) which 
showed activity on a similar scale to APH, for example Graph 5.3(a) where the 
compressive strengths of the two formulations only differed by 1.2 MPa in favour of 
APH and BMIM saccharinate resulted in a stronger 24 hour cure bond. In fact, the 
level of activity displayed by 100 across all of the tests is such that it may be 
considered as a candidate for commercial application. This represents a major 
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breakthrough in the search for and development of anaerobic cure accelerators to 
have a molecule which is capable of matching the activity of those for which 
alternatives are desired. The contrasting activity of the three BMIM based molecules 
also illustrates that the anion may in fact play a much larger role in the mechanism of 
action and that activity may not be primarily as a result of the cation as previously 
thought.  
As noted earlier, lack of cure activity when using stainless steel substrate is not a 
cause for concern due to the inactivity of the metal surface. Tests involving stainless 
steel substrate are very challenging for anaerobic adhesives and for this reason they 
are rarely applied on such substrates. We can see that even APH struggles to achieve 
any significant cure strength after one hour compared to the results of the same tests 
carried out using black oxide bolts with mild steel nuts (Graph 5.1(a) vs. 5.2 (a)). 
Instead, when any level of cure at all is observed, this is used as an indication that 
the compound is indeed capable of affecting the cure mechanism to a significant 
degree as is evident with BMIM saccharinate. 
 
 
5.2.2 Results of Model Product Formulations 
Due to no analysis having been carried out using this formulation previously, the 
evaluation was only carried out using one hour cure times to assess their suitability 
to the formulation. 
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Graph 5.4: Black Oxide Bolts with Mild Steel Nuts 
 
 
 
Graph 5.5: Stainless Steel Nuts and Bolts 
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Graph 5.6: Mild Steel Pins and Collars: 
(a) Compressive Strength and (b) Maximum Load 
 
 
 
 
 
 
 
 
 
 
7 
3.9 
8 
BMIM Saccharinate
0.95 %w/w (0.3 mmol)
BMIM Saccharinate
0.7 mmol
APH
0.7 mmol
Compressive Strength (MPa) 
1 Hour Cure Time
2316.2 
1568.9 
3207.6 
BMIM Saccharinate
0.95 %w/w (0.3 mmol)
BMIM Saccharinate
0.7 mmol
APH
0.7 mmol
Maximum Load (N) 
1 Hour Cure Time
129 
 
With respect to the model formulations analysed (Graphs 5.4-6), this was a 
formulation which has been developed by Henkel and is much closer to a complete 
commercial formulation than the PEGMA only formulation. Since no analysis had 
been carried out using it before, only one of the BMIM accelerators was selected for 
analysis to gain an insight of how the presence of an extra monomer would affect the 
polymerisation interaction, and this was only carried out after one hour cure time.  
Due to the excellent performance of BMIM saccharinate (100) when used as part of 
the PEGMA formulation, e.g. Graph 5.1(a) break torque strength, 100 was chosen as 
the accelerator to be evaluated. The standard amount of accelerator to be used in the 
formulation is 0.95% w/w but, as illustrated in the previous chapter, following the 
gram amount will not necessarily result in optimum activity when the accelerator is 
changed and so in addition to this amount the testing was also performed at 0.7 
mmol per 10 g, the optimum PEGMA formulation concentration. Again BMIM 
saccharinate (100) performed comparably to APH as with the previous formulation 
providing further evidence to support the possible application as a commercial 
accelerator. Interestingly 100 performed best at a level of 0.95% w/w which is less 
than half the mole amount added compared to when 0.7 mmol per 10 g is used 
(Graphs 5.4 and 5.6). This is another example that elevating the catalyst loading 
excessively can result in poorer acceleration of the polymerisation as was observed 
in Section 4.6. 
 
Until the results of BMIM saccharinate are evaluated further, a word of caution must 
be noted. There is the possibility that the increased activity may simply be due to an 
increased amount of saccharin molecules being available in the formulation. We 
know saccharin plays an important role in the curing mechanism, either in an 
uncharged state or possibly as part of a salt formed in the formulation process, and so 
when introducing a saccharinate compound into the adhesive there is the chance that 
any increased activity observed is simply as a result of an increased amount of 
saccharinate species akin to if an increased amount of saccharin had been added. 
Thus, in order to validate the results, testing using range of concentrations of 
saccharin needed to be carried out. 
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5.3 Investigation of the Source of Saccharinate Activity 
In order to determine whether the activity of BMIM saccharinate as an accelerator 
was as a result of the compound or simply due to the addition of extra active 
saccharin to the formulation, a series of formulations were prepared and tested using 
varying levels of saccharin.  
These formulations included; two formulations prepared using the accelerator only 
and no saccharin (one using BMIM saccharinate (I) and one using APH (III) for 
comparative purposes), and one made up using no accelerator but an amount of 
saccharin equal to the sum amount of the accelerator and saccharin which would 
normally be added (II).  
 
All three of these formulations were prepared using both the PEGMA and Model 
formulations as before with the results of the complete BMIM saccharinate 
formulation included for comparison (IV). In the case of the model formulation, the 
24 hour cure time tests of BMIM saccharinate which were not carried out before in 
Section 5.2.2 were done so.  
 
The break torque strength for each compound in both of the nuts and bolts tests is 
presented below (Graphs 5.7(a), 5.8(a), 5.10(a), and 5.11(a)). The complete set of 
results including the prevail torque (Graphs 5.7(b), 5.8(b), 5.10(b), and 5.11(b)) and 
maximum torque (Graphs 5.7(c), 5.8(c), 5.10(c), and 5.11(c)) can be found in 
Appendix C. 
Likewise the compressive strength (Graphs 5.9(a) and 5.12(a)) for each compound 
tested as part of the pins and collars evaluation is presented below with their 
maximum load (Graphs 5.9(b) and 5.12(b)) found in Appendix C. 
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5.3.1 PEGMA Formulations 
 
 
Component Amount contained in each formulation (g) 
No Saccharin 
with BMIM 
Saccharinate 
(I) 
Extra 
Saccharin 
(II) 
No 
Saccharin 
with APH 
(III) 
BMIM 
Saccharinate 
with 
Saccharin (IV) 
PEGMA 9.55 9.55 9.55 9.55 
Premix 16 0.05 0.05 0.05 0.05 
Premix 17 0.05 0.05 0.05 0.05 
Tetramethylbutyl 
hydroperoxide 
(TMBH-L) 
0.2 0.2 0.2 0.2 
Saccharin - 0.183 (1 
mmol) 
- 0.05 (0.27 
mmol) 
Accelerator 0.22 (0.7 
mmol) 
- 0.105 (0.7 
mmol) 
0.22 (0.7 
mmol) 
Note: Mass of saccharin in (II) is equal to mass of IL and saccharin in (IV), 
however this is not an equimolecular comparison 
 
 
Graph 5.7(a): Black Oxide Bolts with Mild Steel Nuts - Break Torque 
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Graph 5.8(a): Stainless Steel Nuts and Bolts - Break Torque 
 
 
 
 
Graph 5.9(a): Mild Steel Pins and Collar - Compressive Strength 
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5.3.2 Model Formulations 
 
Component Amount contained in each formulation (g) 
No Saccharin 
with BMIM 
Saccharinate 
(I) 
Extra 
Saccharin 
(II) 
No 
Saccharin 
with APH 
(III) 
BMIM 
Saccharinate 
with Saccharin 
(IV) 
PEGMA 5 5 5 5 
Oil Cutting 
Rigid Resin 
4.5 4.5 4.5 4.5 
PM17 0.2 0.2 0.2 0.2 
Paramenthane 
Hydroperoxide 
0.1 0.1 0.1 0.1 
PM40 
(Menadione) 
0.04 0.04 0.04 0.04 
Saccharin - 0.195 - 0.1 
Accelerator 0.095 - 0.095 0.095 
 
 
 
Graph 5.10(a): Black Oxide Bolts with Mild Steel Nuts - Break Torque 
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Graph 5.11(a): Stainless Steel Nuts and Bolts - Break Torque 
 
 
 
 
 
Graph 5.12(a): Mild Steel Pins and Collar - Compressive Strength 
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These results illustrate that the increased cure activity is due to the BMIM 
saccharinate compound and is not as a result of simply having extra saccharin 
species in the formulation (Graphs 5.7-11). When we compare the formulation 
containing the elevated level of saccharin (II), to the formulation prepared as normal 
(IV), there is a large difference in cure strength after one hour. For example, we can 
see the break strength in Graph 5.10(a) of 7.3 Nm for II is less than half of that 
observed for IV (14.9 Nm) using the model formulation applied to black oxide bolts 
and mild steel nuts. This trend is broadly seen across both formulations tested but the 
performance is somewhat closer in both pins and collars evaluations (Graphs 5.9(a) 
and 5.12(a)). 
The ability of BMIM saccharinate to fulfil the role of both the neutral saccharin and 
cure accelerator was also investigated. This was carried out by preparing test 
formulations which contained no saccharin whatsoever using BMIM saccharinate as 
the accelerator (I) as well as another which used APH to act as a bench mark to 
compare how a representative adhesive formulation would perform when no 
saccharin was present (III). Whilst the results show a marginal increase in activity 
for the BMIM saccharinate over APH in the PEGMA formulations (Graphs 5.7(a)-
9(a)), this difference is not significant and this trend is reversed for the model 
formulation adhesives (Graphs 5.10(a)-12(a)). Crucially, when they are further 
compared to the standard formulation (IV) in all examinations one can be seen that 
saccharin still plays a key role in the curing mechanism by its presence in the neutral 
form and despite the presence of the saccharinate anion. 
 
5.4 The Development of Ionic Liquids as Cure Accelerators. 
The results of the full accelerator evaluation of the three BMIM based compounds 
(80, 83, 100) confirm the viability of alkyl imidazoliums as cure catalysts. Despite 
the acetate analogue (83) performing very poorly (Graph 5.1(a)), the octyl sulfate 
(80) and particularly the saccharinate (100) derivatives displayed activity to warrant 
further investigation of their properties. 
Considering no prior evaluation of the saccharinate compound had been carried out 
prior to this complete evaluation, the extent of its activity was somewhat unexpected. 
Given the wide range of different activities displayed by the three BMIM compounds 
(80, 83, 100), the initial hypothesis that the activity was primarily as a result of the 
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nitrogen containing cation was revisited. The anion is clearly able to alter the cure 
process significantly, and given the extent to which the saccharinate ion was able to 
do so, added emphasis was placed on thisimportance in the development of 
imidazolium ionic liquids as cure accelerators.  
In terms of studying the activity of the imidazolium cation, the first position chosen 
to begin with was the length of the alkyl chain substitution. By altering the chain 
length an insight into whether this structural characteristic was of significance or not 
could be gained given the wide range of lipophilicities which could potentially be 
applied, as well as an opportunity to look more closely at the possible issue of 
molecule size versus catalytic activity as discussed in the previous chapter. By 
reducing the cation size, the activity of the BMIM derivatives could possibly be 
improved upon even further if this turned out to be the case. Thus  
1-Methyl- (102) and 1-ethyl-3-methylimidazozlium iodide (103), and 1-octyl-3-
methylimidazolium chloride (104) were provisionally selected as compounds of 
interest along with 1-butyl-2,3-dimethyl imidazolium tetrafluoroborate (105). These 
compounds were preliminarily examined as before by first evaluating their solubility 
in PEGMA at 1% w/w. Compounds 102 and 103 proved to be soluble and thus were 
suitable for further analysis using the fixture time test however 104 and 105 proved 
to not be. 
 
As described previously in Section 1.3, there is the possibility that neutral 
accelerators are not the active catalytic species in the adhesive formulation and 
instead form salts with other components such as saccharin which in turn carry out 
the role of catalyst. It would be advantageous if saccharin salts of neutral 
accelerators could be prepared for analysis with their performance then compared to 
the respective “neutral” analogue. This could conceivably allow for the 
determination of this mechanism characteristic i.e. if the two sets of formulations 
possessed the same activity it could be said that salt formation leads to the active 
cure accelerator. In the previous chapter a large number of imidazoles were 
evaluated for their cure activity and to this end the saccharin salt of 1-
methylimidazole was prepared in 96% yield by stirring saccharin and 1.1 equivalents 
of 1-methyl imidazole in acetonitrile at room temperature (Scheme 5.2). The 
formation of the salt compound (106) was confirmed by NMR spectroscopy and 
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attempts were made to synthesise the saccharin salts of further imidazoles such as 1-
butyl- and 1-benzylimidazole but salt formation did not occur in these cases. 
 
 
Scheme 5.2: Synthesis of 1-Methylimidazolium Saccharinate (106) 
 
The solubility of 1-methylimidazolium saccharinate (106) was tested in PEGMA at 
formulation level and surprisingly was found to be insoluble. This was unexpected 
given that both neutral compounds are soluble (as well as several similar ionic 
liquids) and lead to quite good cure acceleration. This may possibly indicate that 
neutral compounds do not rely on salt formation to become cure active however no 
definitive statement can be made on this aspect given only one case was investigated. 
However, the postulation was made that protic imidazolium ionic liquids generated 
from a simple acid base reaction have poor solubility in PEGMA at 1% w/w, most 
likely due to low lipophilicity. 
 
The imidazolium halides (102, 103) which proved soluble in the formulation were 
therefore the only compounds analysed using the fixture time test. Both 1,3-
dimethylimidazolium (MMIM) iodide (102) and 1-ethyl-3-methylimidazoloium 
(EMIM) iodide (103) were used to prepare separate formulations as per the PEGMA 
specification outlined in Table 5.1. These formulations were then used to carry out 
the fixture time test. 
Both of the ionic liquids performed very poorly in this examination with no cure 
observed after three hours. The BMIM compounds (80, 83) analysed previously had 
displayed cure times of 0-5 minutes in this test (Chapter 4, Table 4.7) and, from 
investigation of the cation structure, considering that these compounds only differ in 
shorter alkyl chain length (butyl vs. methyl or ethyl), such a decrease in activity is 
surprising. Both compounds 80 and 83 contain organic anions and so the halide 
counter ion was thought to possibly be the cause for the dramatic decrease in 
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performance. To examine this hypothesis, derivatives of the imidazolium compounds 
paired with organic anions were preapred. 
Of the three organic anions tested to this point (saccharinate, octyl sulfate, and 
acetate), the saccharinate yielded the best results and so anion metathesis of 102-104 
was carried out using a modified version of the method used to prepare the BMIM 
derivative (100) with the sodium dihydrate salt of saccharin.
1
 Two equivalents of the 
sodium saccharinate were stirred with the respective imidazolium compound at room 
temperature in acetone overnight to form MMIM saccharinate (107) and EMIM 
saccharinate (108). In order to purify, the excess staring material and inorganic salt 
by-product were first removed by filtration. The solvent was then evaporated to 
dryness to yield the crude product (MMIM saccharinate – white crystalline solid, 
EMIM saccharinate – hygroscopic white solid, and OMIM saccharinate (109) – 
transparent pale yellow oil
4
). The remainder of the inorganic salt was removed by 
dissolving the product in chloroform and separating the insoluble solid by filtration. 
This method worked quite efficiently for OMIM chloride (104) but did not result in 
the complete removal of all of the sodium iodide formed in the case of the shorter 
chained imidazoliums (102, 103). This was an issue due to the slight solubility of 
NaI in the same range of solvents as the products meaning NaI could not completely 
be removed by precipitation and filtration. This also proved to be an issue in other 
purification methods such as column chromatography as the ionic liquid products 
required a polar mobile phase. 
 
In order to overcome this problem the decision was made to alter the starting 
material used. If this were to contain a cation which upon reaction would form an 
iodide salt insoluble in the majority of polar organic solvents, then the current 
efficient purification method could be retained. Silver iodide is one such salt and 
thus silver saccharinate was prepared by stirring equimolar amounts of sodium 
saccharinate dihydrate with silver nitrate in water at room temperature. This led to 
the precipitation of the product which was easily isolated and dried.
5
 
The silver saccharinate was used in the place of the sodium salt for the successful 
formation of MMIM (107), 92% yield, and EMIM saccharinate (108), 86% yield), 
using the method described above (Scheme 5.2) with the amendment of protecting 
the reaction mixture from light to avoid degradation of the silver salt. 
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Both the OMIM (109) and EMIM (108) saccharinates proved to be soluble in 
PEGMA at 1% and so were able to be evaluated for their accelerator activity but 
unfortunately the MMIM derivative (107) was insoluble at the 1% w/w loading 
examined. 
 
 
Figure 5.2: Structures of Octylsulfate and Saccharinate Anions 
 
In addition to varying the cation structure, variation of the anion used was also 
examined for the effect on activity. If the structures of the octyl sulfate and 
saccharinate anions are compared one can be seen they both contain sulphur 
moieties, namely sulfate and sulfonyl groups respectively, which may be an 
indication as to the source of their activity. In addition to this, the saccharinate 
sulfonyl group exists as part of a sulphonamide functionality (Figure 5.2). It is 
believed that the activity of cure accelerators is as a result of the amine and so the 
increased activity of the saccharinate could be due to a combination of these groups. 
When proposing possible anion structures, those which contained these 
characteristics or which were analogous to saccharin were considered. Phthalimide 
and acesulfame both fulfil some of these requirements (Figure 5.3). 
 
 
Figure 5.3: Structures of Phthalimide and Acesulfame 
 
Phthalimide is structurally identical to saccharin but for the substitution of the 
sulfonyl group for a carbonyl functionality while acesulfame on the other hand 
contains the possibly key sulphonamide moiety. In order to evaluate their cure 
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activity both were paired with the BMIM cation. Since several other anions had 
already been tested as BMIM salts, this would offer a way of quantifying any 
activity shown in the context of the other accelerators developed. BMIM phthalimate 
(111) was prepared through anion metathesis of BMIM chloride and the potassium 
salt of phthalimide (86% yield)
6
 while BMIM acesulfamate (110) was prepared 
through the same process but using the potassium salt of acesulfame (90% yield).
5
 
Both products (110) and (111) were soluble in the monomer and so were eligible to 
be evaluated as cure accelerators along with the other imidazolium saccharinates 
(108 and 109). 
Given the presence of the sulphonamide functional group, acesulfame (112) was also 
evaluayed as a possible alternative to saccharin in the adhesive formulation. This 
could help elucidate the importance of such a functional group with regards to cure 
activity. 
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Table 5.3: Table of Compound Solubility in PEGMA at 1% w/w 
Compound Structure Solubility 
BMIM saccharinate (100) 
 
 
MMIM saccharinate (107) 
 
 
EMIM saccharinate (108) 
 
 
OMIM saccharinate (109) 
 
 
BMIM acesulfamate (110) 
 
 
BMIM phthalimate (111) 
 
 
Saccharin-1-methylimidazole (106)  
 
 
MMIM iodide (101) 
 
 
EMIM iodide (102) 
 
 
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OMIM chloride (103) 
 
 
1-Butyl-2,3-dimethyl imidazolium 
tetrafluoroborate (104) 
 
 
 
 
 
 
5.4.1 Cure Accelerator Activity Evaluation 
The two alkyl-imidazolium saccharinates (108, 109), along with BMIM 
acesulfamate (110), BMIM phthalimate (111), and acesulfame (112) as a saccharin 
alternative were tested as cure accelerators. Given the likelihood of positive cure 
activity, decision was made to evaluate them using the more extensive adhesion tests 
as opposed to the primary fixture time method. Also, given the greater similarity to 
commercial products and thus better indication of practical applicability, the 
accelerators were tested as part of the model formulation only and not the PEGMA 
formulation as was included previously. The formulations were prepared as per 
Table 5.2 with the neutral acesulfame paired with APH as an accelerator. As before, 
APH was used in the control formulation. 
 
The break torque strength for each compound in both of the nuts and bolts tests is 
presented below (Graphs 5.13(a) and 5.14(a)). The complete set of results including 
the prevail torque (Graphs 5.13(b) and 5.14(b)) and maximum (Graphs 5.13(c) and 
5.14(c)) torque can be found in Appendix C. 
Likewise the compressive strength (Graph 5.15(a)) for each compound tested as part 
of the pins and collars evaluation is presented below with their maximum load 
(Graph 5.15(b)) found in Appendix C. 
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Graph 5.13(a): Black Oxide Bolts with Mild Steel Nuts - Break Torque 
 
 
 
 
Graph 5.14(a): Stainless Steel Nuts and Bolts - Break Torque 
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Graph 5.15(a): Mild Steel Pins and Collars - Compressive Strength 
 
 
 
 
As can be seen from the results (Graphs 5.13(a)–15(a)), all compounds tested 
performed at and above the level of APH in the formulation with the exception of the 
stainless steel substrate for reason discussed in section 5.1.3. Both EMIM (108) and 
OMIM saccharinate (109) performed similar to each other as well as to the level 
exhibited by BMIM saccharinate in the previous analysis (100) (Black oxide beak 
torques of 10.1, 11.8, and 14.9 Nm respectively – Graph 5.13(a) and 5.4(a)). Whilst 
the BMIM analogue performs the best of the three compounds, the difference in 
activity observed is not significant and when the activity of 108 and 109 is compared 
to that of APH across all the tests we can see that they are effective cure accelerators 
in their own right. This would suggest that the length of alkyl chain substitution on 
the imidazolium ring has no discernable effect on catalyst activity and that this is 
possibly due to the properties of the charged heterocyclic ring. 
The acesulfamate (110) and phthalimate (111) derivatives also performed to a high 
level in the formulation analysis (Graph 5.15(a)). Across all tests both compounds 
performed to a specification which would suggest their suitability as possible 
commercial cure accelerators. In particular 111 displayed notable 24 hour cure 
activity in the stainless steel nuts and bolts test (Graph 5.14 (a-c)) illustrating the 
excellent level of catalytic activity. The activity of neither acesulfamates nor 
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phthalimates as anaerobic cure accelerators has been documented before and so the 
significance of these results should not be understated.  
In the case of the acesulfamate, this is potentially further evidence as to the role of 
the sulphonamide group in polymerisation catalysis. This is further backed up by the 
performance exhibited by neutral acesulfame (112) when used as a replacement for 
saccharin. When paired with APH in an adhesive system, this resulted in better 
activity than the control formulation, which was prepared using saccharin, after one 
hour cure time in both nuts and bolts tests (Graphs 5.13(a)-14(a)). While there is no 
current requirement to replace saccharin in anaerobic adhesives, it is nevertheless 
significant to discover an alternative compound capable of performing at and above 
the same level of efficiency. One should note that the reason neutral phthalimide was 
not tested in this capacity also was because this compound had previously been 
found to display poor activity (D. Birkett, personal communication). 
 
 
5.5 Further Development of  Ionic LiquidCure Accelerators 
The results described above display that imidazolium based ionic liquids can act as 
extremely effective cure accelerators regardless of the length of alkyl chain 
substitution. However, this does not demonstrate whether any unique structural 
characteristic of the imidazolium cation which is responsible for this activity, only 
reinforce the weight of evidence for the application of the compound family as cure 
catalysts. 
For example, this activity could be as a result of features such as the aromaticity, the 
presence of more than one nitrogen centre, or the presence of the lone pair of 
electrons on the nitrogen atom and/or their confirmation. If the importance of 
features such as these could be determined it would be invaluable in the design of 
new cure accelerators. 
To study properties such as these a list of cations was drawn up which if tested could 
possibly lead to more information about the structure activity relationship. (Figure 
5.4). 
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Figure 5.4: Cations of Interest 
 
Testing of a pyridinium cation could determine whether the presence of the lone pair 
of electrons on the nitrogen group is essential to activity or not. Given that anaerobic 
accelerators are all nitrogen containing compounds, and given that all in general use 
largely have no charge, the lone pair is intact in all and could play a key role in the 
curing mechanism. This would be of particular significance if the active compound 
relied on the formation of species such as charge transfer complexes. 
Quarternarisation of pyrrolidine would also allow for the evaluation of the necessity 
of the nitrogen lone pair. In addition to this, its evaluation could also lead to 
information about the importance of aromaticity to the cure process. While the first 
cure accelerators were compounds such as tributylamine, they were not able to affect 
the cure time nearly as efficiently as aromatic compounds such as DMpT and THQ. 
By preparing sulphonium based ionic compounds, the necessity of nitrogen based 
compounds as a whole to the cure process could be evaluated. The previous tests 
where the anion has been varied have shown the capability of altering the cure time 
significantly (Graphs 5.13-15) but it is not known whether this is completely 
irrespective of the cation present or not. The elucidation of such information would 
definitively outline the role of each constituent and determine whether one of the 
cation or anion can be structurally altered to prepare catalysts with custom properties 
such as; low toxicity, varying solubility/selectivity, environmentally benign without 
comprising the cure activity attributed to the other. 
In addition to compounds selected to directly study the structure-activity 
relationship, other compounds were prepared to assess their possible cure activity. 
Compounds such as THQ and DMpT have been used to great effect as accelerators 
in commercial products and display better activity than other neutral compounds 
such as imidazole. When salts based on imidazole were prepared a substantial 
increase in activity over the neutral analogues was observed (80, 100, 108-111). 
147 
 
Therefore, if salts based on compounds which already possessed exemplary activity 
were to be prepared, and if this had the analogous effect on activity, then compounds 
capable of extremely efficient cure catalysis could be yielded and even lead to a 
reduction in the catalyst loading required resulting in an overall more efficient and 
sustainable product. To this end, quarternarised derivatives of THQ and DMpT were 
therefore targeted for synthesis and evaluation. 
 
N-methylpyridinium iodide (113) was prepared through stirring 1.1 equivalents of 
methyl iodide with pyridine at reflux in methanol. Cooling to room temperature 
resulted in precipitation of the product which was isolated and washed with ethyl 
acetate to give 91% yield.
7
 N,N,N-Trimethyl-p-toluidinium iodide (TMpT) (114) was 
prepared from DMpT via the same method in 90% yield. 
N,N-dimethyltetrahydroquinolinium iodide
8
 (115) and N,N-dimethylpyrrolidinium 
iodide
9
 (116) were prepared using five equivalents of the alkyl halide as well as one 
equivalent of sodium carbonate by refluxing in 1:1 methanol:H2O (87% and 75%  
yields respectively). 
Since the imidazolium iodide compounds evaluated in the fixture time test 
previously performed very poorly (102, 103), anion metathesis was performed using 
these compounds without any assessment of their applicability as cure accelerators. 
The acesulfamate (110), phthalimate (111), and saccharinate (100) anions had all 
performed very well in the previous testing and so by pairing each with the cations 
prepared, a large library of ionic liquids could be constructed which differed in the 
structural make up and could help form a basis for the structure-activity relationship. 
The saccharinate (117), acesulfamate (118), and phthalimate (119) salts of TMpT 
were thus prepared (66%, 89%, and 62% yields respectively) through metathesis of 
TMpT iodide using a single equivalent of the respective silver salt. Once dried and 
purified, their solubility in PEGMA at 1% w/w was determined. However, all three 
compounds proved to be insoluble and so could not be evaluated as cure catalysts. 
Since all three derivatives of TMpT were insoluble, only the saccharinate salt of 
methylpyridinium (95% yield) (120), dimethylpyrrolidinium (84% yield) (121), and 
dimethyltetrahydroquinolinium (77% yield) (122) were prepared in order to 
determine the potential solubility of each series in the formulation instead of 
preparing the three salts of each. This caution was well founded as these compounds 
were also found to be insoluble in the monomer and so no further salts of these 
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cations were prepared as they too most likely would prove to be unsuitable for 
evaluation. 
Trimethylsulfonium iodide
10
 (123) was prepared by stirring 1.25 equivalents of 
methyl iodide with dimethyl sulfide neat at room temperature. The white solid was 
then taken up in acetonitrile before being evaporated to dryness to remove the excess 
starting material. Silver saccharinate was added and the mixture allowed stir; the 
saccharinate salt (124) was isolated as a white solid but it too proved to be insoluble 
(87% yield). 
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Table 5.4: Solubility of Methyl Derivatised Ionic Liquids in PEGMA at 1% w/w 
Compound Structure Solubility 
Trimethyl-p-toluidinium saccharinate (117) 
 
 
Trimethyl-p-toluidinium acesulfamate (118) 
 
 
Trimethyl-p-toluidinium phthalimate (119) 
 
 
N-Methylpyridinium saccharinate (120) 
 
 
N,N-Dimethylpyrrolidinium saccharinate 
(121) 
 
 
N,N-Dimethyltetrahydroquinolinium 
saccharinate (122) 
 
 
Trimethylsulphonium saccharinate (123) 
 
 
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Quarternarisation using methyl groups did not result in salts which were soluble in 
PEGMA at 1% w/w (117-123). This was thought to be as a result of the short alkyl 
chain substitution as when these compounds are compared to the imidazolium 
saccharinates synthesised (100, 107-109), we also see that the MMIM (107) 
analogue is insoluble in PEGMA but that increasing the chain length resolves this 
issue (100, 108-109). Thus, the decision was made  to synthesise more lipophilic 
derivatives and a chain length of four was chosen as this offered the best balance 
between potential toxicity and environmental effects whilst still altering the 
solubility profile of the compounds. 
The halide salt of each butyl-derivatised cation was prepared using the same 
synthetic method described for compounds 117-121 with 1-bromobutane and 1-
iodobutane acting as the alkyl halides. Evaluation of the accelerator activity was not 
carried out until anion metathesis was completed and, after doing so, resulted in 
compounds 127-133 (Table 5.5)  
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Table 5.5: Solubility of Butyl Derivatised Ionic Liquids 
Compound Structure Solubility Yield 
% 
N-Butyl-N,N-dimethyl-p-
toluidinium saccharinate (127) 
 
 97 
N-Butylpyridinium 
saccharinate (128) 
 
 92 
N-Butylpyridinium 
acesulfamate (129) 
 
 87 
N-Butylpyridinium 
phthalimate (130) 
 
 71 
N,N-Dibutylpyrrolidinium 
saccharinate (131) 
 
 93 
N,N-Dibutylpyrrolidinium 
acesulfamate (132) 
 
 93 
N,N-Dibutylpyrrolidinium 
phthalimate (133) 
 
 77 
BMIM bistriflimide (134) 
 
 91 
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BMIM cyclamate (135) 
 
 89 
OMIM cyclamate (136) 
 
 84 
Ammonium saccharinate 
(137) 
 
 93 
 
 
N-Butyl-N,N-dimethyl-p-toluidinium saccharinate (127) proved to be insoluble at 
1% w/w in PEGMA and so the acesulfamate and phthalimate derivatives were not 
prepared. Fortunately, both N-Butylpyridinium (NBP) saccharinate (128) and N,N-
dibutylpyrrolidinium (BDP) saccharinate (129) proved to be so and so the 
preparation of their acesulfamate and phthalimate salts was proceeded with and their 
solubility evaluated. 
In addition to these cations, other compounds of interest were synthesised. 
Ammonium saccharinate (137) was prepared through dissolution and stirring of 
saccharin in ethanolic ammonia but it too could not be evaluated as an accelerator 
due to insolubility. 
Likewise, cyclamate based imidazolium salts (135-136) were prepared using silver 
cyclamate. The cyclamate anion contains a sulphonic acid group bonded to an amine 
which is similar to the sulphonamide moiety found in both saccharin and acesulfame 
and therefore could potentially possess interesting cure activity. The BMIM 
derivative
11
 was first prepared (135) as it could be readily compared to the other 
BMIM based accelerators (80, 83, 100, 110-111) but was found to be insoluble in 
PEGMA at the required level. In an effort evaluate the activity of the cyclamate 
group anyway, the OMIM derivative (136) was prepared as it was expected the 
longer alkyl chain could lead to better solvation but no change of the solubility in 
PEGMA was observed. One additional compound which was able to be evaluated 
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was BMIM bistriflimide (NTf2) (134). This was prepared through anion metathesis 
using lithium bistriflimide
12
 and also contains the key sulphonamide moiety.  
 
 
5.5.1 Cure Accelerator Activity Evaluation 
All compounds which proved to be soluble in PEGMA were analysed in the lead 
cure accelerator tests (128-129, 131-132, 134). 
The break torque strength for each compound in both of the nuts and bolts tests is 
presented below (Graphs 5.16(a) and 5.17(a)). The complete set of results including 
the prevail torque (Graphs 5.16(b) and 5.17(b)) and maximum torque (Graphs 
5.16(c) and 5.17(c)) can be found in Appendix C. 
Likewise the compressive strength for each compound tested as part of the pins and 
collars evaluation is presented below (Graph 5.18(a)) with their maximum load 
(Graph 5.18(b)) found in Appendix C. 
 
 
Graph 5.16(a): Black Oxide Bolts with Mild Steel Nuts - Break Torque 
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Graph 5.17(a): Stainless Steel Nuts and Bolts - Break Torque 
 
 
 
 
Graph 5.18(a): Mild Steel Pins and Collars - Compressive Strength 
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All compounds displayed cure strength at and above the level of the control 
formulation (which contained APH as the accelerator) in all tests apart from the 
stainless steel nuts and bolts examination (Graphs 5.16(a)-18(a)) and is further 
evidence to illustrate the high cure activity possessed by the saccharinate and 
acesulfamate anions.  
By testing the pyridinium (128, 129) and pyrrolidinium (131, 132) ionic liquids, it 
had been postulated that this may lead to the importance of properties such as 
aromaticity and the nitrogen lone pair of electrons to efficient polymerisation 
catalysis being established. Both cations however performed at comparable levels to 
each other despite the difference in aromaticity, as well as to the imidazolium 
saccharinates and acesulfamate (100, 108-110) examined in Section 5.3 where the 
lone pair of electrons is present. This can be seen from their black oxide break 
torques measured of 14.7 (128), 12.1 (129), 11.3 (131), and 7.2 Nm (132) (Graph 
5.16(a)) which may point to either of these properties being not as essential to 
activity as was postulated. Alternatively, this could suggest that the anion is indeed 
the major source of any cure activity and that the cation may be used to custom 
design the molecule‟s properties outside of polymerisation time. 
BMIM NTf2 (134) also displayed good catalytic activity and illustrated the 
advantages of molecules containing a sulphonamide moiety (Graphs 5.16(a)-18(a)). 
This was not to the same level as BMIM saccharinate (100) however (Graphs 
5.10(a)-12(a)) and if the anion component is indeed the major source of cure activity, 
then this difference may be explained by properties such as being non-aromatic in 
comparison. Significantly, curing of the adhesive bond was observed after one hour 
when applied to stainless steel (Graph 5.17(a)).  
Likewise, the 24 hour cure strengths observed for the dibutylpyrrolidinium based 
ionic liquids (131, 132) on stainless steel means that they are possibly the most 
active catalysts of the series (128, 129, 131, 132, 134). The inactivity of the stainless 
steel surface towards anaerobic adhesives has been discussed previously and so any 
level of curing achieved can be very significant. Both DBP compounds are able to 
form 24 hour cure strengths similar to that of APH. Despite the exemplary activity of 
the previous ionic compounds tested as part of the model formulation, this level of 
activity had only been seen in BMIM phthalimate (111) and is representative of 
accelerators which are able to greatly affect the curing process. Further to this, in the 
other tests performed (Graphs 5.16(a), 5.18(a)) both resulted in high cure strengths 
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when applied as threadlockers in the nuts and bolts tests as well as retainers in the 
pins and collars examination. 
In conclusion, the molecules which were of sufficient solubility in the adhesive 
formulation (128-129, 131-132, 134) were evaluated as catalysts using nuts and bolts 
threadlocking and pins and collars shear tests. The imidazolium saccharinates (100, 
108-109), acesulfamate (110), and phthalimate (111), along with the pyridinium 
(128-129) and pyrrolidinium (131-132) compounds were proven in these tests to 
possess an excellent ability to affect the cure time of the adhesive and suggested that 
the source of activity was as a result of the anion selected. 
 
 
5.6 Anti-Microbial Test Results 
The set of lead accelerator compounds were submitted for anti-microbial screening 
by Dr Marcel Spulak at Charles University, Prague to gain a better insight into their 
possible toxicity profile. 
The compounds were submitted for analysis before cure the accelerator studies 
described in section 5.4.1 were conducted and so compounds within that set were not 
considered for analysis without knowing their applicability as cure catalysts. The 
compounds submitted were 80, 83, 100, 107-111, 122. 
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5.6.1 Anti-Bacterial Test Results 
For each of the eight strains tested against, where the MIC recorded is >2000 µM no 
activity was observed within the parameters of the test. 
Note: Due to dissolution problems in the media, BMIM phthalimate (111) could 
only be tested to a max concentration of 500 µM and OMIM saccharinate (109) to 
1000 µM. 
 
Table 5.6: Anti-Bacterial Activity of Compounds 80, 83, 100, 110, and 111 
Bacterial 
Strain 
Time (h) Compound - MIC/IC95 (µM) 
80 83 100 110 111 
SA 24 >2000 >2000 >2000 >2000 >500 
48 >2000 >2000 >2000 >2000 >500 
MRSA 24 >2000 >2000 >2000 >2000 >500 
48 >2000 >2000 >2000 >2000 >500 
SE 24 >2000 >2000 >2000 >2000 >500 
48 >2000 >2000 >2000 >2000 >500 
EF 24 >2000 >2000 >2000 >2000 >500 
48 >2000 >2000 >2000 >2000 >500 
EC 24 >2000 >2000 >2000 >2000 >500 
48 >2000 >2000 >2000 >2000 >500 
KP 24 >2000 >2000 >2000 >2000 >500 
48 >2000 >2000 >2000 >2000 >500 
KP-E 24 >2000 >2000 >2000 >2000 >500 
48 >2000 >2000 >2000 >2000 >500 
PA 24 >2000 >2000 >2000 >2000 >500 
48 >2000 >2000 >2000 >2000 >500 
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Table 5.7: Anti-Bacterial Activity of Compounds 107-109, and 122 
Bacterial 
Strain 
Time (h) Compound - MIC/IC95 (µM) 
107 108 109 122 
SA 24 >2000 >2000 500 62.5 
48 >2000 >2000 500 62.5 
MRSA 24 >2000 >2000 100 1000 
48 >2000 >2000 1000 1000 
SE 24 >2000 >2000 1000 125 
48 >2000 >2000 1000 125 
EF 24 >2000 >2000 1000 2000 
48 >2000 >2000 1000 2000 
EC 24 >2000 >2000 500 1000 
48 >2000 >2000 500 1000 
KP 24 >2000 >2000 1000 1000 
48 >2000 >2000 1000 1000 
KP-E 24 >2000 >2000 >1000 2000 
48 >2000 >2000 >1000 2000 
PA 24 >2000 >2000 1000 1000 
48 >2000 >2000 1000 1000 
 
 
5.6.2 Anti-Fungal  Test Results 
For each of the twelve strains tested against, where the MIC recorded is >2000 µM 
no activity was observed within the parameters of the test. 
Note: Due to dissolution problems in the media, BMIM phthalimate (111) could 
only be tested to a max concentration of 500 µM and OMIM saccharinate (109) to 
1000 µM. 
 
 
159 
 
Table 5.8: Anti-Fungal Activity of Compounds 80, 83, 100, 110, and 111 
Fungal 
Strain 
Time (h) Fungal Response – MIC IC80/IC50
a
 (µM) 
80 83 100 110 111 
CA1 24 >2000 2000 >2000 >2000 >500 
48 >2000 2000 >2000 >2000 >500 
CA2 24 >2000 >2000 >2000 >2000 >500 
48 >2000 >2000 >2000 >2000 >500 
CP 24 >2000 2000 >2000 >2000 >500 
48 >2000 2000 >2000 >2000 >500 
CK1 24 >2000 2000 >2000 >2000 >500 
48 >2000 2000 >2000 >2000 >500 
CK2 24 >2000 2000 >2000 >2000 >500 
48 >2000 2000 >2000 >2000 >500 
CT 24 2000 >2000 >2000 >2000 >500 
48 2000 >2000 >2000 >2000 >500 
CG 24 >2000 2000 >2000 >2000 >500 
48 >2000 2000 >2000 >2000 >500 
CL 24 >2000 >2000 >2000 >2000 >500 
48 >2000 >2000 >2000 >2000 >500 
TA 24 >2000 2000 >2000 >2000 >500 
48 >2000 2000 >2000 >2000 >500 
AF 24 >2000 >2000 >2000 >2000 >500 
48 >2000 >2000 >2000 >2000 >500 
AC 24 >2000 >2000 >2000 >2000 >500 
48 >2000 >2000 >2000 >2000 >500 
TM 24 2000 2000 >2000 >2000 >500 
48 2000 2000 >2000 >2000 >500 
a
IC50 values were assessed for AF, AC, and TM. For all other fungi strains IC80 
values were obtained 
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Table 5.9: Anti-Fungal Activity of Compounds 107-109, and 122 
Fungal Strain Time (h) Fungal Response – MIC IC80/IC50
a
 (µM) 
107 108 109 122 
CA1 24 >2000 >2000 1000 250 
48 >2000 >2000 1000 250 
CA2 24 >2000 >2000 1000 500 
48 >2000 >2000 1000 500 
CP 24 >2000 >2000 500 500 
48 >2000 >2000 500 500 
CK1 24 >2000 >2000 125 250 
48 >2000 >2000 125 250 
CK2 24 >2000 >2000 125 250 
48 >2000 >2000 125 250 
CT 24 >2000 >2000 125 250 
48 >2000 >2000 125 250 
CG 24 >2000 >2000 500 1000 
48 >2000 >2000 500 1000 
CL 24 >2000 >2000 1000 1000 
48 >2000 >2000 1000 1000 
TA 24 >2000 >2000 1000 >2000 
48 >2000 >2000 1000 >2000 
AF 24 >2000 >2000 1000 500 
48 >2000 >2000 1000 500 
AC 24 >2000 >2000 1000 500 
48 >2000 >2000 1000 500 
TM 24 >2000 >2000 1000 1000 
48 >2000 >2000 1000 1000 
a
IC50 values were assessed for AF, AC, and TM. For all other fungi strains IC80 
values were obtained 
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As can be seen from the results, all compounds screened against the eight bacterial 
strains and twelve fungal strains were largely inactive. 
The only compounds to display activity in the anti-bacterial screening were OMIM 
saccharinate (109) and N,N-dimethyltetrahydroquinolinium saccharinate (122). This 
is due to the increased lipophilicity of the eight carbon chain in the case of OMIM, 
particularly when compared to the inactivity of the other short chain imidazoliums 
screened (80, 83, 100, 108-111). This increase in lipophilicity allows for greater 
interaction between the molecule and the cell membrane which leads to the 
inhibitory activity observed. 
Anti-fungal activity, as explained in Chapter 2, can be a better representation of 
possible mammalian toxicity due to similarities in their cellular makeup. The same 
trends that were noted in the anti-bacterial screening were observed for compounds 
109 and 122 here also. In addition to this, some activity in certain fungal strains was 
observed at the upper limit of the test specifications for BMIM octyl sulfate (80) and 
BMIM acetate (83). Again this is likely due to similar reasons, particularly for the 
octyl sulfate derivative where it too will have an increased lipophilicity and in turn 
cell membrane interaction due to long alkyl chain substitution. 
This set of anti-microbial data as a whole is a positive sign with respect to designing 
safer anaerobic cure accelerators. One can see that several of the compounds which 
resulted in the highest performance in the cure catalyst studies (100, 108, 110, 111) 
display no inhibition to any of the bacterial or fungal strains whatsoever. Others then 
such as 80 and 83 either did not exhibit as good cure activity or none at all when 
analysed as catalysts and so their inhibitory activity, even though only to a low 
degree, is not of as large a consequence. 
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5.7 Cytotoxicity Screening and Direct Comparison with Anti-Microbial 
Activity 
As part of the toxicity evaluation of the lead cure accelerators identified, eight of the 
compounds which displayed a combination of good catalytic activity and structural 
variation were selected for analysis along with APH (100, 108-111, 128, 131, 132). 
The work was carried out by Dr. Anne Kahru at the National Institute of Chemical 
Physics and Biophysics, Tallinn. 
The toxicity of these compounds was first evaluated against two cell lines, A549 
cells from carcinomatous tissue of human lungs (ATCC CCL-185) and Caco-2 cells 
from colorectal adenocarcinomatous tissue of human colon (ATCC HTB-37). This 
was done by incubating the cells with each compound at 0.1 mM, 0.5 mM, and 1.0 
mM concentrations for 24 hours and their inhibition measured using the neutral red 
uptake assay. 
In order to determine any possible correlation between cytotoxicity and anti-
microbial activity, the same stock solutions of the eight compounds were evaluated 
for inhibition activity against the bacteria, Vibrio fischeri, in a bioluminescence 
“flash” assay. This was carried out at 0.1, 0.5, 1.0, 1.5 mM concentrations with the 
change in luminescence of the bacteria measured after 5 seconds, 15, and 30 
minutes. 
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Graph 5.19: Caco-2 Cell Inhibition: 
(a) 0.1 mM, (b) 0.5 mM, and (c) 1 mM     
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Graph 5.20: A549 Cell Inhibition 
(a) 0.1 mM, (b) 0.5 mM, and (c) 1 mM     
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Graph 5.21: Vibrio fischeri 15 Minute Luminescence Inhibition: 
(a) 0.1 mM, (b) 0.5 mM, (c) 1.0 mM, and (d) 1.5 Mm 
 
 
 
 
  
  
1.35 0.42 0 1.57 
63.36 
3.88 1.41 0 2.6 
0.1 mM 15 Minute Inhibition (%) 
4.96 2.67 0.07 4.03 
97.21 
15.96 
4.59 0 
16.29 
0.5 mM 15 Minute Inhibition (%) 
168 
 
 
 
 
  
 
 
  
  
8.48 6.99 3.55 7.22 
98.9 
27.8 
8.22 
0.3 
34.85 
1.0 mM 15 Minute Inhibition (%) 
12.14 11.44 9.33 10.11 
99.19 
37.24 
12.7 
2.54 
47.41 
1.5 mM 15 Minute Inhibition (%) 
169 
 
Graph 5.22: Vibrio fischeri 30 Minute Luminescence Inhibition: 
(a) 0.1 mM, (b) 0.5 mM, (c) 1.0 mM, and (d) 1.5 Mm 
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As part of the cell line assay (Graphs 5.19-20), a level of cell inhibition of 50% or 
higher a compound can be considered toxic towards the cells in question. 
The postulation was made that cytotoxicity screening could act as a model and offer 
an accurate representation of the mammalian toxicity of established accelerators, 
such as APH, of which it is the aim to design safer alternatives to. However, it can be 
seen from the cell viabilities measured for each cell line and concentration that APH 
is of low toxicity towards them. This does not mean that APH can be considered a 
safe, low toxicity accelerator however as it is already known to be acutely toxic 
towards mammals.
13
 Instead this means that the toxicity and risk of APH does not 
come from anability to target and inhibit cells but from another mode of action. 
Comparing the data generated by both cell lines, one can see that the Caco-2 cell line 
(Graph 5.19) is more sensitive to these types of compounds than the A549 cells 
(Graph 5.20) and so it is recommended that the Caco-2 cells could be used as part of 
a primary indicator of cell toxicity. 
When  the structures of the cure accelerators screened are compared, there is a 
definite trend between alkyl chain length and cell inhibition. The imidazolium 
compounds illustrate this with EMIM saccharinate (108) displaying quite low 
inhibition across all concentrations and both cell lines but as the chain length 
increases as in the three BMIM analogues (100, 110, 111), the inhibition % gets 
larger and rises above the 50% threshold at 0.5 mM for the Caco-2 cells (Graph 5.19 
(b)). In the case of the eight carbon chain of OMIM saccharinate (109) it possesses 
cell inhibition of >90% for both cell lines at 1 mM. This interaction is most likely 
due to the enhanced lipophilicity of long alkyl chains resulting in interaction with the 
cell membrane. 
One can also see from the BMIM derivatives analysed (100, 110, 111) that they all 
largely possess similar cell activity at the different concentrations. This may possibly 
mean that saccharinate, acesulfamate, and phthalimate anions are of low toxicity 
towards cells with the inhibition mainly being caused by the cation. Thus when  N-
butylpyridinium saccharinate is considered, (128) which also displayed some 
inhibitory activity, particularly at higher concentrations, it may be reduced through 
substitution of the pyridinium cation for a more benign alternative. 
In fact, this can be readily seen in the results of N,N-dibutylpyrrolidinium 
saccharinate (131) and acesulfamate (132). Both display very low inhibition of the 
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two cell lines, even at the higher concentration, and lower than that of APH. This 
suggests that DBP is a cation which does not readily interact with cells and when 
paired with saccharinate or acesulfamate results in a compound which is benign in 
terms of cellular toxicity. 
The activity of compounds 100, 109, and 110 towards Caco-2 cells has been 
previously investigated with the same outcomes observed.
14
 OMIM saccharinate 
(109) displays higher toxicity than the shorter chained BMIM derivatives (100, 110) 
which are similar in their inhibitory effect. The study also included pyrrolidinium 
and pyridinium derivatives which, while different structurally, also displayed the 
same trends observed in graphs 5.19-20 with pyrrolidinium being the least active. 
The bioluminescence assay using Vibrio fischeri largely showed the same trends 
(Graphs 5.21-22). N-Butylpyridinium saccharinate (128) showed similar levels of 
activity to APH. The bacteria were not as sensitive to the change in alkyl chain 
length as was observed for the two mammalian cell lines however. BMIM 
saccharinate (100) and 110-111 unexpectedly display similarly low levels of 
inhibition to EMIM saccharinate (108). This may be due to the relative low toxicity 
of the saccharinate anion present as studies of the alkyl chain length of imidazolium 
compounds involving other anions have shown a clear increase in inhibition as the 
chain grows.
15–17
 OMIM saccharinate on the other hand possesses remarkable 
inhibition of the metabolic activity of the bacteria owing to the C8 chain (Graph 
5.21(a)). This level of almost 100% inhibition at concentrations of 0.5 mM and 
higher (Graphs 5.21 (b-d)) is to a level that merited further investigation at 0.05 mM. 
At this concentration the compound still retained sizeable inhibitive activity of 41% 
after 15 minutes and 23% after 30 minutes. In fact after 5 seconds, the compound 
showed sizeable inhibitory activity with an EC50 of 0.37 mM.  
While the flash assay was not as sensitive to structural modifications such as alkyl 
chain length as the Caco-2 or A549 mammalian cells, it was able to identify the 
higher cytotoxicity of the pyridinium based compound (128) and APH over the 
pyrrolidiniums (130-131) evaluated. Further to this OMIM saccharinate (62) was 
identified as the most inhibitive compound and illustrates that anti-microbial analysis 
can be used as a primary indicator of the cytotoxicity of a compound. 
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5.8 Environmental Fate Study of Adhesive Formulations and Possible 
Biodegradation of Lead Cure Accelerators 
 
5.8.1 Environmental Fate of Anaerobic Adhesives 
The environmental fate and persistence of cure accelerators has been a key property 
in this project to design novel polymerisation catalysts. However, when we consider 
that they often only constitute 1% w/w of an anaerobic adhesive product, then the 
biodegradability of the rest of the formulation components cannot be ignored if a 
truly environmentally benign product is to be designed. 
In order to investigate this, two complete anaerobic adhesive products Loctite 2400 
(138) and 2700 (139), were analysed. Since the monomer(s) is the largest 
formulation component by some extent, four monomers frequently used in anaerobic 
products were submitted in addition for evaluation. These monomers were PEGMA 
(1), flex III resin (140), oil cutting rigid resin (141), and ethoxylated bisphenol A 
dimethacrylate (142). Compounds 140-142 are custom monomers developed by 
Henkel for use in their adhesive product line. 
The five compounds were submitted for biodegradation analysis using the CO2 
headspace test (OECD Test No. 310) and eco-toxicity evaluation using the microtox 
assay and daphnia magna. This work was carried out by Dr. Teresa Garcia, IQAC, 
Barcelona. Samples 1 and 138 were analysed separately to the other three and so 
their biodegradation results are reported along with a second SDS standard control 
reference. 
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Table 5.10: Microtox Activity of Formulation Components 
Compound MICROTOX 
(30 min) 
EC50 concentration 
range 
(mg/L) 
EC50 
mg/L 
IC95% 
PEGMA (1) 
17 16-18 10 to 100 
Loctite 2400 (138) 34 27-41 
Loctite 2700 (139) 30 21-43 
Flex III Resin* (140) - -  
Oil Cutting Rigid Resin* (141) - - 
 
Ethoxylated Bisphenol A 
Dimethacrylate* (142) 
- - 
*Due to compound insolubility in the test medium no toxicity could be determined 
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Table 5.11: Daphnia Magna Activity of Formulation Components 
Compound Daphnia magna 
(48 h) 
EC50 
concentration 
range (mg/L) 
Hazard 
Classes 
(OECD, 
2001) 
EC50 
mg/L 
IC95% 
Oil Cutting Rigid Resin 
(141) 
55 30-80 10 to 100 Acute toxicity 
III 
(harmful to 
aquatic life) 
PEGMA (1) 
>100 - >100 - 
Loctite 2400 (138) 
>100 - 
Loctite 2700 (139) 
>100 - 
Flex III Resin (140) 
>100 - 
Ethoxylated Bisphenol 
A Dimethacrylate (142) 
>100 - 
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Table 5.12: Biodegradability of Formulation Components 
Compound Biodegradation (%) Inhibition 
(%) 6 
Days 
13 
Days 
21 
Days 
28 
Days 
SDS Standard 1 67 80 81 87±4.6 
Loctite 2400 (138) 52 69 71 73±4.3 0 
Loctite 2700 (139) 31 50 55 55±1.7 0 
Oil Cutting Rigid Resin* (141) 13 18 23 27±2.9 0 
Ethoxylated Bisphenol A 
Dimethacrylate* (142) 
4 12 14 22±7.4 0 
SDS Standard 2 80 93 95 97±3.6  
PEGMA (1) 48 83 94 97±6.0 0 
Flex III Resin (140) 39 50 66 67±4.6 0 
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In terms of their threat to the aquatic environment, the samples evaluated largely 
pose little risk. Under OECD classification for the daphnia magna evaluation, only 
one of the monomers required to be assigned a hazard label and this was at the 
lowest level, acute toxicity III (141). The remaining compounds (1, 138-140, 142) 
have an EC50 of >100 mg/L and therefore outside of the hazard limits. In the 
microtox bioluminescence assay, differing activity was observed with both adhesive 
formulations (138-139) and PEGMA (1) displaying lower EC50 values of 34, 30, and 
17 mg/L respectively. 
Of the samples, one of the complete formulations, 138, and two of the monomers, 1 
and 140, were found to reach the 60% degradation threshold to be considered readily 
biodegradable. PEGMA will readily undergo degradative processes such as 
hydrolysis and so over 28 days nearly mineralises completely. Due to this extremely 
high level of degradation, any adhesive product primarily made up of PEGMA will 
also pass biodegradation evaluations and this is evident in the case of 138.  
Historically anaerobic adhesives have been based on PEGMA but in order to 
customise the bond properties such as strength or elasticity, there is often additional 
monomers added to the formulation. Since these are also included in large amounts, 
they have the ability to significantly affect the environmental fate of the product. 
Monomer 140 is made up of 1,6-hexanediol, toluene diisocyanate (TDI), and adipic 
acid groups bonded and end capped with PEGMA. Whilst this monomer still offers 
several sites for cleavage to occur, the degradation has dropped to 67% and in the 
case of 141 and 142 this level has dropped even further below the threshold. There is 
conflicting evidence as to the biodegradability of bisphenol A with this chemcial 
being classified as readily biodegradable under the OECD 301F manometric test but 
not readily biodegradable in the OECD closed bottle test, OECD modified sturm 
test, and MITI test for biodegradability.
18
 There is no previously published 
biodegradation information on ethoxylated bisphenol A (142) but it is conceivable 
that, if the bisphenol A fragment is indeed persistent, the ethoxy portion may 
degrade to some extent leading to the low level of degradation observed but not 
enough to class the compound as readily degradable. 
By investigating complete adhesive products and their major components, a greater 
perspective of the environmental fate of the complete formulation as opposed to 
simply a single component is gained. This also serves to highlight the areas where 
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improvements can be made if further readily degradable adhesives are to be designed 
and how monomers can be altered to achieve this. 
 
5.8.2 Possible Environmental Fate of Lead Accelerator Compounds 
The lead cure accelerators have been identified based on their catalyst activity and 
their potential risk has been investigated using anti-microbial and cytotoxicity 
analysis, however the environmental fate of the compounds remains unknown. 
Of the ionic liquid cure accelerators investigated, BMIM saccharinate (100) is the 
only compound to have published biodegradation data. Using the CO2 headspace 
test, 100 was found to degrade by 41% over 28 days and as such is deemed not 
readily biodegradable.
1
 The persistence of short chain alkyl imidazolium ionic 
liquids is well studied
19
 and so this does not come as a surprise. For these reasons, 
similarly low biodegradation levels would be expected if the other short chain 
imidazolium cure accelerators were to be analysed (108, 110-111). An investigation 
into the biodegradability of ionic liquids which incorporate an acesulfamate anion 
has been carried out where it is paired with 1-alkoxymethyl-3-hydroxypyridinium 
based cations.
20
 As part of this study the biodegradation of acesulfamate, 
saccharinate, and chloride anions of several pyridinium derivatives under the OECD 
closed bottle test was compared. None of the acesulfamate compounds were found to 
be readily degradable and possessed degradation levels similar to that of the chloride 
analogues. However, this does not necessarily mean the acesulfamate anion 
encourages persistence in the environment as only one of the saccharinate 
compounds, an anion which we believe to be readily degradable, was found to pass 
the test. This may instead point to the persistence of the cation itself with partial 
degradation of the C11 chain found in the readily degradable compound along with 
degradation of the saccharinate anion owing to the positive result obtained. 
If we consider the possible fate of OMIM saccharinate, there are several reported 
biodegradation studies on OMIM halide ionic liquids which indicate that it degrades, 
at least partially, unlike the shorter chain imidazoliums. Docherty et al. determined 
OMIM bromide to not be fully degradable with a level of 41%. However this level is 
significant when we compare it to the lack of degradation of BMIM halides which 
degrade only by 0-1%.
21
 Further to this, Stolte carried out a primary biodegradation 
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study of OMIM chloride coupled with metabolite analysis which indicated that the 
cation is degraded to a 1-carboxymethyl-3-methylimidazolium ion.
22
  
If we compare the low degradability of BMIM halides (0-1%
21
) to the level of 
BMIM saccharinate (100) (41%
1
) it could be inferred that the saccharinate anion is 
almost fully degradable. Likewise, if we then consider the moderate degradation of 
OMIM bromide (41%
23
), substitution of the counter ion to form OMIM saccharinate 
(109) may result in a readily biodegradable compound (>60%). 
The N,N-dibutylpyrrolidinium (131-132)  and N-butylpyridinium (128-129) cure 
accelerators may not be determined to be readily biodegradable however if already 
published data is followed.
24
 N-alkylpyridinium halides have been found to be 
persistent
22
 but if ester functionality can be incorporated into the alkyl chain then 
their fate is markedly improved and readily degradable compounds may be 
prepared.
25
 Likewise, alteration of the alkyl chain substitution of the pyrrolidinium 
cation may be required to prepare readily degradable compounds. While no 
degradation studies of the N,N-dibutyl- derivative have been published to date, N-
methyl-N-butylpyrrolidinium compounds amongst others have been shown to be 
non-degradable
26
. 
 
5.9 Conclusion 
Through analysis of imidazolium based ionic liquids as cure accelerators using the 
fixture time test, the lead compound BMIM saccharinate (100) was identified 
displaying activity equivalent to existing commercial accelerators. In an effort to 
identify the source of this efficient cure activity, further alkyl imidazolium ionic 
liquids as well as those with pyridinium and pyrrolidinium based cations amongst 
others were prepared. These compounds were paired with saccharinate, 
acesulfamate, and phthalimate counter ions before analysis.  
The molecules which were of sufficient solubility in the adhesive formulation were 
evaluated as catalysts using nuts and bolts threadlocking and pins and collars shear 
tests. The imidazolium saccharinates (100, 108-109), acesulfamate (110), and 
phthalimate (111), along with the pyridinium (128-129) and pyrrolidinium (131-132) 
compounds were proven in these tests to possess an excellent ability to affect the 
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cure time of the adhesive and suggested that the source of activity was as a result of 
the anion selected. 
In order to evaluate the potential hazard or risk posed by these compounds, and in 
turn their suitability to replace existing harmful cure accelerators, their activity 
against several strains of bacteria, fungi, as well as two mammalian cell lines was 
determined. Through these tests it was discovered that increasing alkyl chain length 
leads a growth in toxicity whilst use of the saccharinate, acesulfamate, or 
phthalimate anions appears to have no effect as observed from the imidazoliums 
examined (100, 108-111). Although EMIM saccharinate (108) displayed low 
inhibition of the mammalian cells and bacterial strains, the N,N-dibutylpyrrolidinium 
compounds (131-132) prepared resulted in the lowest activity of all compounds 
examined in the cytotoxicity assay, even lower than that of APH. 
 
From these studies on cure activity and cytotoxicity, the compounds which offer the 
best combination of polymerisation time efficiency with low risk are the 
pyrrolidiniums (131-132) examined. They possess cure times and strengths 
analogous to that of commercial accelerators (Graphs 5.16-18) whilst also 
performing the best in the series examined as part the cytotoxicity/anti-microbial 
investigation exhibiting no discernable cell inhibition. 
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Chapter 6: 
Conclusion and 
Future Work  
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6.1 Conclusion 
Existing commercial cure accelerators used are done so with the caveat that they 
pose health risks to the user and are labelled accordingly as acutely toxic or 
hazardous. For these reasons it would be desirable if alternative compounds could be 
developed which were capable of efficient catalytic performance but did not possess 
any of these drawbacks and, furthermore, were environmentally benign. 
There are many mechanisms proposed which may account for cure acceleration 
activity and at the start of this project the suitability of each mechanistic pathway for 
the different compound classes was unknown. A similar problem regarding 
accelerator toxicity also was also present and, due to limited toxicity data, SAR 
studies would not generate reliable identification of trends to predict low toxicity 
examples. Additional data was required and this was achieved through first the 
identification of a primary “first generation” set of compounds which were of 
varying accelerator activity but of which their level of toxicity was unknown. These 
compounds were then screened for properties such as their anti-microbial toxicity, 
cytotoxicity, biodegradability, eco-toxicity, and accelerator activity in order to begin 
to elucidate the structure-activity relationship. Further to this, given that the set 
contained several compounds which are currently applied as commercial 
accelerators, they were to act as a bench mark for these properties against which the 
performance of novel accelerators designed could be compared. 
Anti-microbial toxicity evaluation was carried out in order to investigate whether a 
correlation between the mammalian toxicity and anti-microbial activity of these 
compounds could be constructed. This could then be used to act as an efficient 
primary indicator of the possible mammalian toxicity of any compounds designed. 
Whilst a complete relationship between the two properties could not be constructed 
for this first generation of accelerator compounds, there was a clear link between the 
anti-fungal activity and mammalian toxicity of some compounds. This was evident 
in the case of APH (16) displaying the application of anti-microbial screening as a 
primary means of evaluating the mammalian toxicity of compounds.  
Biodegradation of the same set of compounds illustrated how persistent this family 
of nitrogen heterocycles can be with only three of the fifteen compounds proving to 
be readily biodegradable (16, 30, 33). This persistence is due to structural features 
such as fused multi-cyclic frames, heterocyclic fragments, and tertiary amines but 
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methods of alleviating their effect were illustrated with the presence of oxygen 
containing functional groups and hydrolysable bonds in the compounds which were 
readily degradable. Likewise, the aquatic toxicity study displayed the design rules by 
which low toxicity compounds can be made. By increasing the water solubility of 
any compound designed, their ability to interact with and cross the membrane of any 
organism is reduced along with their potential to cause harm. 
As a whole, this first generation of compounds provided a base set of data from 
which design traits could be used to synthesise new cure accelerators. For example 
the data showed APH to be of low aquatic toxicity and to be readily biodegradable, 
two qualities which should be retained, but since APH is also acutely toxic then 
further development is required. 
These design traits were put into practice through synthesising and testing 
benzomorpholine derivatives. It was postulated that the introduction of an oxygen 
atom into the fused heterocyclic framework may result in increased biodegradability 
and lower the aquatic toxicity whilst still possessing cure activity comparable to the 
THQ or indoline analogues. However this was not the case with the compounds 
synthesised proving to be just as persistent in the environment. 
This research was carried out with green chemistry principles in mind and with that; 
the possibility of designing cure catalysts from natural sources was explored. Given 
their structural similarity to existing accelerators such as indoline, the application of 
tryptophan and several purines was explored. The synthesis of derivatives of these 
compounds highlighted a significant challenge when attempting to design 
compounds which combine several properties, such as cure activity, low toxicity, 
and biodegradability, in that structural changes to enhance them can be made on 
paper, but once synthesised there is no guarantee that the compound prepared will be 
soluble in the adhesive formulation and be suitable for testing. For these reasons 
significant time was spent developing these compounds simply to be able to 
primarily evaluate the presence of any activity as opposed to improve upon and 
develop this property. 
Emphasising the development of compounds with enhanced biodegradation and 
lower toxicity profiles meant less priority was given to aspects such as the cure 
activity of the molecules. For this reason, heterocyclic compounds which were 
capable of variation and derivitisation without the loss of solubility were explored. 
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Imidazoles met this criterion with a preliminary study of a broad variety of 
derivatives displaying their wide ranging solubility in PEGMA at 1% w/w. With 
their suitability assessed, and after altering the adhesive formulation based on mole 
amounts to make the results more comparable, the catalyst applicability of a range of 
imidazoles was assessed with several outcomes.  
The study illustrated the effect of catalyst loading on cure activity displaying that an 
increased amount of accelerator may not result in an increase in cure time observed, 
along with a potential relationship between molecule size and cure activity. 
The investigation of imidazoles as cure accelerators also allowed for the exploration 
of the application of charged compounds through the synthesis of imidazolium 
derivatives. Primary evaluation of BMIM octyl sulfate (80) and BMIM acetate (83) 
in the fixture time test resulted in activity on a par with established commercial 
accelerators. This level of activity merited further investigation and the compounds 
were tested in a further range of adhesive tests as lead cure accelerator candidates. 
Along with these two compounds, a further BMIM based molecule was also tested 
(100). This compound incorporated the saccharinate anion, the charged analogue of 
saccharin which is already known to be cure active and widely included in anaerobic 
adhesives. Testing of these lead compounds showed that 100 possessed a high level 
of activity and the possibility for commercial application. 
In order to explore the source of this activity, a number of ionic liquid compounds 
with varying cations and anions were synthesised along with further alkyl 
imidazoliums. They were tested for their capability to act as threadlockers and their 
shear strength as part of the nuts & bolts and pins & collars tests. This investigated 
structural properties such as aromaticity, and the nitrogen lone pair of electrons 
through pyridinium and pyrrolidinium derivatives, and paired them with the 
acesulfamate, phthalimate, and saccharinate anions.  
All of these compounds tested displayed efficient activity comparable to that of APH 
and illustrated the primary role which the anion plays in the cure accelerator ability 
of the molecule. The phthalimate, acesulfamate, and saccharinate anions all 
exhibited their ability to act as effective anaerobic cure accelerators. 
In order to assess the potential level of risk they may pose, a range of these lead cure 
accelerators were submitted for evaluation of their cytotoxicity against two 
mammalian cell lines and anti-microbial toxicity against a range of fungal and 
187 
 
bacterial strains. Study of imidazolium saccharinates 100, 108, and 109 showed that 
by increasing the alkyl chain length, the toxicity increased due to enhanced 
interaction with the cell membrane. Substitution of the anion (100, 110, 111) resulted 
in no discernable change in toxicity and suggested that the acesulfamate, 
phthalimate, and saccharinate may all be of a low toxicity and given this, if paired 
with a cation also of low toxicity, may result in an effective cure accelerator which 
poses low risk to the user. 
In fact, this was readily achieved with the results of the two pyrrolidinium 
compounds designed. Both N,N-dibutylpyrrolidinium saccharinate (131) and 
acesulfamate (132) possessed remarkable cure accelerator ability whilst also proving 
to be of lower microbial toxicity and cytotoxicity than APH – a key goal of this 
research. The two compounds resulted in strong adhesive bonds after short cure 
times, whilst also displaying low cell inhibition against the cell lines and strains 
tested. 
In terms of their environmental impact, it is likely that both 131 and 132 may not be 
readily degradable but alteration of the N-alkyl substation to contain alcohol and 
ether functional groups has proven in previous studies to result in readily 
biodegradable pyrrolidinium compounds. Such derivitisations would also likely 
increase the water solubility of the compounds and in turn lower the potential aquatic 
toxicity. 
 
6.2 Future Work 
From these studies, the source of cure activity within ionic liquid compounds may 
possibly be solely the result of the anion constituent. This would allow freedom to 
develop the cation with the promotion of other properties such as toxicity, 
biodegradability, bond strength in mind. 
This could potentially lead to custom designed cure accelerators which may be 
altered depending on the application of the adhesive and durability required. Before 
any such development can take place however, the mechanism through which 
polymerisation occurs and the role of the cure accelerator within it should be further 
elucidated. 
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This may be done through studying the potential interaction of each of the 
components of the formulation with the cure accelerator in isolation. For instance, 
ionic liquids may form metal based compounds in the presence of a suitable metal 
ion and likewise may interact with peroxides through hydrogen bonding. 
Occurrences such as these could have a significant effect on the polymerisation 
observed and thus their likelihood to arise may be evaluated through reaction of the 
cure accelerator with the respective analyte at concentrations representative of 
formulation conditions. 
Examination of the properties of the polymer and bond formed may also lead to 
information regarding the curing mechanism of anaerobic adhesives. Specifically 
this would be with the aim of determining the source of bond properties such as the 
strength. In this thesis, measurements of the force required to break the adhesive 
bond formed after specific cure times were used as an indicator of the level of 
polymerisation which had occurred. However, the chance remains that the level of 
force required to cause bond failure may have been as a result of polymer properties 
such as cross-linking as opposed to solely the result of the accelerator increasing the 
rate of polymerisation. Experiments should therefore be carried out in order to study 
the effect of the cure accelerator on the level of cross-linking which occurs within 
the polymer system. 
With more information about the role of the accelerator within the adhesive curing 
mechanism established, development of other properties of the compounds may be 
carried out. As alluded to earlier, if the anion is the major source of cure activity then 
this may allow the cation to be designed with respect to affecting other properties of 
the overall molecule such as toxicity, biodegradability, and adhesive bond properties. 
Ionic liquids containing a N-methyl-N-hydroxypropyl pyrrolidinium cation have 
been shown to be readily biodegradable and if similar transformations were made to 
the N,N-dibutylpyrrolidinium compounds prepared as part of this research then this 
may result in a highly active, biodegradable cure accelerator which is also of low 
anti-microbial and cytotoxicity. 
If we are to consider long-term adhesive applications where high strength and 
durability are matters of priority, then the cation component may be designed to 
maximise bond life and strength. Initially this would entail evaluation of cations such 
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as tetrahydroquinoliniums and alkyl-toluidiniums which are based on neutral 
compounds already of high cure activity. 
In addition, adhesive properties other than the overall strength may also be 
incorporated into the design of ionic liquid cure accelerators. Maleimides can be 
used to enhance the thermal resistance of adhesive bonds and so if the cation were to 
incorporate this functionality the analogous effect may be achieved. This is an 
example whereby ionic liquid cure accelerators could potentially offer multi-
functionality with respect to the adhesive curing process and remove the need for 
additives to be included in product formulations. 
As a result of this research the capability of ionic liquids to act as anaerobic cure 
accelerators has been established. This has not only lead to the discovery of several 
new accelerator molecules, but perhaps more importantly has opened a whole new 
avenue for their development and expansion. 
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Chapter 7: 
Experimental 
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7.1 Biodegradation Screening – IQAC, Barcelona 
In order to evaluate the biodegradability of anaerobic cure accelerators and 
accelerator-like compounds, samples of each compound were submitted to a 
collaborating research group at the “Department of Chemical and Surfactants 
Technology, Institute of Advanced Chemistry of Catalonia”. The samples were 
evaluated using the “CO2 Headspace” test which is a standardised method of 
analysing the aerobic degradation of a test compound.  
A bottle containing a mineral salts medium was inoculated with activated sludge 
containing micro-organisms, which was collected from an aeration tank at a sewage 
treatment plant located in Manresa, Barcelona. The test samples were prepared in 
either water or, for poorly water soluble samples; analytical grade hexane or ethyl 
acetate. A sample was then incubated in the test bottle at a carbon concentration of 
20 mg/L., leaving a “headspace” of air in the bottle. 
Since the test sample is the only source of carbon within the bottle, any CO2 
produced is as a direct result of its biodegradation and thus the extent to which the 
sample degrades can be calculated by measuring this level of CO2. Each sample was 
tested in quadruplicate with the same number of “blank” bottles used and sodium n-
dodecyl sulfate was used as a control. The level of inorganic carbon was measured at 
seven day intervals, and by subtracting the mean amount of inorganic carbon in the 
blank bottles from that of the test samples, the level of total inorganic carbon (TIC) 
produced as a result of sample degradation was determined. This level was then 
expressed as a percentage of the theoretical maximum amount of inorganic produced 
by the sample (ThIC) and the confidence levels calculated. 
In order for a compound to be considered “readily biodegradable”, degradation by a 
minimum level of 60% over 28 days is required. 
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7.2 Aquatic Toxicity Screening – IQAC, Barcelona 
In order to evaluate the aquatic toxicity of anaerobic cure accelerators and 
accelerator-like compounds, samples of each compound were submitted to a 
collaborating research group at the “Department of Chemical and Surfactants 
Technology, Institute of Advanced Chemistry of Catalonia”. Each sample was 
evaluated using MICROTOX and Daphnia magna tests.  
Microtox uses bioluminescent bacteria, Vibrio fischeri, which when exposed to toxic 
substances, exhibit a decrease in light output as a result of their respiratory process 
being disrupted. By measuring this change in luminescence, the toxicity of a test 
sample may be evaluated. 
Evaluations carried out using Daphnia magna involve adding a defined number of 
organisms to a test medium containing the substance to be evaluated. At various time 
intervals the number of offspring produced as well as the number of deceased 
organisms are counted and the toxicity of the substance determined. 
 
 
7.3 Anti-Bacterial Screening – Charles University, Prague 
In vitro anti-bacterial evaluation of anaerobic cure accelerators and accelerator-like 
compounds were carried out by a collaborating research group at the “Department of 
Biological and Medical Sciences, Charles University”.  
The compounds were evaluated on a panel of three ATCC strains (Staphylococcus 
aureus ATCC 6538, Escherichia coli ATCC 8739, Pseudomonas aeruginosa  ATCC 
9027) and five clinical isolates (Staphylococcus aureus MRSA H 5996/08, 
Staphylococcus epidermidis H 6966/08, Enterococcus sp. H 14365/08, Klebsiella 
pneumoniae D 11750/08, Klebsiella pneumoniae ESBL H 14368/08) from the 
collection of bacterial strains deposited at the Department of Biological and Medical 
Sciences, Faculty of Pharmacy, Charles University, Hradec Králové, Czech 
Republic. The abovementioned ATCC strains also served as the quality control 
strains. All the isolates were maintained on Mueller-Hinton dextrose agar prior to 
being tested. 
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Dimethyl sulfoxide (100 %) served as a diluent for all compounds; the final 
concentration did not exceed 2 %. Mueller-Hinton agar (MH, HiMedia, adersky-
Envitek, Czech Republic) buffered to pH 7.4 (±0.2) was used as the test medium. 
The wells of the microdilution tray contained 200 μL of the Mueller-Hinton medium 
with 2-fold serial dilutions of the compounds (2000 or 1000 to 0.488 μmol/l) and 10 
μL of inoculum suspension. Inoculum in MH medium was prepared to give a final 
concentration of 0.5 McFarland scale (1.5 × 10
8
 cfu.mL-1). The trays were incubated 
at 36°C and MICs were read visually after 24 h and 48 h. The MICs were defined as 
95 % inhibition of the growth of control. MICs were determined twice and in 
duplicate. The deviations from the usually obtained values were no higher than the 
nearest concentration value up and down the dilution scale. 
 
7.4 Anti-Fungal Screening – Charles University, Prague 
In vitro anti-fungal evaluation of anaerobic cure accelerators and accelerator-like 
compounds were carried out by a collaborating research group at the “Department of 
Biological and Medical Sciences, Charles University”. 
In vitro antifungal activities of the compounds were evaluated on a panel of four 
ATCC strains (Candida albicans ATCC 44859, Candida albicans ATCC 90028, 
Candida parapsilosis ATCC 22019, Candida krusei ATCC 6258) and eight clinical 
isolates of yeasts (Candida krusei E28, Candida tropicalis 156, Candida glabrata 
20/I, Candida lusitaniae 2446/I, Trichosporon asahii 1188) and filamentous fungi 
(Aspergillus fumigatus 231, Absidia corymbifera 272, Trichophyton mentagrophytes 
445) from the collection of fungal strains deposited at the Department of Biological 
and Medical Sciences, Faculty of Pharmacy, Charles University, Hradec Králové, 
Czech Republic. Three of the above ATCC strains (Candida albicans ATCC 90028, 
Candida parapsilosis ATCC 22019, Candida krusei ATCC 6258) also served as the 
quality control strains. All the isolates were maintained on Sabouraud dextrose agar 
prior to being tested. Minimum inhibitory concentrations (MICs) were determined 
by the microdilution format of the NCCLS M27-A guidelines. 
Dimethyl sulfoxide (100 %) served as a diluent for all compounds; the final 
concentration did not exceed 2 %. RPMI 1640 (Sevapharma, Prague) medium 
supplemented with L-glutamine and buffered with 0.165 M 
morpholinepropanesulfonic acid (Serva) to pH 7.0 by 10 N NaOH was used as the 
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test medium. The wells of the microdilution tray contained 100 μL of the RPMI 
1640 medium with 2-fold serial dilutions of the compounds (2000 or 1000 to 0.48 
μmol/L) and 100 μL of inoculum suspension. Fungal inoculum in RPMI 1640 was 
prepared to give a final concentration of 5 × 10
3
 ± 0.2 cfu.mL-1. The trays were 
incubated at 35°C and MICs were read visually for filamentous fungi and 
photometrically for yeasts as an absorbance at 540 nm after 24 h and 48 h. The 
MIC/IC50 values for the dermatophytic strain (T. mentagrophytes) were determined 
after 72 h and 120 h and for A. fumigatus, A. corymbifera after 24 and 48 h. For all 
other strains MIC/IC80 values were evaluated. The MICs were defined as 50 % or 
80 % inhibition of the growth of control. MICs were determined twice and in 
duplicate. The deviations from the usually obtained values were no higher than the 
nearest concentration value up and down the dilution scale. 
 
7.5 Mammalian Cell Culture Screening – NICPB, Tallinn 
Autoclaved MilliQ water (18 MΩ, Millipore) was used throughout the study. Media 
components for cell culture were from the following companies: Minimum Essential 
Medium (MEM) with GlutaMAX, sodium pyruvate, non-essential amino acids 
(NEAA), streptomycin-penicillin (10 000 U/mL) all from Gibco, Life Technologies; 
fetal bovine serum (FBS) obtained from Biological Industries. Phosphate buffered 
saline (PBS) from Lonza, neutral red (NR) dye was from AppliChem GmbH. Acetic 
acid was from Sigma-Aldrich along with sodium dodecyl sulphate (SDS) and 
dimethyl sulfoxide (DMSO). 
All samples except sample OMIM saccharinate were dissolved in water by 
sonicating for 1 minute (40W, Branson probe sonicator, USA). OMIM Saccharinate 
was dissolved in 5% DMSO in water with all other stock solutions prepared as 3 mM 
in MilliQ water. APH and BMIM phthalimate were prepared fresh before use in any 
experiments. The stock solutions were sterilized by filtration through 0.2 μm filter 
and stored at +4oC in the dark. All the chemicals were tested at their initial pH 
values except N-butyl pyridinium saccharinate which had an initial pH of 2.4 but due 
to the buffering capacity of the culture medium even at the highest tested 
concentration (1 mM) the pH was neutral: pH of the 1mM N-butyl pyridinium 
saccharinate in both test media was 8.1. 
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Cell lines used for the toxicity testing were obtained from American Type Culture 
Collection (ATCC): A549 cells originate from carcinomatous tissue of human lungs 
(ATCC CCL-185) and Caco 2 cells from colorectal adenocarcinomatous tissue of 
human colon (ATCC HTB-37). The cell cultures were maintained according to 
ATCC guidance. A549 cells were cultured in MEM with GlutaMAX and 10%. FBS. 
Caco 2 cells were cultured in MEM with 15% FBS, 1% NEAA, 1% sodium 
pyruvate. All cell culture media were supplemented with 100 μg/mL and 100 U/mL 
of streptomycin-penicillin, respectively. 
The neutral red uptake (NRU) assay in which neutral red dye is taken up only by 
viable cells and is accumulated in lysosomes was carried out essentially according to 
the protocol by Sigma Aldrich. Briefly, the cells were seeded on 96-well plates 
(Cellstar, Greiner) at various initial densities: A549 cells at 5x10
3
 cells per well and 
Caco 2 cells at 1x10
4
 cells per well. The cells were incubated in respective media at 
37C (95% humidity and 5% CO2).  
The stocks of chemicals were prepared at 3 mM as described. Further dilutions were 
prepared in cell culture media. Cells were exposed to 100 μl of chemicals or solvent 
controls at concentrations 0.1 mM, 0.5 mM, and 1 mM. 6.25 - 200 μg/mL sodium 
dodecyl sulphate (SDS) was used as a positive control. The exposed cells were 
incubated at 37C (95% humidity and 5% CO2) for 24 h. After that, test chemicals or 
cell culture medium were removed, the adhered cells washed with PBS, and 
incubated for 3 h in a medium supplemented with neutral red (50 μg/ml). After 3 h 
the neutral red reagent was removed, cells were washed with PBS and 100 μL of NR 
solubilisation solution (1% acetic acid in 50% ethanol) was added. The plates were 
gently shaken for 1 h at room temperature and the absorbance was measured at 540 
nm using a microplate reader (Multiskan, Thermo Scientific). Cell viability was 
determined by the formula: cell viability (%) = (ODtest – ODblank) / (ODcontrol – 
ODblank) x 100.  
Where the data is expressed as the loss of viability (INH%), the INH% value was 
calculated as 100% - viability%. All exposures were performed in at least three 
technical replicates in three independent experiments (0.1 mM concentration) or in 
one independent experiment (0.5 mM and 1.0 mM concentration). The positive 
control SDS was used in all runs. 
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7.6 Anti-Bacterial Screening – NICPB, Tallinn 
All samples except OMIM saccharinate were dissolved in water by sonicating for 1 
minute (40W, Branson probe sonicator, USA). OMIM saccharinate was dissolved in 
5% DMSO in water at 3 mM with all other stock prepared at a concentration of 3 
mM in MilliQ water. For the analysis, the stocks prepared for the mammalian cell 
culture testing (sterilized by filtration through 0.2 µm filter and stored at +4
o
C in the 
dark) were used in order to compare the data of bacterial assays and mammalian cell 
assays in vitro. Most of the stock solutions were prepared on June 2 or June 9, 2015 
with stocks for APH and BMIM phthalimate prepared June 22,  2015. 
For the testing with Vibrio fischeri, NaCl was added to the stocks of the chemicals 
(as an average, 60 mg of NaCl was added to the 3 ml of the stock solution), to adjust 
the salinity of the sample to 2% NaCl, i.e. physiologically optimal salinity for this 
marine bacterium. 
As a positive control 3,5-dichlorophenol (3,5-DCP) was used (suggested by ISO 
21338:2010). All samples except N-butyl pyridinium saccharinate were tested at 
their initial pH values. Stock of N-butyl pyridinium saccharinate had an initial pH 
2.4 and as 2% NaCl has no buffering capacity the pH of this chemical was adjusted 
with NaOH to pH 6.3 prior to toxicity testing. 
The kinetic Vibrio fischeri bioluminescence inhibition assay (flash assay) is an ISO 
standardized acute toxicity test. It is a very rapid and sensitive method to 
evaluate/screen toxic properties of different chemical substances (including synthetic 
NPs and solid/coloured environmental samples, e.g. sediments, soil suspensions, 
wastewater, sludge extracts, etc.
)
 by measuring the reduction of light production of 
test bacteria (naturally luminescent marine bacteria V. fischeri) due to interactions 
between bacteria and toxic compounds. The decrease in bacterial luminescence 
occurs already after brief contact of bacteria with toxicants (in the scale of seconds to 
minutes, depending on the compounds). The decrease in bioluminescence reflects the 
inhibition of bacterial metabolic activity and is proportional to the toxicity of test 
sample. 
Toxicity tests were conducted with Vibrio fischeri strain NRRL B-11177. The 
bacterial suspension used for the toxicity measurements was reconstituted from 
freeze-dried V. fischeri reagent (Aboatox, Turku, Finland). The V. fischeri 
bioluminescence inhibition assay (an acute test, exposure times of 5 seconds, 15 min 
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and 30 min) was performed at room-temperature (~ 20° C) in 96-well polypropylene 
white microplates (Greiner Bio-One, Frickenhausen, Germany) following the 
modified Flash Assay protocol (ISO, 2010). Briefly, 100 μl of test solution in 2% 
NaCl was pipetted into each well, which was supplemented with 100 μl of bacterial 
suspension by automatic dispensing in the Microplate Luminometer Orion II 
(Berthold Detection Systems, Pforzheim, Germany) testing chamber. The changes in 
the bioluminescence of the test bacteria upon exposure to different concentrations 
(0.1-1.5 mM) of different test chemicals were recorded during the first 5 seconds 
after the dispensing of the bacterial suspension in each well, after 15 and 30 minute 
incubation, the light output was recorded again. 
All chemicals and their dilutions were supplemented by NaCl to contain 2% NaCl. 
Each test was performed in at least 4 technical replicates in two independent 
experiments. Controls, both negative (2% NaCl) and positive (3,5-dichlorophenol, 
3,5-DCP), were included in each measurement series. 
The inhibition of bacterial bioluminescence (INH%) by different concentrations of 
the tested compounds at 15 and 30 min was calculated as a percentage of the 
unaffected control (2% NaCl): 





 

t
t
IC
IT
INH
100
100%  
where 
tIT  – luminescence of bacteria exposed to certain concentration of chemicals after 
certain time of exposure (t=15 min, 30 min); 
tIC  – luminescence of bacteria in the control solution (2% NaCl) after certain time 
of incubation (t=15 min, 30 min). 
 
EC50 values are usually applied as a quantitative measure of the toxicity of a 
chemical. In the current study 15 minute and 30 minute EC50 is the concentration of 
the chemicals (mM) that causes the inhibition of bacterial luminescence by 50% after 
15 or 30 minute exposure to the chemical, respectively. The EC50 value was 
calculated from the concentration-effect data. Due to the low toxicity of most of the 
chemicals in the concentration range tested (up to 1.5 mM), only the EC50 for the 
most toxic chemical, OMIM saccharinate, was able to be calculated. The coefficient 
of variation of INH% values obtained in different days did not exceed 5%. 
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7.7 Cure Accelerator Evaluation 
In order to evaluate cure accelerator activity, adhesive formulations were prepared as 
per Tables 7.1 or 7.2 as stated. 
 
Table 7.1: PEGMA Formulation Specification 
Component % Weight 
Polyethylene glycol dimethacrylate 95.5 
Saccharin 0.5 
Trigonox TMBH-L 2 
PM 16 0.5 
PM 17 0.5 
Accelerator 1 
 
Table 7.2: Model Formulation Specification 
Component % Weight 
Polyethylene glycol dimethacrylate 50 
RROC  45.05 
PM17 2 
Saccharin 1 
Paramenthane Hydroperoxide 1 
PM40 0.4 
Accelerator 0.95 
 
These formulations were then applied as part of several tests: 
Fixture Time Test 
The fixture time test was used as primary method of evaluation of possible cure 
accelerators. The mild steel substrate surface is pre-treated prior to use by grit-
blasting. A series of bonds are prepared by bonding two pieces of the mild steel such 
that they have a half inch overlap. At 30 minute cure time intervals, the strength of 
the bond is tested by attach a 3 kg weight by means of a spring to one of the pieces 
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of steel. If the bond is capable of holding the weight for five minutes it is deemed to 
have passed the test. Through preparing further series‟ of bond specimens, the cure 
time is determined to within five minutes. 
 
Determination of Torques Strength – Nuts and Bolts (ISO 10964) 
The torque strength of the adhesive bond formed was measured as per ISO 10964. 
The test was carried out suing two types of specimens; stainless steel nuts & bolts 
and black oxide bolts with mild steel nuts. The adhesive was applied to bolts and the 
threaded joint fastened. These bonds were allowed cure for either 1 hour or 24 hours 
cure time after which the torque strength was measured in terms of the break torque, 
prevail torque at 180, and maximum torque. 
 
Determination of Shear Strength – Pins and Collars (ISO 10123) 
The shear strength of the anaerobic adhesive bonds formed were measured as per 
ISO 10123.  
 
7.8 Chemicals 
All chemicals were purchased from Sigma Aldrich, TCI Chemicals, or Acros 
Organics. Silica gel from Sigma Aldrich was used for column chromatography. 
THF, methanol, ethanol, DCM, and diethyl ether were all dried over molecular 
sieves and distilled prior to use. THF was also dried over sodium/benzophenone. 
7.9 NMR Analysis 
All NMR analysis was performed using a Bruker 400 MHz spectrometer, operating 
at 400 MHz for 
1
H NMR and 100 MHz for 
13
C NMR, or, a Bruker 600 MHz 
spectrometer, operating at 600 MHz for 
1
H NMR and 150 MHz for 
13
C NMR. 
Samples were dissolved in chloroform-d, DMSO-d6, deuterium oxide, or 35% 
deuterium chloride in D2O prior to analysis. Chemical shifts are reported in parts per 
million (ppm) and coupling constants (J) are measured in Hertz (Hz). Splitting 
patterns of sample peaks are reported using the following abbreviations: s – singlet, d 
– doublet, t – triplet, q – quartet, dd – doublet of doublets, ddd – doublet of doublet 
of doublets, dt – doublet of triplets, tt – triplet of triplets, m – multiplet. 
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7.10 Synthetic Procedures 
 
N-Butyl Tetrahydroquinoline (29)
1
 
 
The compound was prepared by addition of tetrahydroquinoline (2.50 g, 2.36 mL, 
19.0 mmol), diisopropylethylamine (3.64 g, 4.90 mL, 28.0 mmol), and DMF (20 
mL) to a round bottomed flask. 1-Bromobutane (3.86 g, 3.62 mL, 28.0 mmol) was 
added gradually and the solution was stirred at reflux for 2 hours. The reaction 
solution was allowed cool to RT upon which the DIPEA bromide salt precipitated 
and was removed by filtration. The reaction mixture was diluted with deionised 
water (40 mL) and diethyl ether (20 mL) and washed with a further 20 mL of Et2O. 
The organic layers were combined and washed with deionised water (3x20 mL) and 
dried over MgSO4. The organic layer was filtered, then evaporated to dryness to 
yield a brown oily liquid (86%, 3.2 g, 17 mmol). 
1
H NMR (400 MHz, Chloroform-d) δ 7.17 – 7.07 (m, 1H, -ArH), 7.05 – 6.98 (m, 
1H, -ArH), 6.68 – 6.58 (m, 2H, -ArH), 3.39 – 3.25 (m, 4H, -ArNCH2CH2CH2Ar, -
NCH2CH2CH2CH3 ), 2.83 (t, J = 6.4 Hz, 2H, -ArCH2CH2CH2N), 2.07 – 1.96 (m, 2H, 
-ArCH2CH2CH2), 1.72 – 1.59 (m, 2H, -CH2CH2CH3), 1.52 – 1.38 (m, 2H, -
CH2CH3), 1.04 (t, J = 7.3 Hz, 3H, -CH3). 
13
C NMR (100 MHz, Chloroform-d) δ 145.38 (-ArC), 129.18 (-ArCH), 127.10 (-
ArCH), 122.16 (-ArC), 115.20 (-ArCH), 110.47 (-ArCH), 51.28 (-OCH2CH2N), 
49.52 (-CH2CH2CH2CH3), 28.44 (-ArCH2CH2CH2N), 28.30 (-CH2CH2CH3), 22.32 
(-ArCH2CH2CH2), 20.55 (-CH2CH3), 14.16 (-CH3). 
1
H Spectrum in agreement with reported literature spectrum
1
. 
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Tetrahydroquinoline “Diol” (35)1 
  
The compound was prepared as per a slight modified method of that outlined
1
. To a 
250 mL round bottomed flask, tetrahydroquinoline (7.00 g, 6.60 mL, 54.0 mmol) 
and glycidol (4.00 g, 3.60 mL, 54.0 mmol) were added under nitrogen. The mixture 
was heated to 60C for one hour before a paste formed upon which 20 mL of 
methanol was added in order to dissolve and allow the reaction mixture to be stirred. 
The mixture was heated to 60C and allowed stir for 18 hours after which deionised 
water (100 mL) was added before the mixture was stirred at 60C for a further 9 
hours. The precipitate was isolated via vacuum filtration and recrystallized from 
IPA/deionised water to give the title compound as a white solid in 59% yield (5.48g, 
32.0 mmol). 
1
H NMR (400 MHz, Chloroform-d) δ 7.11 – 7.01 (m, 1H, ArH), 6.98 (d, 1H, ArH), 
6.74 – 6.60 (m, 2H, ArH), 4.11 – 4.01 (m, 1H, -CH2CH(OH)CH2OH), 3.81 (dd, J = 
11.3, 3.3 Hz, 1H, -CH(OH)CH2OH), 3.60 (dd, J = 11.3, 5.4 Hz, 1H, -
CH(OH)CH2OH), 3.45 – 3.23 (m, 4H, -ArCH2CH2CH2N, -NCH2CH(OH)CH2OH), 
2.83 – 2.75 (m, 2H, -ArCH2CH2CH2N), 2.51 (s, 1H, -OH), 2.10 (s, 1H, -OH), 2.02 – 
1.89 (m, 2H, -ArCH2CH2CH2N). 
13
C NMR (100 MHz, Chloroform-d) δ 145.71 (-ArC), 129.53 (-ArCH), 127.24 (-
ArCH), 123.19 (-ArC), 117.06 (-ArCH), 111.86 (-ArCH), 69.54 (-
CH2CH(OH)CH2OH), 64.49 (-CH(OH)CH2OH), 54.99 (-ArCH2CH2CH2N), 50.90 (-
NCH2CH(OH)CH2OH), 28.03 (-ArCH2CH2CH2N), 22.12 (-ArCH2CH2CH2N). 
1
H and 
13
C spectra in agreement with literature
2
. 
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Indoline “Diol” (36)1 
 
Indoline (2.50 g, 2.35 mL, 21.0 mmol), glycidol (1.55 g, 21.0 mmol, 1.40 mL) and 
deionised water (5 mL) were added to a round bottomed flask and the solution stirred 
at 0C for 2 hours upon which a white solid formed. This precipitate was isolated by 
vacuum filtration and recrystallized from acetone to give the title compound (15) in 
62% yield (2.54 g, 13.0 mmol). 
1H NMR (400 MHz, Deuterium Oxide) δ 7.17 – 7.05 (m, 2H, -ArH), 6.78 – 6.69 
(m, 1H, -ArH), 6.57 (d, J = 7.9 Hz, 1H. -ArH), 4.04 – 3.94 (m, 1H, -
CH(OH)CH2OH), 3.83 (dd, J = 11.4, 3.4 Hz, 1H, -CH(OH)CH2OH), 3.62 (dd, J = 
11.4, 5.3 Hz, 1H, -CH(OH)CH2OH), 3.59 – 3.48 (m, 1H, -ArCH2CH2N), 3.38 – 3.20 
(m, 2H, -ArCH2CH2N, -NCH2CH(OH)CH2), 3.09 – 2.91 (m, 3H, -
NCH2CH(OH)CH2, -ArCH2CH2), 2.84 (s, 1H, -OH), 2.35 (s, 1H -OH). 
13
C NMR (100 MHz, Deuterium Oxide) δ 152.73 (-ArC), 130.08 (-ArC), 127.52 (-
ArCH), 124.74 (-ArCH), 118.82 (-ArCH), 107.72 (-ArCH),  69.61 (-
CH(OH)CH2OH), 64.56 (-CH(OH)CH2OH), 54.94 (-ArCH2CH2N), 53.61 (-
NCH2CH(OH)CH2), 28.90 (-ArCH2CH2). 
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Dihydrotryptophan (42)
3
 
 
L-Tryptophan (1.50 g, 7.30 mmol) was dissolved in 1 M hydrochloric acid (30 mL) 
in a round bottomed flask along with 10% Pd/C (300 mg). A balloon of hydrogen 
was attached and the mixture allowed stir at RT for 24 hours before the flask was 
flushed with nitrogen gas and the catalyst removed by filtration. The reaction 
solution made alkaline using 1 M ammonium hydroxide (40 mL). The reaction 
solution was evaporated to dryness and the product recrystallised from deionised 
water resulting in a mixture of stereoisomers (55%, 0.82 g, 4.0 mmol). 
1H NMR (600 MHz, Deuterium Oxide) δ 7.27 (dd, J = 18.2, 7.2 Hz, 1H, -ArH), 
7.17 (t, J = 7.6 Hz, 1H, -ArH), 6.95 – 6.84 (m, 2H, -ArH), 3.81 (m, 1H, -CH2NH), 
3.74 – 3.63 (m, 1H, -CH2NH), 3.48 (m, 1H, -CHNH2), 3.24 – 3.17 (m, 1H, -
CHCH2NH), 2.36 – 2.17 (m, 1H, -CH2CH(NH2), 2.16 – 1.97 (m, 1H, -CH2CH(NH2). 
13
C NMR (150 MHz, Deuterium Oxide) δ 174.71 (-C(O)O), 174.44 (-C(O)O), 
150.14 (-ArC), 132.93 (-ArC), 132.74 (-ArC), 128.23 (-ArC), 128.19 (-ArC), 124.27 
(-ArC), 124.07 (-ArC), 120.62 (-ArC), 120.55 (-ArC), 111.93 (-ArC), 111.92 (-ArC), 
53.47 (-CHNH2), 53.41 (-CHNH2), 52.01 (-CH2NH), 51.97 (-CH2NH), 38.32 (-
CHCH2NH), 37.97 (-CHCH2NH), 35.84(-CH2CH(NH2)), 35.34 (-CH2CH(NH2)). 
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L-Tryptophan Methyl Ester Hydrochloride Salt (43)
4
 
 
L-Tryptophan (2.01 g, 9.8 mmol) was added to MeOH (30 mL) and the mixture 
cooled to 0C. SOCl2 (2.0 mL, 29.0 mmol) was added drop wise before the solution 
was allowed warm to RT and stir overnight. Et2O was added causing the product to 
precipitate. The title compound was isolated and washed with Et2O to yield the 
hydrochloride salt (82%, 2.06 g, 8.1 mmol). 
1H NMR (400 MHz, Deuterium Oxide) δ 7.56 (d, J = 7.9 Hz, 1H, -ArH), 7.49 (d, J 
= 8.2 Hz, 1H, -ArH), 7.29 – 7.18 (m, 2H, -ArH, -IndoleH), 7.19 – 7.10 (m, 1H, -
ArH), 4.45 – 4.37 (m, 1H, -CH(NH2)C(O)O), 3.76 (s, 2H, -CH2CH(NH2)), 3.51 – 
3.35 (m, 3H, -CH3). 
13C NMR (100 MHz, Deuterium Oxide) δ 170.35 (-C(O)OCH3), 136.18 (-ArC), 
126.26 (-ArC), 125.29 (-ArC), 122.15 (-ArC), 119.52 (-ArC), 117.94 (-ArC), 111.97 
(IndC), 105.87 (IndC), 53.46 (-CH3), 53.21 (-CH(NH2)C(O)O), 25.57 (-
CH2CH(NH2)). 
1
H and 
13
C spectra in agreement with literature
5
. 
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L-Tryptophan Ethyl Ester Hydrochloride Salt (44)
4
 
 
The product was prepared as per the method described for L-tryptophan methyl ester 
HCl   using L-tryptophan (0.50 g, 2.4 mmol), EtOH (8 mL), and SOCl2 (0.40 mL, 
5.5 mmol). The title compound was isolated a white solid (85%, 0.55 g, 2.0 mmol). 
1H NMR (400 MHz, Deuterium Oxide) δ 7.59 (d, J = 7.9 Hz, 1H, -ArH), 7.49 (d, J 
= 8.2 Hz, 1H, -ArH), 7.29 – 7.18 (m, 2H, -ArH, -IndoleH), 7.15 (td, J = 7.6, 1.0 Hz, 
1H, -ArH), 4.38 (t, J = 6.4 Hz, 1H, -CH(NH2)C(O)O), 4.18 (q, J = 7.1 Hz, 2H, -
CH2CH3 ), 3.54 – 3.36 (m, 2H, -CH2CH(NH2) ), 1.16 (t, J = 7.2 Hz, 3H, -CH3). 
13C NMR (100 MHz, Deuterium Oxide) δ 169.91 (-C(O)OC2H5), 136.18 (-ArC), 
126.30 (-ArC), 125.25 (-ArCH), 122.14 (-ArCH), 119.48 (-ArCH), 117.96 (-ArCH), 
111.95 (IndC), 105.96 (IndC), 63.50 (-CH2CH3) , 53.29 (-CH(NH2)C(O)O), 25.65 (-
CH2CH(NH2)), 12.91 (-CH3). 
 
 
L-Tryptophan Butyl Ester Hydrochloride Salt (45)
4
 
 
The product was prepared as per a modified method of that described for L-
tryptophan methyl ester using L-tryptophan (1.0 g, 4.9 mmol), BuOH (16 mL), and 
SOCl2 (1.06 mL, 14.7 mmol). This mixture was heated at 100C overnight and upon 
cooling to RT, the precipitate was isolated from solution and washed with cold pet-
ether to yield the  title compound (70%, 1.01 g, 3.4 mmol). 
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1H NMR (400 MHz, Deuterium Oxide) δ 7.58 (d, J = 8.0 Hz, 1H, -ArH), 7.49 (d, J 
= 8.2 Hz, 1H, -ArH), 7.29 – 7.20 (m, 2H, -ArH, -IndoleH), 7.15 (t, J = 7.3 Hz, 1H, 
ArH), 4.40 (t, J = 6.4 Hz, 1H, -CH(NH2)C(O)O), 4.12 (t, J = 6.5 Hz, 2H, -
CH2CH2CH2CH3), 3.45 (d, J = 6.4 Hz, 2H, -CH2CH(NH2)C(O)O), 1.53 – 1.41 (m, 
2H, -CH2CH2CH3), 1.15 (tq, J = 7.4, 7.4 Hz, 2H, -CH2CH3), 0.79 (t, J = 7.4 Hz, 3H, 
-CH3). 
13C NMR (100 MHz, Deuterium Oxide) δ 167.41 (-C(O)OC4H9), 133.50 (-ArC), 
123.60 (-ArC), 122.44 (-ArCH), 119.43 (-ArCH), 116.76 (-ArCH), 115.23 (-ArCH), 
109.26 (IndC), 103.27 (IndC), 64.42 (-CH2CH2CH2CH3, 50.61 (-CH(NH2)C(O)O), 
26.74 (-CH2CH2CH3), 23.09 (-CH2CH(NH2)), 15.49 (-CH2CH3), 10.02 (-CH3). 
 
 
L-Tryptophan Octyl Ester Hydrochloride Salt (46)
4
 
 
The product was prepared as per a modified method of that described for L-
tryptophan methyl ester using L-tryptophan (1.0 g, 4.9 mmol), Octanol (40 mL), and 
SOCl2 (1.0 mL, 14.7 mmol). This mixture was stirred at 100C overnight and 
cooling to RT, the precipitate was isolated from solution and washed with DCM to 
yield the  title compound (52%, 0.9 g, 2.55 mmol). 
1
H NMR (400 MHz, DMSO-d6) δ 11.22 (s, 1H, -NH)  8.81 (br. s, 3H, -NH3), 7.52 
(d, J = 7.9 Hz, 1H, -ArH), 7.37 (d, J = 8.1 Hz, 1H, -ArH), 7.26 (d, J = 2.2 Hz, 1H, -
IndoleH), 7.06 (t, J = 7.4 Hz, 1H, -ArH), 6.98 (t, J = 7.4 Hz, 1H, -ArH), 4.19 – 4.11 
(m, 1H, -CH(NH2)C(O)O), 3.95 (m, 2H, -CH2C7H15), 3.39 (m, 1H, - 
CH2CH(NH2)C(O)O), 3.28 (dd, J = 14.6, 7.5 Hz, 1H, - CH2CH(NH2)C(O)O), 1.45 – 
1.32 (m, 2H, -CH2CH2C5H10CH3), 1.30 – 1.01 (m, 10H,- CH2CH2C5H10CH3), 0.85 
(t, J = 7.0 Hz, 3H, -CH3). 
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13
C NMR (100 MHz, DMSO-d6) δ 169.44 (-C(O)OC8H17), 136.27 (-ArC), 126.99 (-
ArC), 124.87 (IndC), 121.05 (-ArCH), 118.47 (-ArCH), 118.01 (-ArCH), 111.60 (-
ArCH), 106.52 (IndC), 65.51 (-OCH2C7H15), 60.76 (-CH(NH2), 52.79 (-
OCH2CH2C6H13), 31.31 (-CH2CH(NH2)), 28.67 (-OCH2CH2CH2C5H11), 28.62 (-
CH2C4H9), 27.80(-CH2C3H7), 25.16 (-CH2C2H5), 22.18 (-CH2CH3), 14.02 (-CH3). 
 
 
Dihydrotryptophan Methyl Ester (47)
3
 
 
Dihydrotryptophan methyl ester was prepared using a modified method of that used 
to prepare dihydrotryptophan. L-tryptophan methyl ester hydrochloride (1.01 g, 3.4 
mmol) was added to a flask along with deionised water (30 mL) and 10% Pd/C (20% 
w/w). Conc. HCl (0.2 mL) was added before a balloon of hydrogen gas was attached 
and the mixture allowed stir overnight. Upon work-up, the reaction was not complete 
and so fresh catalyst was added and the mixture allowed stir at RT for 24 hours. This 
process was repeated once more before the catalyst was removed and the solution 
neutralised using 1M ammonium hydroxide. The solvent was removed by rotary 
evaporation and the crude product recrystallised from water to yield the title 
compound as a mixture of stereoisomers. (52%, 0.39 g, 1.8 mmol). 
1
H NMR (600 MHz, Deuterium Oxide) δ 7.18 (t, J = 6.7 Hz, 1H, -ArH), 7.12 (t, J 
= 7.6 Hz, 1H, -ArH), 6.86 (t, J = 7.4 Hz, 1H, -ArH), 6.81 (d, J = 7.8 Hz, 1H, -ArH), 
3.74 – 3.68 (m, 3H, -OCH3), 3.68 – 3.58 (m, 1H, -CH(NH2)), 3.58 – 3.48 (m, 1H, m, 
1H, -CH2NH), 3.45 – 3.28 (m, 1H, -CHCH2CH(NH2)), 3.14 – 3.05 (m, 1H, -
CH2NH), 2.21-1.97 (m, 1H, -CH2CH(NH2)), 1.97-1.76 (m, 1H, -CH2CH(NH2)). 
13C NMR (150 MHz, Deuterium Oxide) δ 176.38 (-C(O)O), 176.27 (-C(O)O), 
150.33 (-ArC), 150.25 (-ArC), 133.24 (-ArC), 133.21 (-ArC), 128.05 (-ArC), 128.02 
(-ArC), 124.19 (-ArC), 120.42 (-ArC), 120.38 (-ArC), 111.81 (-ArC), 52.73 (-
208 
 
CH(NH2)), 52.69 (-CH(NH2)), 52.43 (-OCH3), 52.08 (-CH2NH), 51.96 (-CH2NH), 
38.26 (-CHCH2CH(NH2), 38.17 (-CHCH2CH(NH2), 37.64 (--CH2CH(NH2), 37.61 (-
CH2CH(NH2)). 
 
 
Dihydrotryptophan Butyl Ester (48)
3
 
 
The product was prepared as per the procedure for dihydrotryptophan methyl ester 
using L-tryptophan butyl ester hydrochloride (0.25 g, 0.9 mmol). This title 
compound was isolated in  39% yield (100 mg, 0.38 mmol). 
1H NMR (600 MHz, Deuterium Oxide) δ 7.43 – 7.24 (m, 2H, -ArH), 7.18 – 7.08 
(m, 2H, -ArH), 4.30 – 4.16 (m, 3H, -CH2C3H7, -CH2NH), 3.88 – 3.78 (m, 1H, -
CH2NH), 3.72 – 3.64 (m, 1H, -C3H), 3.42 – 3.34 (m, 1H, -CH(NH2)C(O)O), 2.54 – 
2.13 (m, 2H, -CH2CH(NH2)), 1.72 – 1.62 (m, 2H, -CH2CH2CH3), 1.44 – 1.32 (m, 
2H, -CH2CH3), 0.94 – 0.86 (m, 3H, -CH3). 
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N-Boc-L-Tryptophan (49)
6
 
 
Boc protected tryptophan was prepared as per the published method. L-Tryptophan 
(2.05 g, 10.0 mmol) was dissolved in 1:1 H2O:dioxane (40 mL) before 1M NaOH 
(10 mL) and di-tert-butyl carbonate (2.21 g, 10.0 mmol) were added. The mixture 
was stirred at RT for 24 hours before the pH was adjusted to 2 using 1 M HCl. The 
product was extracted using EtOAc (3 x 80 mL) and the organic layers pooled and 
dried over MgSO4. After filtration, the solvent was removed by rotary evaporation to 
yield the title compound (77% yield, 2.33 g, 7.66 mmol). 
1
H NMR (400 MHz, DMSO-d6) δ 12.61 (s, 1H –OH), 10.87 (s, 1H, -IndoleNH), 
7.57 (d, J = 7.8 Hz, 1H, -ArH), 7.37 (d, J = 8.0 Hz, 1H, -ArH), 7.19 (s, 1H, -
IndoleH), 7.10 (t, J = 7.1 Hz, 1H, -ArH), 7.05 – 6.97 (m, 2H, -ArH, -NH(COO)), 
4.22 (m, 1H, -CH(NH)C(O)O) 3.19 (dd, J = 14.5, 4.6 Hz, 1H, -CH2CH(NH)C(O)O), 
3.03 (dd, J = 14.6, 9.4 Hz, 1H, -CH2CH(NH)C(O)O), 1.35 (s, 9H, -C(CH3)3). 
13
C NMR (100 MHz, DMSO-d6) δ 174.22 (-CH2C(O)O), 155.61 (-NHC(O)O), 
136.26 (-ArC), 127.35 (-ArC), 124.01 (IndC), 121.09 (-ArCH), 118.54 (-ArCH), 
118.33 (-ArCH), 111.58 (-ArCH), 110.33 (IndC), 78.21 (-C(CH3)3), 66.51 (-
CH(NH)C(O)O), 54.72 (-CH2CH(NH)C(O)O), 28.33 (-C(CH3)3). 
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N-Boc-1-Butyl-L-Tryptophan Butyl Ester (50)
6
 
 
N-Boc-L-Tryptophan (1.51 g, 5.0 mmol) was dissolved in DMSO (15 mL) before 
NaOH (10 mmol) was added. This solution was heated to 40C before bromobutane 
(1.62 mL, 15.0 mmol) was added and stirred for 4 hours. The product solution was 
diluted with H2O (100 mL) and extracted using EtOAc (3 x 30 mL). The organic 
layers were dried using Na2SO4, filtered, and evaporated to dryness to yield the 
crude product. The title compound was purified by column chromatography 
(DCM:MeOH, 80:20) to yield a white solid (72%, 3.6 mmol, 1.32 g). 
1
H NMR (400 MHz, Chloroform-d) δ 7.56 (t, J = 8.2 Hz, 1H, -ArH), 7.32 (m, 1H, 
-ArH), 7.24 –7.16 (m, 1H, -ArH), 7.15-7.06 (m, 1H, -ArH), 6.90 (s, 1H, -IndoleH),  
5.08 (m, 1H, -CH2CH(NH2)), 4.67 – 4.57 (m, 1H, -CH2CH(NH2)), 4.05 (m, 4H, -
OCH2, -NCH2), 3.27 (m, 1H, -CH(NH)), 1.83-1.74 (m, 2H, -OCH2CH2C2H5),  1.62 – 
1.47 (m, 2H, -NCH2CH2C2H5), 1.44 (s, 9H, C(CH3)3), 1.41 – 1.21 (m, 4H, -
OC2H4CH2CH3, -NC2H4CH2CH3), 0.91 (m, 6H, -OC3H6CH3, -NC3H6CH3). 
13
C NMR (100 MHz, Chloroform-d) δ 172.56 (-CHC(O)O), 155.36 (-NHC(O)O), 
136.24 (-ArCN(C4H9)), 128.40 –ArC), 126.56 (-IndoleCN(C4H9)), 121.61 (-ArCH), 
119.05 (-ArCH), 109.49 (-ArCH), 108.67 (-ArCH), 79.79 (-C(CH3)3), 65.27 (-
OCH2), 54.45 (-CHNH), 46.07 (-NCH2), 32.39 (-OCH2CH2), 30.58 (-NCH2CH2), 
28.45 (-C(CH3)3), 20.27 (-OC2H4CH2CH3), 19.12 (-NC2H4CH2CH3), 13.83 (-
OC3H6CH3), 13.80 (-NC3H6CH3). 
1
H and 
13
C spectra in agreement with literature
5
. 
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1-Butyl Tryptophan (51)
6
 
 
N-Boc-1-Butyl-L-Tryptophan Butyl Ester (1.48 g, 3.6 mmol) was dissolved in 
DMSO (20 mL) and 1M NaOH (12 mL) and stirred at RT for 30 minutes whilst 
monitoring by TLC (DCM:MeOH, 9:1). H2O (100 mL) was added to the solution 
and the pH adjusted to 2 using 1M HCl before extraction using EtOAc (6 x 30 mL). 
The solvent was removed by rotary evaporation and the crude product dissolved in 
TFA:DCM 1:4 (20 mL) and stirred for 2 hours. The solvent was removed and the 
crude product taken up in H2O (10 mL) and adjusting to neutral pH precipitated the 
product in 40% yield (1.4 mmol, 0.36 g). 
1
H NMR (400 MHz, DMSO-d6) δ 7.57 (d, J = 7.8 Hz, 1H, -ArH), 7.42 (d, J = 8.2 
Hz, 1H, -ArH), 7.21 (s, 1H, -IndoleH), 7.15 – 7.08 (m, 1H, -ArH), 7.05 – 6.96 (m, 
1H, -ArH), 4.08 (t, J = 7.1 Hz, 2H, -CH2CH2CH2CH3), 3.61-3.58 (m, 1H, -
CHCH2(NH2)) 3.29 (dd, J = 15.1, 4.3 Hz, 1H, -CH2(NH2)C(O)O), 3.01 (dd, J = 15.1, 
8.4 Hz, 1H, -CH2(NH2)C(O)O), 1.70 (m, 2H, -CH2CH2CH3), 1.40 – 1.21 (m, 2H, -
CH2CH3), 0.89 (t, J = 7.4 Hz, 3H, -CH3). 
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9-Butyl Adenine (54)
7
 
 
The compound was prepared using adenine (0.27 g, 2.0 mmol) dissolved in DMF (8 
mL) along with K2CO3 (400 mg) before 1-bromobutane (0.26 mL, 2.40 mmol) was 
added. The mixture was stirred at RT under nitrogen for 96 hours before the solvent 
was removed by rotary evaporation and the title compound purified by column 
chromatography to yield a white solid (8:1:1, CHCL3:MeOH:cC6H12) (0.35 g, 1.8 
mmol, 90%). 
1
H NMR (400 MHz, DMSO-d6) δ 8.13 (d, J = 2.7 Hz, 2H, H2, H8), 7.21 (s, 2H, -
NH2), 4.12 (t, J = 7.1 Hz, 2H, -CH2CH2CH2), 1.81 – 1.70 (m, 2H, -CH2CH2CH3), 
1.28 – 1.18 (m, 2H, -CH2CH3), 0.87 (t, J = 7.4 Hz, 3H, -CH3). 
13C NMR (100 MHz, DMSO) δ 155.98, 152.39 (C2), 149.57, 140.89 (C8), 118.75, 
42.62 (-CH2CH2CH2CH3), 31.49 (-CH2CH2CH3), 19.30 (-CH2CH3), 13.44 (-CH3). 
1
H and 
13
C spectra in agreement with literature
5
. 
ESI-HRMS m/z calcd. for C9H13N5[M+H]
+
: 192.1244 Found: 192.1236 
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Tris-Boc Adenine (55)
8
 
 
Adenine (1.35 g, 10.0 mmol), DMAP (0.12 g, 1.0 mmol), and Boc2O (9.04 g, 40 
mmol) were added to a flask along with dried THF (50 mL). The mixture was 
allowed stir at RT under nitrogen for 36 hours whilst being monitored by TLC (7:3, 
Hexane:EtOAc). The solvent was evaporated to dryness and the product purified by 
column chromatography (7:3, Hexane:EtOAc) to yield 85% (3.7 g, 8.5 mmol). 
1
H NMR (400 MHz, Chloroform-d) δ 9.00 (s, 1H, H2), 8.50 (s, 1H, H8), 1.70 (s, 
9H, -N(C(O)OC(CH3)3, 1.41 (s, 18H, -N(C(O)OC(CH3)3)2. 
13
C NMR (100 MHz, Chloroform-d) δ 154.18 (C2), 152.54, 151.28, 150.11, 
145.70, 143.30 (C8), 129.67, 87.61 (-C(CH3)3), 84.08 (-(C(CH3)3)2), 28.02 (-
N(C(O)OC(CH3)3), 27.83 (-N(C(O)OC(CH3)3)2). 
1
H and 
13
C spectra in agreement with literature
8
. 
 
 
N
6
-Cbz-Adenine (56)
9
 
 
0.66 g of NaH (60% dispersion in oil, 17.0 mmol) was washed with dry DMF before 
being added to a flask containing DMF (25 mL) along with adenine (0.29 g, 2.0 
mmol). The mixture was cooled on ice before ClCOOBn (0.43 mL, 3.0 mmol) was 
added. The reaction mixture was warmed to RT and stirred for 36 hours. Ice-cold 
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deionised water (50 mL) was added before the pH was adjusted to 7 using 1 M HCl. 
A white solid precipitate was formed which was collected by filtration and the title 
compound was recrystallised from DCM:MeOH (0.21 g, 0.78 mmol, 39%). 
1
H NMR (400 MHz, DMSO-d6) δ 12.30 (s, 1H, -N
9
H ), 11.00 (s, 1H, -N
6
H), 8.59 
(s, 1H, H2), 8.44 (s, 1H, H8), 7.49 – 7.33 (m, 5H, -C6H5), 5.28 (s, 2H, -
NHCH2C6H5). 
13C NMR (150 MHz, DMSO) δ 161.81 (C4), 153.63 (-CO), 151.20 (C2), 
145.97(C6), 144.47 (C8), 135.92 (-ArC), 128.49 (-ArC), 128.20 (-ArC), 128.00 (-
ArC), 112.84 (C5), 66.88 (-CH2). 
 
 
1
H and 
13
C spectra in agreement with literature
9
. 
Benzomorpholine (57)
10
 
 
Benzomorpholine was prepared by dissolving 2H-1,4-benzoxazin-3(4H)-one (5.01 g, 
33.5 mmol) in dry THF (60 mL). This solution was added drop wise to a flask 
containing 2.4 M LiAlH4 in THF (83 mmol) whilst cooling on ice. The mixture 
stirred at reflux for 24 hours before being quenched using 6 mL of deionised water 
and 3 mL of 15% w/w NaOH. It was diluted with a further 100 mL if deionised 
water and filtered to remove the salts formed which were washed with THF and 
added to the reaction solution. The product was then extracted using EtOAc (3 x 100 
mL) and the layers combined and dried over Na2SO4. The solvent was removed by 
rotary evaporation to yield a brown oil (94%, 4.27 g, 31.6 mmol). 
1
H NMR (400 MHz, Chloroform-d) δ 6.91 – 6.79 (m, 2H, -ArH), 6.73 (td, J = 7.6, 
1.6 Hz, 1H, -ArH), 6.63 (dd, J = 7.7, 1.6 Hz, 1H, -ArH), 4.31 – 4.24 (m, 2H, -
COCH2CH2), 3.77 (s, 1H, -NH), 3.43 – 3.36 (m, 2H, -CNHCH2CH2). 
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13
C NMR (100 MHz, Chloroform-d) δ 143.97 (-ArC), 133.68 (-ArC), 121.22 (-
ArCH), 118.62 (-ArCH), 116.58 (-ArCH), 115.56 (-ArCH), 65.09 (-OCH2CH2N), 
40.84 (-NCH2CH2O). 
ESI-HRMS m/z calcd. for  C8H9NO[M+H]
+
: 136.0757 Found: 136.0754 
 
 
N-Ethyl Benzomorpholine (58)
11
 
 
The product was prepared as per the described method. Benzomorpholine (7.7 mmol, 
1.05 g) was added to a flask along with acetic acid (25 mL) and cooled on ice before 
NaBH4 (3.03 g, 80 mmol) was added in portions. The solution was stirred at RT for 3 
hours before being neutralised with 15% w/w NaOH and the product extracted with 
EtOAc (2 x 100 mL). The organic layers were combined and evaporated to dryness 
and the product purified by column chromatography (9:1, Hexane:EtOAc) to yield 
the title compound as brown oil (47%, 0.60 g, 3.6 mmol). 
1
H NMR (400 MHz, DMSO-d6) δ 6.80 – 6.71 (m, 1H, -ArH), 6.68 (ddd, J = 7.8, 
4.1, 1.5 Hz, 2H, -ArH), 6.55 – 6.45 (m, 1H, -ArH), 4.19 – 4.12 (m, 2H, -
COCH2CH2), 3.29 (q, J = 7.0 Hz, 2H, -CH2CH3), 3.25 – 3.20 (m, 2H, -CNCH2CH2), 
1.04 (t, J = 7.0 Hz, 3H, -CH3). 
13
C NMR (100 MHz, DMSO-d6) δ 143.90 (-ArC), 134.86 (-ArC) , 121.32 (-ArCH), 
116.73 (-ArCH) , 115.83 (-ArCH), 112.16 (-ArCH), 64.14 (-OCH2CH2N) , 45.29 (-
CH2CH3), 44.04 (-NCH2CH2O), 10.00 (-CH3). 
1
H and 
13
C spectra in agreement with literature
11
. 
ESI-HRMS m/z calcd. for C10H13NO[M+H]
+
: 164.1070 Found: 164.1066 
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N-Butyl Benzomorpholine (59)
11
 
 
The product was prepared as per the method described for N-ethyl benzomorpholine 
using benzomorpholine (1.1 g, 8.4 mmol), butyric acid (40 mL), and NaBH4 (3.3 g, 
85 mmol). The title compound was purified by column chromatography (DCM) to 
yield the title compound as a brown oil (61%, 5.1 mmol, 0.98 g). 
1
H NMR (400 MHz, Chloroform-d) δ 7.01 – 6.89 (m, 2H, -ArH), 6.83 – 6.76 (m, 
1H, -ArH), 6.77 – 6.68 (m, 1H, -ArH), 4.37 – 4.29 (m, 2H, -COCH2CH2), 3.46 – 
3.31 (m, 4H, -CNCH2CH2, -CH2CH2CH2), 1.77 – 1.70 (m, 2H, -CH2CH2CH3), 1.62 
– 1.41 (m, 2H, -CH2CH3 ), 1.11 (t, J = 7.4 Hz, 3H, -CH2CH3). 
13
C NMR (100 MHz, Chloroform-d) δ 143.90 (-ArC), 135.28 (-ArC), 121.47 (-
ArCH), 116.91 (-ArCH), 116.16 (-ArCH), 111.89 (-ArCH), 64.39 (-OCH2CH2N), 
50.64 (-CH2CH2CH2CH3), 46.87 (-NCH2CH2O), 28.10 (CH2CH2CH3), 20.36 (-
CH2CH3), 13.97 (-CH3). 
 
 
 
N-Methoxyethyl Benzomorpholine (60)
11
 
 
The product was prepared as per the method described for N-ethyl benzomorpholine 
using benzomorpholine (0.92 g, 6.8 mmol), methoxyacetic acid (30 mL), and NaBH4 
(2.7 g, 70 mmol). The title compound was purified by column chromatography 
(DCM) to yield an orange/brown oil (65%, 4.4 mmol, 0.85 g). 
1
H NMR (400 MHz DMSO-d6) δ 6.81 – 6.71 (m, 1H, -ArH), 6.70 (ddd, J = 8.1, 2.8, 
1.6 Hz, 2H, -ArH), 6.57 – 6.48 (m, 1H, -ArH), 4.16 – 4.08 (m, 2H, -COCH2CH2), 
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3.55 – 3.48 (m, 2H, -CH2OCH3), 3.45 – 3.38 (m, 2H, -NCH2CH2OCH3), 3.38 – 3.33 
(m, 2H, -CNCH2CH2), 3.26 (s, 3H, -OCH3). 
13
C NMR (100 MHz, DMSO-d6) δ 143.59 (-ArC), 135.00 (-ArC), 121.31 (-ArCH), 
116.60 (-ArCH), 115.88 (-ArCH), 111.94 (-ArCH), 69.21 (-NCH2CH2OCH3), 
63.98 (-OCH2CH2N), 58.19 (-OCH3), 49.75 (-NCH2CH2OCH3), 47.37 (-
NCH2CH2O). 
 
 
2,4,5-Triphenylimidazole (78)
12
 
 
The compound was prepared using a modified method of that reported in the 
literature
12
. Benzoin (0.23 g, 1.0 mmol), ammonium acetate (5.0 mmol), sodium 
bisulphite (0.02 g, 0.2 mmol), and benzaldehyde (0.15 mL, 1.5 mmol) were added to 
a flask along with 1:1 ethanol:H2O (10 mL). The solution was heated to 90C and 
stirred for five hours. Upon cooling, the precipitate was collected by filtration and 
the title compound recrystallised from ethanol in 72% yield (0.21 g, 0.7 mmol). 
1
H NMR (400 MHz, DMSO-d6) δ 12.71 (s, 1H, -NH), 8.11 – 8.04 (m, 2H, -
C2ArH), 7.57 – 7.18 (m, 13H, -ArH). 
13C NMR (151 MHz, DMSO) δ 145.81 (C2), 137.36, 135.25, 131.16, 130.42, 
128.97, 128.93, 128.62, 128.60, 128.50, 128.46, 128.06, 127.36, 126.86, 125.45 
1
H and 
13
C spectra in agreement with literature
13
. 
ESI-HRMS m/z calcd. for C21H16N2[M+H]
+
: 297.1386 Found: 297.1391 
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1-Butyl-3-methylimidazolium Acetate (83)
14
 
 
Equimolar amounts of BMIM chloride (0.18 g, 1 mmol) and silver acetate (0.17 g, 1 
mmol) were added to H2O and the flask wrapped in aluminium foil. The solution 
was stirred at RT for 3 hours following which the AgCl was removed by filtration. 
Charcoal was added to the solution and stirred for 12 hours to remove coloured 
impurities before being filtered off. The solvent was removed by rotary evaporation 
and to yield the title compound as a colourless oil (0.19 g, 0.96 mmol, 96%). 
1
H NMR (400 MHz, DMSO-d6) δ 10.25 (s, 1H, -C2H), 7.97 (t, J = 1.7 Hz, 1H, -
C4/5H), 7.89 (t, J = 1.6 Hz, 1H, -C4/5H), 4.20 (t, J = 7.2 Hz, 2H, -CH2C3H7), 3.88 
(s, 3H, -CH3), 1.78 – 1.67 (m, 2H, -CH2CH2C2H5), 1.58 (s, 3H, -CH3COO), 1.20 (h, 
J = 7.4 Hz, 2H, -C2H4CH2CH3), 0.84 (t, J = 7.4 Hz, 3H, -C3H6CH3). 
3
C NMR (150 MHz, DMSO-d6) δ 175.02 (-COO), 136.92 (C2), 123.82 (C4/5), 
122.47 (C4/5), 48.79 (-CH2C3H7), 35.95 (-CH3), 31.64 (-CH2CH2C2H5), 25.52 (-
CH3COO), 19.04 (C2H4CH2CH3), 13.54 (-C3H6CH3). 
1
H and 
13
C spectra in agreement with literature
15
. 
 
 
1-Butyl-3-methylimidazolium Saccharinate (100)
16
 
 
BMIM chloride (1.9 g, 11 mmol) was added to acetone (70 mL) before sodium 
saccharinate.2H2O (4.8 g, 20 mmol) was added. The mixture was stirred at RT for 24 
hours before the excess starting material and NaCl were removed by filtration 
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through celite. The solvent was removed by rotary evaporation to yield the title 
compound (3.2 g, 10 mmol, 87%). 
1
H NMR (600 MHz, Chloroform-d) δ 9.80 (s, 1H, -C2H), 7.79 – 7.70 (m, 2H, -
ArH), 7.59 – 7.51 (m, 2H, -ArH), 7.40 (t, J = 1.7 Hz, 1H, -C4/5H), 7.31 (t, J = 1.8 
Hz, 1H, --C4/5H), 4.24 (t, J = 7.4 Hz, 2H, -CH2C3H7), 4.03 (s, 3H, -CH3), 1.84 – 
1.76 (m, 2H, -CH2CH2C2H5), 1.33 – 1.26 (m, 2H, -C2H4CH2CH3), 0.87 (t, J = 7.4 
Hz, 3H, -C3H6CH3). 
13
C NMR (150 MHz, Chloroform-d) δ 170.42 (-CO), 144.65 (-ArC), 137.68 (C2), 
134.78 (-ArC), 132.09 (-ArCH), 131.47 (-ArCH), 123.55 (-ArCH), 123.24 (-ArCH), 
121.92 (C4/5), 119.71 (C4/5), 49.83 (-CH2C3H7), 36.59 (-CH3), 32.12 (-
CH2CH2C2H5), 19.45 (C2H4CH2CH3), 13.43 (-C3H6CH3). 
1
H and 
13
C spectra in agreement with literature
16
. 
ESI-HRMS m/z calcd. for [C8H15N2]
+
: 139.1230 Found: 139.1228 
m/z calcd. for [C7H4NO3S]
-
: 181.9917 Found: 181.9913 
 
 
Saccharin-1-methylimidazole (106)
17
 
 
The title compound was synthesised through addition of saccharin (0.2 g, 1 mmol) to 
1-methylimidazole (0.9 mL, 1.1 mmol) in acetonitrile (20 mL). The solution was 
stirred at RT for 18 hours before the reaction mixture was concentrated under 
reduced pressure.  The solid was washed with hexane to remove residual impurities 
(10 mL) and the title compound dried (0.25 g, 0.96 mmol, 96%). 
1
H NMR (600 MHz, DMSO-d6) δ 9.00 (s, 1H, -C2H), 7.74 – 7.65 (m, 2H, -C4/5H), 
7.65 – 7.57 (m, 4H, -ArH), 3.86 (s, 3H, -CH3). 
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13
C NMR (150 MHz, DMSO-d6) δ 167.73 (-CO), 144.99 (-ArC), 135.92 (C2), 
134.40 (-ArC), 131.78 (-ArCH), 131.29 (-ArCH), 123.03 (C4/5), 122.63 (-ArCH), 
120.18 (C4/5), 119.26 (-ArCH), 35.30 (-CH3). 
1
H and 
13
C spectra in agreement with literature
18
. 
ESI-HRMS m/z calcd. for [C4H7N2]
+
: 83.0609 Found: 83.0607 
m/z calcd. for [C7H4NO3S]
-
: 181.9917 Found: 181.9914 
 
 
1-Octyl-3-methylimidazolium Saccharinate (109)
16
 
 
The title compound was prepared through a modified version of the published 
method. OMIM chloride (0.23g, 1 mmol) was dissolved in acetone (20 mL) before 
sodium saccharinate.2H2O (0.48 g, 2 mmol) was added. The mixture was allowed 
stir at RT for 24 hours before the excess starting material and NaCl were removed by 
filtration through celite. The title compound was isolated as a pale yellow oil after 
removal of the solvent by rotary evaporation (0.31 g, 0.82 mmol, 82%). 
1
H NMR (600 MHz, Chloroform-d) δ 9.30 (s, 1H, -C2H), 7.74 – 7.64 (m, 2H, -
ArH), 7.55 – 7.47 (m, 2H, -ArH), 7.36 (t, J = 1.8 Hz, 1H, -C4/5H), 7.24 (t, J = 1.8 
Hz, 1H, -C4/5H), 4.13 – 4.06 (m, 2H, -CH2C7H15), 3.93 (s, 3H, -CH3), 1.73 – 1.63 
(m, 2H, -CH2CH2C6H13), 1.21 – 1.07 (m, 10H, -C2H4C5H10CH3), 0.78 (t, J = 7.2 Hz, 
3H, -CH3). 
13
C NMR (151 MHz, Chloroform-d) δ 170.28 (-CO), 144.36 (-ArC), 136.93 (C2), 
134.34 (-ArC), 132.23 (-ArCH), 131.62 (-ArCH), 123.72 (C4/5), 123.33 (-ArCH), 
121.92 (C4/5), 119.72 (-ArCH), 49.91 (-CH2C7H15), 36.47 (-CH3), 31.67 (-
C6H12CH3), 30.11 (-C6H12CH3), 28.99 (-C6H12CH3), 28.89 (-C6H12CH3), 26.15 (-
C6H12CH3), 22.57 (-C6H12CH3), 14.07 (-C7H14CH3). 
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1
H and 
13
C spectra in agreement with literature
19
. 
ESI-HRMS m/z calcd. for [C12H23N2]
+
: 195.1856 Found: 195.1847 
m/z calcd. for [C7H4NO3S]
-
: 181.9917 Found: 181.9919 
 
1-Butyl-3-methylimidazolium Acesulfamate (110)
20
 
 
BMIM choride (0.71 g, 4 mmol) was added to a flask along with potassium 
acesulfamate (1.61 g, 8 mmol) and acetone (30 mL). The mixture was allowed stir at 
RT for 24 hours before the excess starting material and KCl were removed by 
filtration. The acetone was removed by rotary evaporation and the crude product 
resuspended in CHCl3 and filtered once more to remove solid impurities. The title 
compound was dried to yield a colourless oil (1.1 g, 3.5 mmol, 90%). 
1
H NMR (400 MHz, Chloroform-d) δ 9.54 (s, 1H, -C2H), 7.37 (t, J = 1.8 Hz, 1H, -
C4/5H), 7.31 (t, J = 1.8 Hz, 1H, -C4/5H), 5.42 (s, 1H, -CH), 4.20 (t, J = 7.4 Hz, 2H, 
-CH2C3H7), 3.96 (s, 3H, -CH3), 1.98 (s, 3H, -C(O)CH3), 1.86 – 1.73 (m, 2H, -
CH2CH2C2H5), 1.36 – 1.25 (m, 2H, , -C2H4CH2CH3), 0.89 (t, J = 7.4 Hz, 3H, -
C3H6CH3). 
13
C NMR (100 MHz, Chloroform-d) δ 170.12 (-CO), 161.25 (-CO(CH3)), 137.40 
(C2), 123.57 (C4/5), 122.00 (C4/5), 102.20 (-CH), 49.76 (-CH2C3H7), 36.45 (-CH3), 
32.11 (-CH2CH2C2H5), 20.00 (C2H4CH2CH3), 19.43 (-C(O)CH3), 13.45 (-C3H6CH3). 
1
H and 
13
C spectra in agreement with literature
21
. 
ESI-HRMS m/z calcd. for [C8H15N2]
+
: 139.1230 Found: 139.1232 
m/z calcd. for [C4H4NO4S]
-
: 161.9867 Found: 161.9867 
1-Butyl-3-methylimidazolium Phthalimate (111) 
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The title compound was prepared through the addition of BMIM chloride (0.72 g, 4 
mmol) to a flask along with potassium phthalimate (1.48 g, 8 mmol) and acetone (40 
mL). The mixture was allowed stir at RT for 24 hours before the excess starting 
material and KCl were removed by filtration. The acetone was removed by rotary 
evaporation and the crude product resuspended in CHCl3 and filtered once more to 
remove solid impurities. The product was dried to yield the title compound as a 
colourless oil (0.98 g, 3.4 mmol, 86%). 
1H NMR (400 MHz, Deuterium Oxide) δ 7.51 – 7.36 (m, 4H), 7.35 (d, J = 1.8 Hz, 
1H), 7.30 (d, J = 1.7 Hz, 1H), 4.06 (t, J = 7.2 Hz, 2H, -CH2C3H7), 3.76 (s, 3H), 1.72 
(p, J = 7.3 Hz, 2H), 1.20 (h, J = 7.4 Hz, 2H), 0.82 (t, J = 7.4 Hz, 3H). 
13
C NMR (100 MHz, Deuterium Oxide) δ 178.47 (-CO), 177.50 (-CO), 140.44 (-
ArC), 135.81 (-ArC), 133.00 (-ArCH), 131.56 (-ArCH), 130.16 (-ArCH), 129.65 (-
ArCH), 125.79 (C4/5), 124.53 (C4/5), 51.61 (-CH2C3H7), 37.96 (-CH3), 33.66 (-
CH2CH2C2H5), 21.17 (C2H4CH2CH3), 15.07 (-C3H6CH3). 
ESI-HRMS m/z calcd. for [C8H15N2]
+
: 139.1230 Found: 139.1232 
m/z calcd. for [C8H4NO2]
-
: 146.0248 Found: 146.0247 
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Acesulfame (112)
22
 
 
Potassium acesulfamate (1.41 g, 7 mmol) was dissolved in H2O (10 mL) before the 
pH was adjusted to 2 using conc. HCl (2 mL). The solution was allowed stir for 12 
hours before the product was extracted using EtOAc (3 x 20 mL). The organic layers 
were combined and dried over MgSO4 and filtered before being evaporated to 
dryness. Residual starting material was removed by re-suspending the white solid in 
DCM and filtering off the solid impurity.  
1
H NMR (600 MHz, DMSO-d6) δ 9.98 (br. s, 1H, -NH), 6.03 (s, 1H, -CH), 2.18 (d, 
J = 1.0 Hz, 3H, -CH3). 
13
C NMR (150 MHz, DMSO-d6) δ 170.15 (-CO), 168.12 (-CO(CH3)), 96.90 (-CH), 
19.83 (-CH3). 
 
 
General Method A: Preparation of Silver salts of Saccharin, Acesulfame, 
Phthalimide, and Cyclamate
20
 
Equimolar amounts of the sodium or potassium salt of the required anion were 
combined with AgNO3 in H2O. The solution was protected from light and allowed 
stir at RT for 18 hours. The silver salt of the product precipitated from solution and 
was isolated by filtration before being washed with ethanol and H2O and dried. 
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General Method B: Preparation of N-Alkylpyridinium and N,N,N-Trimethyl-p-
toluidinium Halides
23
 
N-methyl pyridinium and N,N,N-trimethyl-p-toluidinium halides were prepared 
through reaction of pyridine or DMpT with 1.1 equivalents of the respective alkyl 
halide. The reagents were refluxed in methanol for 18 hours before being cooled to 
RT and EtOAc added causing a precipitate to occur. The precipitate was isolated and 
washed with EtOAc (10 mL) to yield the title compound. 
 
 
General Method C: Preparation of N,N-Dialkyl-Pyrrolidinium Halides
24
. 
To a solution of pyrrolidine in 1:1 MeOH:H2O was added one equivalent of Na2CO3 
and four equivalents of the respective alkyl halide. The solution was stirred at reflux 
for 18 hours before being cooled to RT and the solvent removed by rot. evap. The 
crude product was suspended in DCM and the insoluble impurities removed to yield 
the title compound. 
 
 
General Method D: Preparation of Saccharinate, Acesulfamate, Phthalimate, 
and Cyclamate Salts of Nitrogen Heterocycles 
The halide salt of the nitrogen heterocycle was dissolved in 1:1 Acetone:H2O (50 
mL) before an equimolar amount of the silver salt of the respective anion was added. 
The mixture was protected from light and allowed stir at RT for 18 hours. The silver 
halide salt was removed by filtration before the solvent was evaporated to dryness. 
The product was then dissolved in DCM or ACN and the insoluble impurities 
removed before being dried once more to yield the purified title compound. 
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1,3-Dimethylimidazolium Saccharinate (107) 
 
The title compound was prepared as per general method D using 1,3-
dimethylimidazolium iodide (0.68 g, 3.0 mmol) and silver saccharinate 0.87 g, 3.0 
mmol) to yield the title compound as a white solid (0.77 g, 2.8 mmol, 92%). 
1
H NMR (600 MHz, Chloroform-d) δ 9.56 (s, 1H, -C2H), 7.75 – 7.66 (m, 2H, -
ArH), 7.56 – 7.49 (m, 2H, -ArH), 7.31 (d, J = 1.5 Hz, 2H, -C4/5H), 3.94 (s, 6H, -
(CH3)2). 
13
C NMR (150 MHz, Chloroform-d) δ 170.34 (-CO), 144.59 (-ArC), 138.07 (C2), 
134.73 (-ArC), 132.18 (-ArCH), 131.55 (-ArCH), 123.42 (-ArCH), 123.22 (C4/5), 
119.68 (-ArCH), 36.45 (-(CH3)2). 
ESI-HRMS m/z calcd. for [C5H9N2]
+
: 97.0760  Found: 97.0757  
m/z calcd. for [C7H4NO3S]
-
: 181.9917 Found: 181.9914 
 
 
1-Ethyl-3-methylimidzolium Saccharinate (108) 
 
The title compound was prepared as per general method D using 1-ethyl-3-
methylimidazolium iodide (0.71 g, 3.0 mmol) and silver saccharinate (0.85 g, 3 
mmol) to yield the title compound (0.76 g, 2.6 mmol, 86%). 
1
H NMR (400 MHz, Chloroform-d) δ 7.80 – 7.67 (m, 1H, -ArH), 7.72 – 7.63 (m, 
3H, -ArH), 7.32 (d, J = 2.0 Hz, 1H, -C4/5H), 7.25 (d, J = 2.0 Hz, 1H, -C4/5H), 4.08 
(q, J = 7.4 Hz, 2H, -CH2CH3), 3.75 (s, 3H, -CH3), 1.36 (t, J = 7.4 Hz, 3H, -CH2CH3). 
226 
 
13
C NMR (100 MHz, Chloroform-d) δ 174.83 (-CO), 144.24 (-ArC), 136.25 (-
ArCH), 135.74 (-ArCH), 134.74 (-ArC), 126.01 (-ArCH), 125.71 (C4/5), 124.13 
(C4/5), 122.67 (-ArCH), 47.09 (-CH2CH3), 37.89 (-CH3), 16.78 (-CH2CH3). 
ESI-HRMS m/z calcd. for [C6H11N2]
+
: 111.0917  Found: 111.0921 
m/z calcd. for [C7H4NO3S]
-
: 181.9917 Found: 181.9908 
 
 
N-Methylpyridinium Iodide (113)
23
 
 
The title compound was prepared as per general method B using pyridine (6.11 mL, 
76 mmol) and methyl iodide (5.23 mL, 84 mmol) to yield the title compound as a 
white solid (15.23 g, 69 mmol, 91%). 
1H NMR (400 MHz, Deuterium Oxide) δ 8.81 (d, J = 5.9 Hz, 2H, -ArH), 8.54 (t, J 
= 7.9 Hz, 1H, -ArH), 8.07 (t, J = 7.0 Hz, 2H, -ArH), 4.41 (s, 3H, -CH3). 
13C NMR (100 MHz, Deuterium Oxide) δ 145.31 (-ArCH), 145.10 (-ArCH), 
128.00 (-ArCH), 48.44 (-CH3). 
1
H and 
13
C spectra in agreement with literature
25
. 
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N,N,N-Trimethyl-p-toluidinium Iodide (114)  
 
The title compound was prepared as per general method B using DMpT (6.32 mL, 
44 mmol) and methyl iodide (3.42 mL, 55 mmol) to yield the title compound as a 
white solid (11.16 g, 39 mmol, 90%). 
1H NMR (400 MHz, Deuterium Oxide) δ 7.64 (d, J = 9.0 Hz, 2H, -ArH), 7.39 (d, J 
= 8.8 Hz, 2H, -ArH), 3.57 (s, 9H, -(CH3)3), 2.32 (s, 3H, -CH3). 
13
C NMR (100 MHz, Deuterium Oxide) δ 143.99 (-ArCN), 141.04 (-ArC), 130.65 
(-ArCH), 119.25 (-ArCH), 56.91 (-(CH3)3), 19.90 (-CH3). 
1
H spectrum in agreement with literature
26 
 
 
N,N-Dimethyltetrahydroquinolinium Iodide (115)
27
 
 
To a flask was added THQ (0.13 mL, 1 mmol) along with Na2CO3 (0.11 g, 1 mmol), 
methyl iodide (0.31 mL, 10 mmol) and 50 mL of 1:1 MeOH:H2O. The solution was 
heated to reflux and stirred for 24 hours before being cooled to RT and the solvent 
removed. The crude product was dissolved in H2O and extracted using CHCl3 (3 x 
20 mL). The organic layers were pooled and dried over MgSO4 being evaporated to 
dryness to yield the pure product sample (0.23 g, 0.87 mmol, 87%). 
1
H NMR (400 MHz, Chloroform-d) δ 8.17 – 8.09 (m, 1H, -ArH), 7.46 – 7.31 (m, 
2H, -ArH), 7.28 – 7.20 (m, 1H, -ArH), 4.31 – 4.23 (m, 2H, -NCH2), 3.93 (s, 6H, -
(CH3)2), 3.04 (t, J = 6.6 Hz, 2H-CH2), 2.31 (dt, J = 12.0, 6.5 Hz, 2H, -CH2). 
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13
C NMR (100 MHz, Chloroform-d) δ 142.81 (-ArC), 131.42 (-ArC), 130.29 (-
ArCH), 129.75 (-ArCH), 129.09 (-ArCH), 121.87 (-ArCH), 65.05 (-NCH2), 58.22 (-
(CH3)2), 25.90 (-CH2), 17.88 (-CH2). 
 
 
N,N-Dimethylpyrrolidinium Iodide (116)
24
 
 
The title compound was prepared as per general method C using pyrrolidine (0.16 
mL, 2 mmol) and methyl iodide (0.50 mL, 8 mmol) to yield the title compound (0.34 
g, 1.5 mmol, 75%). 
1H NMR (600 MHz, Deuterium Oxide) δ 3.56 – 3.47 (m, 4H, -N(CH2)2), 3.14 (s, 
6H, -(CH3)2), 2.27 – 2.18 (m, 4H, -(CH2)2). 
13
C NMR (150 MHz, Deuterium Oxide) δ 65.84 (-(NCH2)2), 51.74 (-CH3), 21.65 (-
(CH2)2). 
1
H and 
13
C spectra in agreement with literature
24
. 
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N,N,N-Trimethyl-p-toluidinium Saccharinate (117) 
 
The title compound was prepared as per general method D using TMpT iodide (1.25 
g, 4.5 mmol) and silver saccharinate (1.30 g, 4.5 mmol) to yield the title compound 
as a white salt (0.98 g, 3.0 mmol, 66%). 
1H NMR (600 MHz, Deuterium Oxide) δ 7.78 – 7.65 (m, 4H, -ArH), 7.54 (d, J = 
8.2 Hz, 2H, -ArH), 7.27 (d, J = 8.1 Hz, 2H, -ArH), 3.53 (s, 9H, -(CH3)3), 2.26 (s, 3H, 
-CH3). 
13
C NMR (150 MHz, Deuterium Oxide) δ 172.36 (-CO), 144.12 (-ArCN), 142.00 
(-ArC), 141.14 (-ArC), 133.84 (-ArCH), 133.31 (-ArCH), 132.49 (-ArC), 130.70 (-
ArCH), 123.66 (-ArCH), 120.25 (-ArCH), 119.16 (-ArCH), 56.96 (-(CH3)3), 19.93 (-
CH3). 
ESI-HRMS m/z calcd. for [C10H16N]
+
: 150.1277 Found: 150.1281 
m/z calcd. for [C7H4NO3S]
-
: 181.9917 Found: 181.9918 
 
 
N,N,N-Trimethyl-p-toluidinium Acesulfamate (118) 
 
The title compound was prepared as per general method D using TMpT iodide (1.32 
g, 4.8 mmol) and silver acesulfamate (1.31 g, 4.8 mmol) to yield the title compound 
(1.33 g, 4.3 mmol, 89%). 
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1H NMR (400 MHz, Deuterium Oxide) δ 7.63 – 7.54 (m, 2H, -ArH), 7.36 – 7.28 
(m, 2H, -ArH), 5.49 (s, 1H, -CH), 3.52 (s, 9H, -(CH3)3), 2.27 (s, 3H, -ArCH3), 1.93 
(s, 3H, -CH3). 
13
C NMR (100 MHz, Deuterium Oxide) δ 171.76 (-CO), 163.68 (-CO(CH3)), 
144.00 (-ArCN), 140.98 (-ArC), 130.65 (-ArCH), 119.11 (-ArCH), 100.86 (-CH), 
56.76 (-(CH3)3), 19.86 (-CH3), 18.84 (-CH3). 
ESI-HRMS m/z calcd. for [C10H16N]
+
: 150.1277 Found: 150.1282 
m/z calcd. for [C4H4NO4S]
-
: 161.9867 Found: 161.9872 
 
 
N,N,N-Trimethyl-p-toluidinium Phthalimate (119) 
 
The title compound was prepared as per general method D using TMpT iodide (1.41 
g, 5.1 mmol) and silver phthalimate (1.31 g, 5.1 mmol) to yield the title compound 
(0.94 g, 3.2 mmol, 62 %). 
1H NMR (600 MHz, Deuterium Oxide) δ 7.64 (d, J = 8.8 Hz, 2H, -ArH), 7.54 – 
7.37 (m, 6H, -ArH), 3.55 (s, 9H, -(CH3)3), 2.35 (s, 3H, -CH3). 
13
C NMR (150 MHz, Deuterium Oxide) δ 175.12 (-CO), 174.16 (-CO), 143.33 (-
ArCN), 140.35 (-ArC), 137.33 (-ArC), 132.49 (-ArC), 129.90 (-ArCH), 129.74 (-
ArCH), 128.22 (-ArCH), 126.90 (-ArCH), 126.43 (-ArCH), 118.39 (-ArCH), 56.07 
(-(CH3)3), 19.07 (-CH3). 
ESI-HRMS m/z calcd. for [C10H16N]
+
: 150.1277 Found: 150.1284 
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N-Methylpyridinium saccharinate (120) 
 
The title compound was prepared as per general method D using N-
methylpyridinium iodide (1.2 g, 5.4 mmol) and silver saccharinate (1.57 g, 5.4 
mmol) to yield the title compound (1.42 g, 5.1 mmol, 95%). 
1H NMR (400 MHz, Deuterium Oxide) δ 8.60 (d, J = 5.8 Hz, 2H, -ArH), 8.32 (t, J 
= 7.9 Hz, 1H, -ArH), 7.84 (t, J = 7.1 Hz, 2H, -ArH), 7.71 – 7.53 (m, 4H, -ArH), 4.25 
(s, 3H, -CH3). 
13
C NMR (100 MHz, Deuterium Oxide) δ 172.02 (-CO), 144.97 (-ArC), 144.75 (-
ArC), 141.65 (-ArCH), 133.66 (-ArCH), 133.18 (-SaccArCH), 132.10 (-SaccArCH), 
127.70 (-ArCH), 123.41 (-SaccArCH), 120.09 (-SaccArCH), 47.93 (-CH3). 
ESI-HRMS m/z calcd. for [C6H8N]
+
: 94.0651 Found: 94.0648  
m/z calcd. for [C7H4NO3S]
-
: 181.9917 Found: 181.9921 
 
 
N,N-Dimethylpyrrolidinium saccharinate (121) 
 
The title compound was prepared as per general method D using N,N-
dimethylpyrrolidinium iodide (0.34 g, 1.5 mmol) and silver saccharinate (0.43 g, 1.5 
mmol) to yield the title compound (0.36 g, 1.3 mmol, 84%). 
1H NMR (600 MHz, Deuterium Oxide) δ 7.77 – 7.73 (m, 1H, -ArH), 7.70 – 7.64 
(m, 3H, -ArH), 3.40 – 3.34 (m, 4H, -N(CH2)2), 3.00 (s, 6H, -(CH3)2), 2.11 – 2.06 (m, 
4H, -(CH2)2). 
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13
C NMR (150 MHz, Deuterium Oxide) δ 172.45 (-CO), 141.78 (-ArC), 133.86 (-
ArC), 133.34 (-ArCH), 132.33 (-ArCH), 123.66 (-ArCH), 120.27 (-ArCH), 65.72 (-
(NCH2)2), 51.56 (-(CH2)2), 21.56 (-(CH3)2). 
 
 
N,N-Dimethyltetrahydroquinolinium saccharinate (122) 
 
The title compound was prepared as per general method D using N,N-
tetrahydroquinolinium iodide (0.15 g, 0.55 mmol) and silver saccharinate (0.16 g, 
0.55 mmol) to yield the title compound (0.14 g, 0.42 mmol, 77%). 
1
H NMR (400 MHz, DMSO-d6) δ 8.00 – 7.94 (m, 1H, -ArH), 7.74 – 7.56 (m, 4H, -
ArH), 7.48 – 7.32 (m, 3H, -ArH), 3.93 – 3.85 (m, 2H, -NCH2), 3.56 (s, 6H, -(CH3)2), 
2.91 (t, J = 6.5 Hz, 2H, -CH2), 2.25 – 2.16 (m, 2H, -CH2). 
13
C NMR (100 MHz, DMSO-d6) δ 167.77(-CO), 145.02 , 142.92 , 134.50 , 131.88 , 
131.37 , 131.15 , 130.81 , 129.67 , 128.14 , 122.73 , 121.45 , 119.35 , 63.79 (-CH2), 
56.79 (-(CH3)2), 25.51 (-CH2), 16.91 (-CH2). 
ESI-HRMS m/z calcd. for [C11H16N]
+
 162.1277 Found: 162.1276  
m/z calcd. for [C7H4NO3S]
-
: 181.9917 Found: 181.9925 
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Trimethylsulphonium Saccharinate (123) 
 
Dimethylsulfide (0.15 mL, 2 mmol) was added to a small vial along with methyl 
iodide (0.16 mL, 2.5 mmol) and the solution was allowed stir neat at RT for 3 hours 
to yield a white solid. The reaction mixture was taken up in ACN (10 mL) and 
transferred to a flask where the solvent was removed to yield a white solid. 
The white solid was dissolved in 1:1 acetone:H2O without any further purification 
before silver saccharinate was added (0.16 g, 0.5 mmol). The mixture was protected 
from light and allowed stir at RT for 18 hours. The AgI was removed by filtration 
and the solvent by rotary evaporation. 
1
H NMR (400 MHz, DMSO-d6) δ 7.74 – 7.57 (m, 4H, -ArH), 2.86 (s, 9H, -(CH3)3). 
13
C NMR (100 MHz, DMSO-d6) δ 167.83 (-CO), 144.98 (-ArC), 134.47 (-ArC), 
131.93 (-ArCH), 131.42 (-ArCH), 122.74 (-ArCH), 119.37 (-ArCH), 26.21 (-
(CH3)3). 
ESI-HRMS m/z calcd. for [C3H9S]
+
: 77.0419 Found: 77.0418 
m/z calcd. for [C7H4NO3S]
-
: 181.9917 Found: 181.9912 
 
 
N-Butyl-N,N-dimethyl-p-toluidinium Iodide (124) 
 
To a flask was added DMpT (0.90 mL, 6.3 mmol) along with 1-iodobutane (0.93 
mL, 6.9 mmol) and MeOH (30 mL). The solution was heated to reflux and stirred for 
24 hours. Upon cooling to RT the solvent was removed and EtOAc (50 mL) added to 
the flask. The product was extracted using H2O (3 x 20 mL) and, after pooling, the 
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aqueous layer was washed with EtOAc. The solvent was removed by rotary 
evaporation to yield the title compound as an orange/red oil (1.44 g, 4.5 mmol, 71%) 
1H NMR (600 MHz, Deuterium Oxide) δ 7.60 (d, J = 8.9 Hz, 2H, -ArH), 7.42 (d, J 
= 8.8 Hz, 2H, -ArH), 3.83 – 3.77 (m, 2H, -CH2C3H7), 3.54 (s, 6H, -(CH3)2), 2.35 (s, 
3H, -CH3), 1.41 – 1.33 (m, 2H, -CH2CH2C2H5), 1.24 (h, J = 7.4 Hz, 2H, -CH2CH3), 
0.79 (t, J = 7.4 Hz, 3H, -C3H6CH3). 
13C NMR (150 MHz, Deuterium Oxide) δ 141.44 (-ArCN), 141.03 (-ArC), 130.77 
(-ArCH), 120.23 (-ArCH), 69.24 (-CH2C3H7), 54.21 (-(CH3)2), 24.80 (-
CH2CH2C2H5), 19.94 (-CH3), 18.80 (-CH2CH3), 12.74 (-C3H6CH3). 
 
 
N-Butylpyridinium Bromide (125) 
 
The title compound was prepared as per general method B using pyridine (1.12 mL, 
13.9 mmol) and 1-bromobutane (1.62 mL, 13.9 mmol) to yield the title compound 
(2.48 g, 11.5 mmol, 83%) 
1H NMR (600 MHz, Deuterium Oxide) δ 8.83 (d, J = 5.7 Hz, 2H, -ArH), 8.52 (t, J 
= 7.8 Hz, 1H, -ArH), 8.04 (t, J = 6.9 Hz, 2H, -ArH), 4.60 (t, J = 7.4 Hz, 2H, -
CH2C3H7), 1.98 (p, J = 7.5 Hz, 2H, -CH2CH2C2H5), 1.34 (h, J = 7.4 Hz, 2H, -
CH2CH3), 0.92 (t, J = 7.4 Hz, 3H, -C3H6CH3). 
13C NMR (150 MHz, Deuterium Oxide) δ 145.43 (-ArCH), 144.16 (-ArCH), 
128.15 (-ArCH), 61.71 (-CH2C3H7), 32.54 (-CH2CH2C2H5), 18.69 (-CH2CH3), 12.63 
(-CH3). 
1
H and 
13
C spectra in agreement with literature
28
. 
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N,N-Dibutylpyrrolidinium Iodide (126) 
 
The title compound was prepared as per general method C using pyrrolidine (1.31 
mL, 16 mmol) and 1-iodobutane (4.71 mL, 35 mmol) to yield the title compound 
(3.43 g, 11.0 mmol, 69%). 
1
H NMR (400 MHz, Deuterium Oxide) δ 3.44 (s, 4H, -N(CH2)2), 3.23 – 3.14 (m, 
4H, -(CH2C3H7)2), 2.13 – 2.07 (m, 4H, -(CH2)2), 1.71 – 1.58 (m, 4H, -
(CH2CH2C2H5)2), 1.31 (q, J = 7.4 Hz, 4H, -(CH2CH3)2), 0.89 (t, J = 7.4 Hz, 6H, -
(CH3)2). 
13C NMR (100 MHz, Deuterium Oxide) δ 62.67 (-(NCH2)2), 59.32 (-(CH2C3H7)2), 
24.52 (-(CH2CH2C2H5)2), 21.36 (-(CH2)2), 19.12 (-(CH2CH3)2) 12.74 (-(CH3)2). 
 
 
N-Butyl-N,N-dimethyl-p-toluidinium Saccharinate (127) 
 
The title compound was prepared as per general method D using N-butyl-N,N-
dimethyl-p-toluidinium iodide (0.47 g, 1.45 mmol) and silver saccharinate (0.42 g, 
1.45 mmol) to yield the title compound (0.53 g, 1.41 mmol, 97%). 
1H NMR (400 MHz, Deuterium Oxide) δ 7.79 – 7.64 (m, 4H, -ArH), 7.46 (d, J = 
8.9 Hz, 2H, -TolArH), 7.28 (d, J = 8.6 Hz, 2H, -TolArH), 3.73 – 3.64 (m, 2H, -
CH2C3H7), 3.44 (s, 6H, -(CH3)2), 2.26 (s, 3H, -CH3), 1.33 – 1.20 (m, 2H, -
CH2CH2C2H5), 1.14 (h, J = 7.2 Hz, 2H, -CH2CH3), 0.70 (t, J = 7.3 Hz, 3H, -
C3H6CH3). 
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13C NMR (100 MHz, Deuterium Oxide) δ 172.28 (-CO), 141.71 (-ArCN), 141.24 
(-ArC), 140.85 (-TolArC), 133.72 (-ArCH), 133.19 (-ArCH), 132.25 (-ArC), 130.56 
(-TolArCH), 123.51 (-ArCH), 120.12 (-ArCH), 119.95 (-TolArCH), 69.06 (-
CH2C3H7), 53.90 (-(CH3)2), 24.60 (-CH3), 19.75 (-CH2CH2C2H5), 18.63 (-CH2CH3), 
12.53 (-C3H6CH3). 
ESI-HRMS m/z calcd. for [C13H22N]
+
: 192.1747 Found: 192.1744 
m/z calcd. for [C7H4NO3S]
-
: 181.9917 Found: 181.9912 
 
 
N-Butylpyridinium Saccharinate (128) 
 
The title compound was prepared as per general method D using N-butylpyridinium 
bromide (0.34 g, 1.57 mmol) and silver saccharinate (0.45 g, 1.57 mmol) to yield the 
product compound (0.46 g, 1.44 mmol, 92%). 
1H NMR (400 MHz, Deuterium Oxide) δ 8.64 (d, J = 5.4 Hz, 2H, -PyArH), 8.37 – 
8.31 (m, 1H, -PyArH), 7.87 (t, J = 7.1 Hz, 2H, -PyArH), 7.71 – 7.54 (m, 4H, -ArH), 
4.41 (t, J = 7.4 Hz, 2H, -CH2C3H7), 1.78 (p, J = 7.5 Hz, 2H, -CH2CH2C2H5), 1.17 
(dq, J = 14.8, 7.4 Hz, 2H, -CH2CH3), 0.77 (t, J = 7.4 Hz, 3H, -C3H6CH3). 
13C NMR (100 MHz, Deuterium Oxide) δ 171.58 (-CO), 145.17 (-PyArCH), 
143.89 (-PyArCH), 141.59 (-ArC), 133.71 (-ArCH), 133.27 (-ArCH), 131.98 (-ArC), 
127.93 -PyArCH), 123.48 (-ArCH), 120.13 (-ArCH), 61.52 (-CH2C3H7), 32.43 (-
CH2CH2C2H5), 18.57 (-CH2CH3), 12.50 (-CH3).  
ESI-HRMS m/z calcd. for C9H14N
+
: 136.1121 Found: 136.1125 
m/z calcd. for [C7H4NO3S]
-
: 181.9917 Found: 181.9915 
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N-Butylpyridinium Acesulfamate (129) 
 
The title compound was prepared as per general method D using N-butylpyridinium 
bromide (0.73 g, 3.4 mmol) and silver acesulfamate (0.92 g, 3.4 mmol) to yield the 
title compound (0.86 g, 2.9 mmol, 87%). 
1
H NMR (400 MHz, Deuterium Oxide) δ 8.78 (d, J = 5.6 Hz, 2H, -ArH), 8.47 (t, J 
= 7.9 Hz, 1H, -ArH), 7.99 (t, J = 6.9 Hz, 2H, -ArH), 5.63 – 5.57 (m, 1H, -CH), 4.54 
(t, J = 7.4 Hz, 2H, -CH2C3H7), 2.04 (s, 3H), 1.92 (p, J = 7.5 Hz, 2H, -CH2CH2C2H5), 
1.29 (h, J = 7.4 Hz, 2H, -CH2CH3), 0.87 (t, J = 7.4 Hz, 3H, -C3H6CH3). 
13C NMR (100 MHz, Deuterium Oxide) δ 172.11 (-CO), 164.14 (-CO(CH3)), 
145.29 (-ArCH), 144.07 (-ArCH), 128.02 (-ArCH), 100.70 (-CH), 61.62 (-
CH2C3H7), 32.47 (-CH3), 18.85 (-CH2CH2C2H5), 18.60 (-CH2CH3), 12.51 (-CH3). 
ESI-HRMS m/z calcd. for C9H14N
+
: 136.1121 Found: 136.1123 
m/z calcd. for [C4H4NO4S]
-
: 161.9867 Found: 161.9869 
 
 
N-Butylpyridinium Phthalimate (130) 
 
The title compound was prepared as per general method D using N-butylpyridinium 
bromide (0.68 g, 3.2 mmol) and silver phthalimate (0.83 g, 3.2 mmol) to yield the 
title compound (0.78 g, 2.8 mmol, 71%). 
1
H NMR (400 MHz, DMSO-d6) δ 9.12 (d, J = 5.5 Hz, 2H, -ArH), 8.64 – 8.55 (m, 
1H, -ArH), 8.16 (t, J = 7.1 Hz, 2H, -ArH), 7.70 (d, J = 7.6 Hz, 1H, -ArH), 7.34 – 
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7.16 (m, 3H, -ArH), 4.60 (t, J = 7.4 Hz, 2H, -CH2C3H7), 1.95 – 1.82 (m, 2H, -
CH2CH2C2H5), 1.27 (dq, J = 14.7, 7.4 Hz, 2H, -CH2CH3), 0.90 (t, J = 7.4 Hz, 3H, -
C3H6CH3). 
13
C NMR (150 MHz, DMSO-d6) δ 172.68 (-CO), 169.37 (-CO), 145.42 (-PyArCH), 
144.84 (-PyArCH), 143.92 (-ArC), 134.21 (-ArC), 130.78 (-ArCH), 129.66 (-ArCH), 
128.87 (-ArCH), 128.03 (-PyArCH), 125.80 (-ArCH), 60.46 (-CH2C3H7), 32.70 (-
CH2CH2C2H5), 18.74 (-CH2CH3), 13.32 (-CH3). 
 
 
N,N-Dibutylpyrrolidinium Saccharinate (131) 
 
The title compound was prepared as per general method D using N,N-
Dibutylpyrrolidinium iodide (0.52 g, 1.67 mmol) and silver saccharinate (0.49 g, 
1.67 mmol) to yield the title compound (0.57 g, 1.55 mmol, 93%). 
1H NMR (600 MHz, Deuterium Oxide) δ 7.86 – 7.81 (m, 1H, -ArH), 7.79 – 7.73 
(m, 3H, -ArH), 3.43 – 3.38 (m, 4H, -N(CH2)2), 3.18 – 3.12 (m, 4H, -(CH2C3H7)2), 
2.10 – 2.06 (m, 4H, -(CH2)2), 1.64 – 1.58 (m, 4H, -(CH2CH2C2H5)2), 1.32 – 1.25 (m, 
4H, -(CH2CH3)2), 0.87 (t, J = 7.3 Hz, 6H, -(CH3)2). 
13C NMR (150 MHz, Deuterium Oxide) δ 172.52 (-CO), 142.01 (-ArC), 133.93 (-
ArC), 133.40 (-ArCH), 132.52 (-ArCH), 123.73 (-ArCH), 120.33 (-ArCH), 63.06 (-
(NCH2)2), 59.49 (-(CH2C3H7)2), 24.59 (-(CH2CH2C2H5)2), 21.49 (-(CH2)2), 19.20 (-
(CH2CH3)2), 12.80 (-(CH3)2). 
ESI-HRMS m/z calcd. for [C12H26N]
+
: 184.2060 Found: 184.2068 
m/z calcd. for [C7H4NO3S]
-
: 161.9917 Found: 181.9915 
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N,N-Dibutylpyrrolidinium Acesulfamate (132) 
 
The title compound was prepared as per general method D using N,N-
Dibutylpyrrolidinium iodide (0.90 g, 2.9 mmol) and silver acesulfamate (0.78 g, 2.9 
mmol) to yield the title compound (0.94 g, 2.7 mmol, 93%). 
1
H NMR (400 MHz, Deuterium Oxide) δ 5.61 (s, 1H, -CH), 3.45 – 3.40 (m, 4H, -
N(CH2)2), 3.22 – 3.13 (m, 4H, -(CH2C3H7)2), 2.12 – 2.06 (m, 4H, -(CH2)2), 2.05 (s, 
3H, -CH3), 1.70 – 1.57 (m, 4H, -(CH2CH2C2H5)2), 1.30 (h, J = 7.4 Hz, 4H, -
(CH2CH3)2), 0.88 (t, J = 7.4 Hz, 6H, -(CH3)2). 
13C NMR (100 MHz, Deuterium Oxide) δ 172.14 (-CO), 164.04 (-CO(CH3)), 
100.79 (-CH), 62.62 (-(NCH2)2), 59.30 (-(CH2C3H7)2), 24.49 (-(CH2CH2C2H5)2), 
21.33 (-(CH2)2), 19.09 (-(CH2CH3)2), 18.84 (-CH3), 12.70 (-(CH3)2). 
ESI-HRMS m/z calcd. for [C12H26N]
+
: 184.2060 Found: 184.2066 
m/z calcd. for [C4H4NO4S]
-
: 161.9867 Found: 161.9864 
 
 
N,N-Dibutylpyrrolidinium Phthalimate (133) 
 
The title compound was prepared as per general method D using N,N-
Dibutylpyrrolidinium iodide (0.93 g, 3.0 mmol) and silver phthalimate (0.76 g 3.0 
mmol) to yield the title compound (0.76 g, 2.3 mmol, 77%). 
1
H NMR (600 MHz, DMSO-d6) δ 7.74 – 7.69 (m, 1H, -ArH), 7.33 – 7.28 (m, 2H, -
ArH), 7.24 – 7.17 (m, 1H, -ArH), 3.48 – 3.41 (m, 4H, -N(CH2)2), 3.21 – 3.15 (m, 
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4H, -CH2C3H7), 2.06 – 1.99 (m, 4H, -(CH2)2), 1.63 – 1.54 (m, 4H, -(CH2CH2C2H5)2), 
1.30 (h, J = 7.4 Hz, 4H, -(CH2CH3)2), 0.92 (t, J = 7.4 Hz, 6H, -(CH3)2). 
13
C NMR (150 MHz, DMSO-d6) δ 172.43(-CO), 169.23 (-CO), 130.71, 129.68 , 
128.93(-ArCH), 128.08 (-ArCH), 125.86 (-ArCH), 99.55 ,  62.10 (-(NCH2)2), 58.49 
(-(CH2C3H7)2), 24.47 (-(CH2CH2C2H5)2), 21.40 (-(CH2)2), 19.26 (-(CH2CH3)2), 
13.53 (-(CH3)2). 
 
1-Butyl-3-methylimidazolium Bistriflimide (134)
29
 
 
Anion metathesis was carried by stirring BMIM chloride (0.57g, 3 mmol) and 
LiNTf2 (0.87 g, 3 mmol) in 15 mL oh H2O. The solution was stirred at RT for 18 
hours forming a biphasic mixture which was then further diluted with H2O (10 mL) 
before the product was extracted using chloroform (3 x 20 mL). The organic layers 
were pooled, washed with H2O, and dried over MgSO4 before the solvent was 
evaporated to dryness to yield the product as a7 colourless liquid (1.13 g, 2.7 mmol, 
91%).  
1
H NMR (400 MHz, Chloroform-d) δ 8.72 (s, 1H, -C2H), 7.32 – 7.28 (m, 2H, -
C4/5H), 4.14 (dt, J = 14.5, 7.4 Hz, 2H, -CH2C3H7), 3.92 (s, 3H, -CH3), 1.90 – 1.79 
(m, 2H, -CH2CH2C2H5), 1.41 – 1.27 (m, 2H, -CH2CH3), 0.95 (t, J = 7.4 Hz, 3H, -
C3H6CH3). 
13
C NMR (100 MHz, Chloroform-d) δ 136.13 (C2), 123.77 (C4/5), 122.35 (C4/5), 
119.34 (q, J = 320.4 Hz), 50.04 (-CH2C3H7), 36.42 (-CH3), 32.04 (-CH2CH2C2H5), 
19.44 (-CH2CH3), 13.33 (-CH3). 
19
F NMR (376 MHz, Chloroform-d) δ -79.13 . 
1
H and 
13
C spectra in agreement with literature
30
. 
ESI-HRMS m/z calcd. for [C8H15N2]
+
: 139.1230 Found: 139.1231 
m/z calcd. for [C2F6NO4S2]
-
: 279.9178 Found: 279.918 
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1-Butyl-3-methylimidazolium Cyclamate (135) 
 
The title compound was prepared as per general method D using BMIM chloride 
(1.65 g, 9.5 mmol) and silver cyclamate (2.70 g, 9.5 mmol) to yield the title 
compound (2.66 g, 8.4 mmol, 89%). 
1
H NMR (600 MHz, Chloroform-d) δ 9.84 (s, 1H, -C2H), 7.52 (t, J = 1.7 Hz, 1H, -
C4/5H), 7.38 (t, J = 1.7 Hz, 1H, -C4/5H), 4.22 (t, J = 7.4 Hz, 2H, -CH2C3H7), 4.00 
(s, 3H, -CH3), 3.22 – 3.14 (m, 1H, -CH), 2.08 – 2.02 (m, 2H), 1.86 – 1.77 (m, 2H), 
1.67 – 1.60 (m, 2H), 1.55 – 1.48 (m, 1H), 1.36 – 1.19 (m, 4H), 1.16 – 1.03 (m, 3H), 
0.90 (t, J = 7.4 Hz, 3H, -C3H6CH3). 
13
C NMR (150 MHz, Chloroform-d) δ 138.12 (C2), 123.77 (C4/5), 122.0177 
(C4/5) , 52.91 , 49.70 , 36.45 , 34.51 , 32.19 , 25.83 , 25.12 , 19.49 , 13.47 (-CH3). 
ESI-HRMS m/z calcd. for [C8H15N2]
+
: 139.1230 Found: 139.1229 
m/z calcd. for [C6H12NO3S]
-
: 178.0543 Found: 178.0543 
 
 
1-Octyl-3-methylimidazolium Cyclamate (136) 
 
The title compound was prepared as per general method D using OMIM chloride 
(0.37 g, 1.6 mmol) and silver cyclamate (0.46 g, 1.6 mmol) to yield the title 
compound (0.49 g, 1.3 mmol, 84%). 
1H NMR (600 MHz, Deuterium Oxide) δ 7.43 (d, J = 2.0 Hz, 1H, -C4/5H), 7.39 
(d, J = 2.0 Hz, 1H, -C4/5H), 4.15 (t, J = 7.1 Hz, 2H, -CH2C7H15), 3.85 (s, 3H, -CH3), 
3.07 – 3.00 (m, 1H, -CH), 1.97 – 1.91 (m, 2H, -cC6H11, -C7H15), 1.87 – 1.79 (m, 2H, 
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-cC6H11, -C7H15), 1.72 – 1.65 (m, 2H, -cC6H11, -C7H15), 1.58 – 1.51 (m, 1H, -cC6H11, 
-C7H15), 1.33 – 1.06 (m, 15H, -cC6H11, -C7H15), 0.83 (t, J = 7.0 Hz, 3H, -C7H14CH3). 
13C NMR (150 MHz, Deuterium Oxide) δ 123.37 (C4/5), 122.10 (C4/5), 53.27, 
49.49, 35.51, 33.27, 30.91, 29.08, 28.12, 27.92, 25.21, 25.02, 24.63, 21.92, 13.32 (-
CH3). 
ESI-HRMS m/z calcd. for  [C12H23N2]
+
: 195.1856 Found: 195.1856 
m/z calcd. for [C6H12NO3S]
-
: 178.0543 Found: 178.0543 
 
 
Ammonium Saccharinate (137) 
 
Saccharin (1.99 g, 11 mmol) was added to ethanol (40 mL) along with 1M NH3 (16 
mL). The solution was stirred for 18 hours resulting in a white precipitate. The 
product was isolated by filtration and washed with ethanol (5 mL) to yield 93% (2.04 
g, 10.2 mmol). 
1
H NMR (600 MHz, DMSO-d6) δ 7.71 – 7.64 (m, 1H, -ArH), 7.64 – 7.56 (m, 3H, -
ArH), 7.20 (br. s, 4H, -NH4). 
13
C NMR (150 MHz, DMSO-d6) δ 168.13 (-CO), 145.16 (-ArC), 134.55 (-ArC), 
131.78 (-ArCH), 131.27 (-ArCH), 122.62 (-ArCH), 119.27 (-ArCH). 
ESI-HRMS m/z calcd. for [C7H4NO3S]
-
: 181.9917 Found: 181.9925 
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Appendix A: Compounds used in Evaluation of BIOWIN Prediction 
Software 
BIOWIN Prediction Results for THQ's 
Compoun
d 
SMILES       
  
 Ready 
Biodegradability 
Prediction 
BIOWIN Model: 
  
  
1 2 3 4 5 6 7 
THQ c12c(cccc1)CCCN2 BF DN
BF 
W-
M 
D-
W 
N
R
D 
N
R
D 
DN
BF 
No 
n-Bu 
THQ 
c12c(cccc1)CCCN2CC
CC 
BF BF W-
M 
D-
W 
N
R
D 
N
R
D 
DN
BF 
No 
THQ Diol c12c(cccc1)CCCN2CC
(O)CO 
BF BF W-
M 
D-
W 
N
R
D 
N
R
D 
DN
BF 
No 
Sulfonate
d THQ 
c12c(cc(S(=O)(=O)O)c
c1)CCCN2 
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BF 
DN
BF 
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M 
D-
W 
N
R
D 
N
R
D 
DN
BF 
No 
1 c12c(cccc1)CC(C)(C)C
N2 
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BF 
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BF 
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M 
D-
W 
N
R
D 
N
R
D 
DN
BF 
No 
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2 
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BF 
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M 
D-
W 
N
R
D 
N
R
D 
DN
BF 
No 
3 c12c(cccc1)CC(N)CN2 BF BF W-
M 
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W 
N
R
D 
N
R
D 
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BF 
No 
4 c12c(cccc1)CC(=S)CN
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N
R
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N
R
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BF 
No 
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R
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n1 W D D 
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BIOWIN Prediction Results for Indolines 
 Compound  SMILES BIOWIN Model:  Ready 
Biodegradability 
Prediction 
1 2 3 4 5 6 7 
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DN
BF 
W-
M 
D-
W 
N
R
D 
N
R
D 
DN
BF 
No 
12 O=C1c2c(cccc2)N=N1 BF DN
BF 
W D-
W 
N
R
N
R
BF No 
IV 
 
D D 
13 c12c(C(OC)N=N1)cccc
2 
BF BF W D-
W 
N
R
D 
N
R
D 
DN
BF 
No 
14 c12c(C(C(=O)O)N=N1)
cccc2 
DN
BF 
DN
BF 
W-
M 
D-
W 
N
R
D 
N
R
D 
DN
BF 
No 
15D O=C1C=C2C(C=C1)N
CC2 
BF DN
BF 
W D N
R
D 
N
R
D 
BF No 
16 O=C1C2C(C(=O)CC(=
O)C2)NC1 
BF BF W D-
W 
R
D 
N
R
D 
DN
BF 
Yes 
17 O=C1CNC2C1CC(=O)
CC2=O 
BF BF W D-
W 
R
D 
R
D 
DN
BF 
Yes 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
V 
 
BIOWIN Prediction Results for Benzoxazines 
Compo
und 
SMILES BIOWIN Model: Readily 
Biodegrad
able 
Prediction 
1 2 3 4 5 6 7 
1 C1(C)(C)C=C(O)C=C(N2CCOC
C2)C1 
DN
BF 
DN
BF 
W-
M 
W NR
D 
NR
D 
DN
BF 
No 
2 O=C1C=C(N2CCOCC2)CC(C)(
C)C1 
DN
BF 
DN
BF 
M W NR
D 
NR
D 
DN
BF 
No 
3 C1(C)(C)C=C(N)C=C(N2CCOC
C2)C1 
DN
BF 
DN
BF 
W-
M 
W NR
D 
NR
D 
DN
BF 
No 
4 C1(=S)C=C(N2CCOCC2)CC(C)
(C)C1 
DN
BF 
DN
BF 
M W NR
D 
NR
D 
DN
BF 
No 
5 c32c(cc(C)cc3)CN(c1ccc(OC)cc1
)CO2 
BF BF M D-
W 
NR
D 
NR
D 
DN
BF 
No 
6 c32c(cc(C)cc3)CN(c1ccc(N)cc1)C
O2 
DN
BF 
DN
BF 
M W NR
D 
NR
D 
DN
BF 
No 
7 c32c(cc(C)cc3)CN(c1ccc(O)cc1)
CO2 
BF BF W-
M 
D-
W 
NR
D 
NR
D 
DN
BF 
No 
8 C(#N)c1ccc(N2Cc3c(ccc(C)c3)O
C2)cc1 
BF BF M W NR
D 
NR
D 
DN
BF 
No 
9 c32c(cc(C)cc3)CN(c1ccc(S)cc1)C
O2 
BF DN
BF 
M W NR
D 
NR
D 
DN
BF 
No 
10 c32c(cc(C)cc3)CN(C1C=CC(=O)
C=C1)CO2 
BF DN
BF 
W-
M 
W NR
D 
NR
D 
DN
BF 
No 
11 O=C1C(c2ccccc2)C(=O)CNC1 BF BF W-
M 
D-
W 
NR
D 
NR
D 
DN
BF 
No 
12 O=C(O)c1cc(C2C(C(=O)O)CNC
C2)ccc1 
BF BF W D RD NR
D 
BF Yes 
13 O=C(C2CCNCC2)Oc1ccccc1 BF BF W D RD RD DN
BF 
Yes 
14 O=C1c2c(cccc2)OC(=O)N1 BF BF W D-
W 
NR
D 
NR
D 
DN
BF 
No 
15 c12c(cccc1)NCC(=O)O2 BF BF W D RD RD DN
BF 
Yes 
16 c32c(cccc3)Nc1c(cccc1)O2 BF BF W-
M 
D-
W 
NR
D 
NR
D 
DN
BF 
No 
17 c12c(cccc1)NCCO2 BF BF W-
M 
D-
W 
NR
D 
NR
D 
DN
BF 
No 
18 O=C1C(=N)Nc2c(cccc2)O1 BF BF W D-
W 
NR
D 
NR
D 
DN
BF 
No 
19 O=C(O)c1cc(C2C(=O)CNCC2)c
cc1 
BF BF W-
M 
D-
W 
RD RD DN
BF 
No 
20 c1(O)cc(N2CCOCC2)ccc1 DN
BF 
DN
BF 
W-
M 
D-
W 
NR
D 
NR
D 
DN
BF 
No 
 
Legend: 
BF - Biodegrades fast 
DNBF - Does not 
biodegrade fast 
W-M - Weeks to months 
W - Weeks 
D-W - Days to weeks 
D - Days 
RD - Readily degradable 
NRD - Not readily 
degradable 
VI 
 
Appendix B: Results of BIODEG Database Survey 
Chemical Aerobic Test Anaerobic Test #Ref
s 
 Scree
n 
BTSi
m 
GrSo
i 
GrWa
t 
Field Sumr
y 
Soil Wate
r 
Sum  
Aniline BF1 BFA1 BS2 BF1 BF3 BF1 BSA
3 
BF3 BST
3 
33 
p-Dodecylaniline BF3     BF3    1 
3-Methoxyaniline BF1     BF1    4 
4-Methoxyaniline BF1     BF1    4 
Pyridoxal BF3     BF3    1 
Acetanilide BF1 BFA3  BFA3  BF1    8 
Benzylamine BF1 BFA3  BF1  BF1    5 
Cyclohexanamine BF3     BF3    1 
1,2-
Cyclohexanediamine 
BF3     BF3    1 
1,4-
Cyclohexanediamine 
BF3     BF3    1 
Indole BF3  BF2   BF1  BFA3 BFA
3 
3 
2-Methylpyridine BF1  BF3   BF1 BSA
3 
 BSA
3 
4 
3-Pyridinecarboxylic 
Acid 
BF2  BF3   BF1 BF3  BF3 3 
Pyridine-2,4-
Dicarboxylic Acid 
BF3  BF3   BF2    2 
Pyridine-2,5-
Dicarboxylic Acid 
BF3     BF3 BSA
3 
 BSA
3 
1 
Pyridine-2,6-
Dicarboxylic Acid 
BF2     BF2 BF3  BF3 2 
2-Hydroxypyridine BF3  BF3   BF2 BFA
3 
 BFA
3 
3 
4-Hydroxypyridine BF3  BF3   BF2 BSA
3 
 BSA
3 
3 
Piperidine BF2    BF2     2 
2-Pyrrolidone BF3     BF3    1 
N-Methylpyrrolidone BF1 BFA1 BF3   BF1    4 
Hydroxyproline BF3     BF3    1 
o-Toluidine BF1 BF3    BF1    9 
p-Toluidine BF1     BF1  BSA3 BSA
3 
8 
           
           
1,4-Benzenediamine BFA3     BFA3    2 
2,3-Dimethylaniline BFA3     BFA3    1 
2,4-Dimethylaniline BFA2     BFA2    3 
N,N-Dimethylaniline BFA1     BFA1    5 
M-
Hydroxyacetanilide 
BFA1     BFA1    4 
3-Hydroxypyridine BFA3  BF1   BF2 BSA
3 
 BSA
3 
3 
3-Methylphthalimide BFA3     BFA3    1 
4-Methylpyridine BFA3  BFA
3 
  BFA2  BFA3 BFA
3 
2 
N-Methylpyrrole BFA3     BFA3    1 
N-Phenyl-1-
naphthylamine 
BFA2  BF3 BFA3  BFA1    2 
Quinoline BFA1   BFA1  BFA1    4 
m-Toluidine BFA2     BFA2    4 
2,4-Diaminotoluene BS3 BF3    BFA2    2 
           
           
o-Anilinesulfonic 
Acid 
BS2     BS2    1 
VII 
 
N,N-Diethylaniline BS1     BS1    3 
N-Phenylanthranilic 
Acid 
BS3     BS3    1 
Melamine BS2  BS3   BS2    3 
Morpholine BS1 BST2    BS1    8 
p-Toluidine-m-
sulfonic Acid 
BS2 BSA3    BS1    3 
           
           
N-Methyl-m-
toluidine 
BSA3     BSA3    1 
1,5-
Naphthalenediamine 
BSA3     BSA3    1 
2,6-Diaminopyridine BSA3  BSA
3 
  BSA2    2 
3-(3-Pyridyl)-1-
propanol 
 
BSA3     BSA3    1 
m-
Tolyldiethanolamine 
BSA3     BSA3    1 
2,3,6-
Trimethylpyridine 
BSA3     BSA3 BSA
3 
 BSA
3 
1 
2-Vinylpyridine BSA3     BSA3    1 
3-
Aminobenzenesulfon
ic Acid 
BSA1 BSA2    BSA1    7 
2,4,6-
Trimethylpyridine 
BFA3     BSA3 BSA
3 
 BSA
3 
1 
           
           
1,2-Benzenediamine BST1     BST1    3 
1,3-Benzenediamine BST2     BST2    3 
1-Naphthylamine BST1  BSA
3 
  BST1    4 
N-Phenyl-2-
napthylamine 
BST2     BST2    2 
Pyridine BST1 BFA3 BF3   BST1  BFA3 BFA
3 
10 
4-Pyridinecarboxylic 
Acid 
BST2  BF3   BST1 BFA
3 
 BFA
3 
3 
2,4-
Dimethylpyridine 
BST2  BFA
3 
  BST2 BSA
3 
 BSA
3 
3 
2,6-
Dimethylpyridine 
BST2  BF3   BST2 BSA
3 
 BSA
3 
3 
3-Methylpyridine BST2  BF3   BST1    3 
4-Ethoxyaniline BST2     BST2    2 
2-Methoxyaniline BST1     BST1    4 
N-Methylaniline BST1 BFA3    BST1    5 
p-Phenylazoaniline BST2     BST2    4 
4-
Aminobenzenesulfon
ic Acid 
BST1 BST1    BST1    9 
Benzidine BST2 BST2 BST2   BST2    4 
Pendimethalin    BSA1 BST
1 
BST1  BST1 BST
1 
11 
2,4- Dimethylaniline BF1  BF3   BST1    3 
2,6- Dimethylaniline BS3  BST2   BST2    3 
2,3-
Dihydroxypyridine 
BSA2  BFA
3 
  BST1 BSA
3 
 BSA
3 
3 
5,5-
Dimethylhydantoin 
BSA3 BFA2    BST2    1 
 
 
VIII 
 
BF – Biodegrades fast 
BFA – Biodegrades fast with acclimation 
BS – Biodegrades slow 
BSA – Biodegrades slow with acclimation 
BST – Biodegrades sometimes 
 
1 - Chemical tested in three or more tests, consistent results. 
2 - Chemical tested in two tests, or results in more than two tests are interpretable, 
but conflicting data. 
3 - Only one test or uninterpretable, conflicting data. 
  
IX 
 
Appendix C: Complete Accelerator Performance Results for All 
Compounds Evaluated in the Nuts & Bolts and Pins & Collar Tests. 
 
Graph 5.1: Black Oxide Bolts with Mild Steel Nuts: 
(a) Break Torque, (b) Prevail Torque, and (c) Maximum Torque 
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Graph 5.2: Stainless Steel Nuts and Bolts:  
(a) Max Torque, (b) Prevail Torque, and (c) Maximum Torque 
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Graph 5.3: Mild Steel Pins and Collars:  
(a) Compressive Strength and (b) Maximum Load 
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Graph 5.4: Black Oxide Bolts with Mild Steel Nuts 
 
 
Graph 5.23: Stainless Steel Nuts and Bolts 
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Graph 5.6: Mild Steel Pins and Collars: 
(a) Compressive Strength and (b) Maximum Load 
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Graph 5.7: Black Oxide Bolts with Mild Steel Nuts: 
(a) Break Torque, (b) Prevail Torque, and (c) Maximum Torque 
The composition of each formulation (I-IV) may be found in Section 5.3.1. 
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Graph 5.8: Stainless Steel Nuts and Bolts: 
(a) Break Torque, (b) Prevail Torque, and (c) Maximum Torque 
The composition of each formulation (I-IV) may be found in Section 5.3.2. 
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Graph 5.9: Mild Steel Pins and Collar: 
(a) Compressive Strength and (b) Maximum Load 
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Graph 5.10: Black Oxide Bolts with Mild Steel Nuts: 
(a) Break Torque, (b) Prevail Torque, and (c) Maximum Torque 
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Graph 5.11: Stainless Steel Nuts and Bolts: 
(a) Break Torque, (b) Prevail Torque, and (c) Maximum Torque 
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Graph 5.12: Mild Steel Pins and Collar: 
(a) Compressive Strength and (b) Maximum Load 
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Graph 5.13: Black Oxide Bolts with Mild Steel Nuts: 
(a) Break Torque, (b) Prevail Torque, and (c) Maximum Torque 
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Graph 5.14: Stainless Steel Nuts and Bolts: 
(a) Break Torque, (b) Prevail Torque, and (c) Maximum Torque 
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Graph 5.15: Mild Steel Pins and Collars: 
(a) Compressive Strength and (b) Maximum Load 
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Graph 5.16: Black Oxide Bolts with Mild Steel Nuts: 
(a) Break Torque, (b) Prevail Torque, and (c) Maximum Torque 
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Graph 5.17: Stainless Steel Nuts and Bolts: 
(a) Break Torque, (b) Prevail Torque, and (c) Maximum Torque 
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Graph 5.18: Mild Steel Pins and Collars: 
(a) Compressive Strength and (b) Maximum Load 
 
 
 
 
 
 
 
7.96 7.62 7.18 
8.22 
5.12 
9.02 
6.65 
7.64 
2.56 
7.77 
9.32 8.81 
Compressive Strength (MPa) 
1 Hour Cure Time 24 Hour Cure Time
3209.45 3073.32 2892.16 
3312.47 
2262.32 
3633.42 
2678.12 
3080.06 
1033.58 
3129.82 
3755.87 
3549.78 
Maximum Load (N) 
1 Hour Cure Time 24 Hour Cure Time
